U.S. patent application number 11/932986 was filed with the patent office on 2008-06-12 for diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors.
This patent application is currently assigned to IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY. Invention is credited to Donatella Chianelli, Pascal Furet, Vito Guagnano, Donald S. Karanewsky, Xiaolin Li, Xiaodong Liu, Yi Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Shifeng Pan, Shuli You.
Application Number | 20080139597 11/932986 |
Document ID | / |
Family ID | 37900458 |
Filed Date | 2008-06-12 |
United States Patent
Application |
20080139597 |
Kind Code |
A1 |
Molteni; Valentina ; et
al. |
June 12, 2008 |
DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS
MODULATORS OF C-KIT RECEPTORS
Abstract
Described herein are compounds that include a diarylamine
structural feature. Also described herein are methods for making
such compounds, methods for using such compounds to modulate the
activity of c-kit receptors, and pharmaceutical compositions and
medicaments comprising such compounds. Also described herein are
methods of using such compounds, pharmaceutical compositions and
medicaments to treat and/or prevent and/or inhibit and/or
ameliorate the pathology and/or symptomology diseases or conditions
associated with the activity of c-kit receptors.
Inventors: |
Molteni; Valentina; (San
Diego, CA) ; Li; Xiaolin; (San Diego, CA) ;
Chianelli; Donatella; (San Diego, CA) ; Loren;
Jon; (San Diego, CA) ; Nabakka; Juliet;
(Santee, CA) ; Liu; Xiaodong; (San Diego, CA)
; Pan; Shifeng; (San Diego, CA) ; Liu; Yi;
(San Diego, CA) ; Karanewsky; Donald S.;
(Escondido, CA) ; Furet; Pascal; (Thann, FR)
; Guagnano; Vito; (Basel, CH) ; You; Shuli;
(Shanghai, CN) |
Correspondence
Address: |
WILSON SONSINI GOODRICH & ROSATI
650 PAGE MILL ROAD
PALO ALTO
CA
94304-1050
US
|
Assignee: |
IRM LLC, A DELAWARE LIMITED
LIABILITY COMAPNY
Hamilton HM 11
BM
NOVARTIS, AG
Basel
CH
|
Family ID: |
37900458 |
Appl. No.: |
11/932986 |
Filed: |
October 31, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11535455 |
Sep 26, 2006 |
|
|
|
11932986 |
|
|
|
|
60721015 |
Sep 27, 2005 |
|
|
|
Current U.S.
Class: |
514/275 |
Current CPC
Class: |
A61P 3/06 20180101; A61P
25/16 20180101; A61P 25/28 20180101; A61P 27/14 20180101; C07D
409/04 20130101; A61P 1/00 20180101; A61P 31/18 20180101; C07D
403/12 20130101; A61P 9/02 20180101; A61P 11/06 20180101; A61P
19/02 20180101; A61P 25/24 20180101; A61P 43/00 20180101; A61P
13/08 20180101; A61P 29/00 20180101; A61P 25/20 20180101; A61P
17/04 20180101; C07D 401/12 20130101; C07D 405/12 20130101; A61P
13/00 20180101; A61P 25/04 20180101; A61P 37/02 20180101; C07D
239/42 20130101; A61P 11/10 20180101; A61P 37/08 20180101; A61P
1/18 20180101; A61P 9/00 20180101; A61P 7/10 20180101; C07D 471/04
20130101; A61P 7/02 20180101; C07D 417/12 20130101; C07D 491/10
20130101; A61P 21/00 20180101; A61P 37/06 20180101; C07D 413/12
20130101; A61P 21/04 20180101; A61P 11/08 20180101; A61P 17/00
20180101; A61P 27/02 20180101; A61P 35/00 20180101; A61P 25/18
20180101; A61P 25/30 20180101; A61P 1/04 20180101; A61P 1/16
20180101; A61P 3/04 20180101; A61P 9/10 20180101; A61P 17/12
20180101; A61P 11/02 20180101; A61P 25/22 20180101; A61P 27/04
20180101; C07D 403/04 20130101; A61P 19/06 20180101; A61P 3/10
20180101; A61P 11/00 20180101; A61P 9/12 20180101; A61P 19/08
20180101; A61P 25/02 20180101; A61P 9/08 20180101; A61P 25/00
20180101; A61P 25/14 20180101; A61P 17/06 20180101 |
Class at
Publication: |
514/275 |
International
Class: |
A61K 31/506 20060101
A61K031/506; A61P 43/00 20060101 A61P043/00 |
Claims
1. A pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of a compound having the structure of Formula
(1) or Formula (46): ##STR00871## wherein: Ar is a group comprising
a moiety selected from an optionally substituted five-membered
aromatic heterocycle, an optionally substituted five-membered
aromatic carbocycle, an optionally substituted six-membered
aromatic heterocycle, and a substituted, optionally further
substituted phenyl; Q is a group comprising a non-aromatic tertiary
amine or a non-aromatic secondary amine, with the proviso that Q is
not --NR.sub.aR.sub.b or --SO.sub.2NR.sub.aR.sub.b; wherein each of
R.sub.a and R.sub.b is independently H or C.sub.1-6alkyl optionally
substituted by mono- or di-alkyl (C.sub.1-6) amino; each R.sub.1 is
independently an optionally substituted moiety selected from
-L.sub.1-H or -L.sub.1-C.sub.1-6alkyl; wherein L.sub.1 is selected
from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; each R'' is independently H, OH, halogen,
C.sub.1-6alkyl, substituted C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, or
heteroaryl; or any two adjacent R.sub.1 groups together may form an
optionally substituted 5 to 8-membered heterocyclic, cycloalkyl, or
aryl ring; R.sub.5 is H or C.sub.1-6alkyl; or a pharmaceutically
acceptable salt thereof.
2. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein the Ar is a
group comprising a substituted, optionally further substituted
six-membered aromatic heterocycle.
3. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein said
optional substituents are selected from halogen, OH, halogen,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl.
4. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein Ar is
selected from the group consisting of ##STR00872## ##STR00873##
##STR00874##
5. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein Q is
selected from the group consisting of ##STR00875## ##STR00876##
##STR00877## ##STR00878##
6. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 5, wherein Ar is
selected from the group consisting of ##STR00879##
7. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 6, wherein the compound
is selected from the group consisting of: tert-butyl
2-(4-(2-(4-(2-diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluoroben-
zamido)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzylamino)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzylamino-
)acetate,
2,2'-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl-
azanediyl)diethanol,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylic acid, tert-butyl
2-(4-(2-(4-(2-diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)ac-
etate, methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate,
N-(4-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-
-amine,
1-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl)pipe-
ridine-4-carboxylic acid,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine-
, tert-butyl
2-(4-(2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-2-yl)benzamido)aceta-
te, tert-butyl
2-(4-(2-(4-(2-(4-carbamoylpiperidin-1-yl)ethoxy)phenylamino)pyrimidin-5-y-
l)benzamido)acetate,
4-(2-(4-(2-diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)phenyl
acetate, ethyl
2-(2-(diethylamino)ethoxy)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamin-
o)benzoate, 4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
5-(4-methoxyphenyl)-N-(4-(2-(methyl(pyridin-2-ylamino)ethoxy)phenyl)pyrim-
idin-2-amine, methyl
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzoate,
N-(4-(2-(diethylamino)ethoxyphenyl)-5-(3-fluoro-4-methoxyphenyl)pyrimidin-
-2-amine,
2-(2-(diethylaminoethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylam-
ino)benzoic acid, methyl
2-(2-diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzo-
ate,
N-(3-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-a-
mine,
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-a-
mine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine)-4-ca-
rboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine--
3-carboxamide, tert-butyl
3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propanoate,
5-(4-methoxyphenyl)-N-(4-(piperazin-1-ylmethyl)phenyl)pyrimidin-2-amine,
1-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)eth-
anone,
(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl-
)(tetrahydrofuran-2-yl)methanone,
1-(3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propyl)pyrrol-
idin-2-one,
(S)-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)-
methanol,
(R)--N-(4-((2-(methoxymethyl)pyrrolidin-1-yl)methyl)phenyl)-5-(4-
-methoxyphenyl)pyrimidin-2-amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-3-ol,
methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)cyclopent-
anecarboxylate,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)-2-methylpiperazine-1-
-carboxylic acid,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)pro-
panoic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-3-carboxyli-
c acid, ethyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)ace-
tate,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-y-
l)acetic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidine-3-carboxy-
lic acid, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
morpholine-4-carboxylate,
3-(5-(methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
3-(5-(4-(2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino)-
phenyl 4-methylpiperazine-1-carboxylate, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazine-1-carboxyl-
ate,
4-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-yla-
mino)phenyl 4-methylpiperazine-1-carboxylate,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin-
-1-yl)ethanone,
N1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1,4-dicar-
boxamide, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate,
4-hydroxy-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine--
1-carboxamide,
N-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xamide,
furan-2-yl(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)-
piperazin-1-yl)methanone,
5-(4-methoxyphenyl)-N-(4-(2-(piperazin-1-yl)ethyl)phenyl)pyrimidin-2-amin-
e,
N-(3-(5-(4-(methoxyphenyl)pyrimidin-2-ylamino)phenyl)-N,4-dimethylpiper-
azine-1-carboxamide,
1-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carboxam-
ide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-c-
arboxylic acid, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl
piperazine-1-carboxylate,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carbo-
xylic acid,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetic acid, methyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetate,
(3-(hydroxymethyl)piperidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-
-2-ylamino)phenyl)methanone,
(3-hydroxypyrrolidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phen-
yl)methanone,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-4-carboxa-
mide,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin--
1-yl)propanoic acid,
(S)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)pyrrolidine-2--
carboxylic acid,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethylamino)cyclohexaneca-
rboxylic acid, 4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino
--N-(3-(2-oxopyrrolidin-1-yl)propyl)benzamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxa-
mide,
N-(3-carbamoylphenyl)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
amide,
1,4'-bipiperidin-1'-yl(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)ph-
enyl)methanone,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)pip-
eridin-1-yl)methanone,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(2-pyridin-2-yl)ethyl)benzam-
ide,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyra-
zol-4-yl)benzamide,
(4-(furan-2-carbonyl)piperazin-1-yl)(3-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)phenyl)methanone,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol--
4-yl)benzamide,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(1-methylpiperidin-4-
-yl)piperazin-1-yl)methanone,
1-(4-(3-(5-(4-methoxyphenyl).sub.pyrimidin-2-ylamino)benzoyl
piperazin-1-yl)ethanone,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)
piperidin-1-yl)methanone,
1,4'-bipiperidin-1'-yl(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino
phenyl)methanone,
1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxa-
mide,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-(1-methylpipe-
ridin-4-yl)piperazine-1-carboxamide, methyl
4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenylcarbamoyl)piperazine-1-
-carboxylate,
(R)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-c-
arboxylic acid,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne,
4-acetyl-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperazin-
e-1-carboxamide, and
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne.
8. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein the compound
having the structure of Formula (1) is selected from Formula (2),
Formula: (3), or Formula (44): ##STR00880## wherein: M is selected
from the group consisting of H, OH, SH, NO.sub.2, CN, NR''.sub.2,
and an optionally substituted moiety selected from -L.sub.7-alkyl,
-L.sub.7-cycloalkyl, -L.sub.7-heteroalkyl, -L.sub.7-haloalkyl,
-L.sub.7-aryl, -L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl;
wherein L.sub.7 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR''Y.sup.1C(O)O--, and
--C(O)NR''O--; W is C.sub.1-6 alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (2); each
R'' is independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; each X is
independently selected from N or CR.sub.2, provided that at least
one but no more than 2 X groups are N; each R.sub.2 is
independently selected from the group consisting of H, OH, halogen,
and an optionally substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
and halo-C.sub.1-6alkoxy; or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; or a pharmaceutically
acceptable salt thereof.
9. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein the compound
having the structure of Formula (46) is selected from Formula (47),
Formula (48), or Formula (49): ##STR00881## wherein: M is selected
from the group consisting of H, OH, SH, NO.sub.2, CN, NR''.sub.2,
and an optionally substituted moiety selected from -L.sub.1-alkyl,
-L.sub.7-cycloalkyl, -L.sub.7-heteroalkyl, -L.sub.1-haloalkyl,
-L.sub.7-aryl, -L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl;
wherein L.sub.7 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR''Y.sup.1C(O)O--, and
--(O)NR''O--; W is C.sub.1-6alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (47);
each R'' is independently H, OH, halogen, C.sub.1-6alkyl,
substituted C.sub.1-6alkyl, halo-C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, or
heteroaryl; each X is independently selected from N or CR.sub.2,
provided that at least one but no more than 2 X groups are N; each
R.sub.2 is independently selected from the group consisting of H,
OH, halogen, and an optionally substituted moiety selected from
-L.sub.2-alkyl, -L-cycloalkyl, -L.sub.2-heteroalkyl,
-L.sub.2-haloalkyl, -L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and
-L-heteroaryl; wherein L.sub.2 is selected from a bond, --O--,
--NH--, --S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
13 CR'''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
and halo-C.sub.1-6alkoxy; or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl: ring; or a pharmaceutically
acceptable salt thereof.
10. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of any of claims 1-4, 8 and 9,
wherein Q is selected from the group consisting of ##STR00882##
##STR00883## ##STR00884## ##STR00885## ##STR00886## ##STR00887##
##STR00888## ##STR00889## ##STR00890## ##STR00891## ##STR00892##
##STR00893## ##STR00894## ##STR00895## ##STR00896## ##STR00897##
##STR00898## ##STR00899## ##STR00900## ##STR00901##
11. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein the compound
having the structure of Formula (1) is selected from Formula (23),
Formula (24), or Formula (45): ##STR00902## wherein: M is selected
from the group consisting of H, OH, SH, NO.sub.2, CN, NR''.sub.2,
and an optionally substituted moiety selected from -L.sub.7-alkyl,
-cycloalkyl, -L.sub.7-heteroalkyl, -L.sub.7-haloalkyl,
-L.sub.7-aryl, -L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl;
wherein L.sub.7 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR''Y.sup.1C(O)O--, and
--C(O)NR''O--; W is C.sub.1-6alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (23);
each R'' is independently H, OH, halogen, C.sub.1-6alkyl,
substituted C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; each X is
independently-selected from N or CR.sub.2, provided that at least
one but no more than 2 X groups are N; each R.sub.2 is
independently selected from the group consisting of H, OH, halogen,
and an optionally substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.1-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
and halo-C.sub.1-6alkoxy; or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; each of R.sub.3 and R.sub.4
is independently an optionally substituted moiety selected from -Z,
-L.sub.3-Z, -L.sub.3-H, -L.sub.3-alkyl, -L.sub.3-cycloalkyl,
-L.sub.3-heteroalkyl, -L.sub.3-haloalkyl, -L.sub.3-aryl,
-L.sub.3-heterocycloalkyl, and -L.sub.3-heteroaryl; wherein L.sub.1
is selected from a bond, --C(S)--, --C(O)O--, --C(O)NR'''--,
--(CR''.sub.2).sub.1-6--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, --CR'''.sub.2S(O)NR'''--,
--CR'''.sub.2C(O)NR'''--, --(CR'''.sub.2).sub.1-6NR'''--,
--(CR'''.sub.2).sub.1-6O--, --(CR'''.sub.2).sub.1-6C(O)O--,
--Y.sup.2C(O)O--, and an optionally substituted C.sub.1-6alkylene;
wherein said optional substituents are selected from halogen, --OH,
--O, --Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen or OH
substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --CR'''.sub.2), --C(O)OR.sub.6, --C(O)NR''.sub.2,
--C(O)R.sub.6, or --(O)OR.sub.6; Y.sup.2 is an optionally
substituted cycloalkyl ring or optionally substituted non-aromatic
heterocyclic ring; wherein said optional substituents are selected
from C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN. Y.sup.3 is
optionally substituted aryl, optionally substituted heteroaryl,
optionally substituted cycloalkyl, or optionally substituted
non-aromatic heterocycle; wherein said optional substituents are
selected from C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN. Z is
--H, --OH, --CN, --COOR''', --NR'''.sub.2, or --C.ident.R'''; each
R''' is independently H, alkyl, or substituted alkyl; or two R'''
together may form a 3-6 membered cycloalkyl or heterocyclic ring;
or R.sub.3 and R.sub.4 taken together with the N atom to which they
are attached may form an optionally substituted 3 to 8-membered
heterocyclic ring; wherein said optional substituents are selected
from halogen, --OH, .dbd.O, --Y.sup.3, C.sub.1-6alkyl,
C.sub.1-6alkoxy, halogen or OH substituted C.sub.1-6alkyl, halogen
or OH substituted C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6Y.sup.4,
--CR'''.sub.2).sub.1-6OR.sub.6, --C(O)NR'''R.sub.6, --C(O)OR.sub.6,
--OR.sub.6, --NR'''C(O)OR.sub.6, --NR'''C(O)R.sub.6,
--CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR''C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR.sub.7R.sub.8, --S(O).sub.2NR'''.sub.2,
--C(O)R.sub.6, --OC(O)R.sub.6, --NR.sub.7R.sub.8,
--CR'''.sub.2).sub.1-6C(O)NR.sub.7R.sub.8, --S(O).sub.2R.sub.A, or
--C(O)R.sub.A; Y is aryl, heteroaryl, cycloalkyl, or non-aromatic
heterocycle; R.sub.A is selected from --NH.sub.2, --NEt.sub.2, and
--NH(CH.sub.2).sub.1-6OH; R.sub.6 is H, alkyl, substituted alkyl,
cycloalkyl, non-aromatic heterocycle, aryl, or heteroaryl; each of
R.sub.7 and R.sub.8 is independently H, OH, halogen,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6-alkyl, or
halo-C.sub.1-6alkoxy; or R.sub.7 and R.sub.8 taken together with
the N atom to which they are attached may form a 3 to 6-membered
heterocyclic ring; T.sub.1 is an optionally substituted moiety
selected from -L.sub.4-, -alkylene-L.sub.4, -L.sub.4-alkylene-,
-L.sub.4 cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --NR'''C(O)--,
--(O)--, --C(S)--, --C(O)O--, --C(O)NR'''--, --S(O)--,
--S(O).sub.2--, --OC(O)--,
--C(O)NR'''(CR''.sub.2).sub.1-6--C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6C(O)--,
--CR''.sub.2NR'''CR''.sub.2C(O)O--, --C(O)NR'''NR'''C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6--, --CR''.sub.2C(O)--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl; or a
pharmaceutically acceptable salt thereof.
12. The pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of the compound of claim 1, wherein the compound
having the structure of Formula (46) is selected from Formula (50),
Formula (51), or Formula (52): ##STR00903## wherein: M is selected
from the group consisting of H, OH, SH, NO.sub.2, CN, NR''.sub.2,
and an optionally substituted moiety selected from -L.sub.7-alkyl,
-L.sub.7-cycloalkyl, -L.sub.7-heteroalkyl, -L.sub.7-haloalkyl,
-L.sub.7-aryl, -L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl;
wherein L.sub.7 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR''Y.sup.1C(O)O--, and
--C(O)NR''O--; W is C.sub.1-6alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (50);
each R'' is independently H, OH, halogen, C.sub.1-6alkyl,
substituted C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; each X is
independently selected from N or CR.sub.2, provided that at least
one but no more than 2 X groups are N; each R.sub.2 is
independently selected from the group consisting of H, OH, halogen,
and an optionally substituted: moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
and halo-C.sub.1-6alkoxy; or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; each of R.sub.3 and R.sub.4
is independently an optionally substituted moiety selected from -Z,
-L.sub.3-Z, -L.sub.3-H, -L.sub.3-alkyl, -L.sub.3-cycloalkyl,
-L.sub.3-heteroalkyl, -L.sub.3-haloalkyl, -L.sub.3-aryl,
-L.sub.3-heterocycloalkyl, and -L.sub.3-heteroaryl; wherein L.sub.3
is selected from a bond, --C(S)--, --C(O)O--, --C(O)NR'''--,
--CR''.sub.2).sub.1-6--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, --CR'''.sub.2S(O)NR'''--,
--CR'''.sub.2C(O)NR'''--, --(CR'''.sub.2).sub.1-6NR'''--,
--CR'''.sub.2).sub.1-6O--, --CR'''.sub.2).sub.1-6C(O)O--,
--Y.sup.2C(O)O--, and an optionally substituted C.sub.1-6alkylene;
wherein said optional substituents are selected from halogen, --H,
.dbd.O, --Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen or
OH-substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--C(O)NR'''.sub.2, --C(O)R.sub.6, or --C(O)OR.sub.6; Y.sup.2 is an
optionally substituted cycloalkyl ring or optionally substituted
non-aromatic heterocyclic ring; wherein said optional substituents
are selected from C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN.
Y.sup.3 is optionally substituted aryl, optionally substituted
heteroaryl, optionally substituted cycloalkyl, or optionally
substituted non-aromatic-heterocycle; wherein said optional
substituents are selected from C.sub.1-6alkyl, halogen, --OH,
.dbd.O, and --CN. Z is --H, --OH, --CN, --COOR''', --NR'''.sub.2,
or --C.ident.R'''; each R''' is independently H, alkyl, or
substituted alkyl; or two-R''' together may form a 3-membered
cycloalkyl or heterocyclic ring; or R.sub.3 and R.sub.4 taken
together with the N atom to which they are attached may form an
optionally substituted-3 to 8-membered heterocyclic ring; wherein
said optional substituents are selected from halogen, --OH, .dbd.O,
--Y.sup.3, C.sub.1-6alkyl, C.sub.1alkoxy, halogen or OH substituted
C.sub.1-6alkyl, halogen or OH substituted C.sub.1-6alkoxy,
--(CR'''.sub.2).sub.1-6Y.sup.4, --(CR'''.sub.2).sub.1-6OR.sub.6,
--C(O)NR'''R.sub.6, --C(O)OR.sub.6, --OR.sub.6,
--NR'''C(O)OR.sub.6, --NR'''C(O)R.sub.6,
--CR'''.sub.2).sub.1-6C(O)OR.sub.6, --(CR'''.sub.2),
R'''C(O)OR.sub.6, --(CR''.sub.2).sub.1-6NR.sub.7R.sub.8,
--S(O).sub.2NR'''.sub.2, --C(O)R.sub.6, --OC(O)R.sub.6,
--NR.sub.7R.sub.8, --(CR'''.sub.2).sub.1-6C(O)NR.sub.7R.sub.8,
--S(O).sub.2R.sub.A, or --C(O)R.sub.A; Y.sup.4 is aryl, heteroaryl,
cycloalkyl, or non-aromatic heterocycle; R.sub.A is selected from
--NH.sub.2, --NEt.sub.2, and --NH(CH.sub.2).sub.1-6OH; R.sub.6 is
H, alkyl, substituted: alkyl, cycloalkyl, non-aromatic heterocycle,
aryl, or heteroaryl; each of R.sub.7 and R.sub.8 is independently
H, OH, halogen, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, or halo-C.sub.1-6alkoxy; or R.sub.7 and
R.sub.8 taken together with the N atom to which they are attached
may form a 3 to 6-membered heterocyclic ring; T.sub.1 is an
optionally substituted moiety selected from -L.sub.4-,
-alkylene-L.sub.4-, -L.sub.4-alkylene-, -L.sub.4-cycloalkylene-,
-L.sub.4-heteroalkylene-, -L.sub.4-haloalkylene-,
-L.sub.4-arylene-, -L.sub.4-heteroarylene-, and
-L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from a
bond, --O--, --NH, --S--, --CR''.sub.2--, --NR'''C(O)--, --C(O)--,
--C(S)--, --C(O)O--, --C(O)NR'''--, --S(O)--, --S(O).sub.2--,
--OC(O)--, --C(O)NR'''(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6C(O)--,
--CR''.sub.2NR'''CR''.sub.2C(O)O--, --C(O)NR'''N'''C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6--, --CR''.sub.2C(O)--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6-alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl; or a
pharmaceutically acceptable salt thereof.
13. The pharmaceutically acceptable prodrug, or a pharmaceutically
acceptable solvate of the compound of any of claims 8, 9, 11, and
12, wherein each R.sub.2 is H.
14. A method for modulating the activity of a c-kit kinase receptor
comprising contacting the c-kit kinase receptor with a
pharmaceutically acceptable prodrug or a pharmaceutically
acceptable solvate of a compound having the structure of Formula
(1) or Formula (46) of claim 1.
15. A method of treating a disease in an animal in which modulation
of c-kit receptor activities can prevent, inhibit or ameliorate the
pathology and/or symptomology of the diseases, which method
comprises administering to the animal a therapeutically effective
amount of a pharmaceutically acceptable prodrug or a
pharmaceutically acceptable solvate of a compound having the
structure of Formula (1) or Formula (46) of claim 1.
16. (canceled)
17. (canceled)
Description
CROSS-REFERENCE
[0001] This application claims the benefit of provisional
application Ser. No. 60/721,015 filed Sep. 27, 2005.
FIELD OF THE INVENTION
[0002] Compounds, methods of making such compounds, pharmaceutical
compositions and medicaments comprising such compounds, and methods
of using such compounds to treat or prevent diseases or conditions
associated with c-kit receptor activity are described.
BACKGROUND OF THE INVENTION
[0003] The c-kit gene encodes a receptor tyrosine kinase and the
ligand for the c-kit receptor is called the stem cell factor (SCF),
which is the principal growth factor for mast cells. The activity
of the c-kit receptor protein tyrosine kinase is regulated in
normal cells, and the normal functional activity of the c-kit gene
product is essential for maintenance of normal hematopoeisis,
melanogenesis, genetogensis, and growth and differentiation of mast
cells. Mutations that cause constitutive activation of c-kit kinase
activity in the absence of SCF binding are implicated in various
diseases including malignant human cancers.
SUMMARY OF THE INVENTION
[0004] In one aspect are compounds having a diarylamine structure.
In another aspect is the method of using such compounds having a
diarylamine structure for the modulation of a c-kit receptor.
[0005] In another aspect is the use of such compounds having a
diarylamine structure in the treatment of a disease or condition,
or to produce a medicament for the treatment of a disease or
condition, in which modulation of c-kit receptor activity can
prevent, inhibit or ameliorate the pathology and/or symptoms of the
disease or condition. In further or alternative embodiments, such
diarylamine compounds comprise at least one heterocycle group. In
further or alternative embodiments, such heterocycle groups contain
at least one nitrogen. In further or alternative embodiments, such
heterocycle groups are pyrimidines. In further or alternative
embodiments, such diarylamines further comprise multicyclic aryl
groups. In further or alternative embodiments, such diarylamines
further comprise at least one tricyclic aryl groups. In further or
alternative embodiments, such diarylamines further comprise at
least one bicyclic aryl groups. In further or alternative
embodiments, such diarylamines further comprise at least one
monocyclic aryl groups. In further or alternative embodiments, the
multicyclic aryl groups comprise at least one heterocycle. In
further or alternative embodiments, the tricyclic aryl groups
comprise at least one heterocycle. In further or alternative
embodiments, the bicyclic aryl groups comprise at least one
heterocycle. In further or alternative embodiments, the monocyclic
aryl group is a heterocycle.
[0006] In another aspect are pharmaceutical compositions comprising
such a compound having a diarylamine structure. In further or
alternative embodiments, such diarylamine compounds comprise at
least one heterocycle group. In further or alternative embodiments,
such heterocycle groups contain at least one nitrogen. In further
or alternative embodiments, such heterocycle groups are
pyrimidines. In further or alternative embodiments, such
diarylamines further comprise multicyclic aryl groups. In further
or alternative embodiments, such diarylamines further comprise at
least one tricyclic aryl groups. In further or alternative
embodiments, such diarylamines further comprise at least one
bicyclic aryl groups. In further or alternative embodiments, such
diarylamines further comprise at least one monocyclic aryl groups.
In further or alternative embodiments, the multicyclic aryl groups
comprise at least one heterocycle. In further or alternative
embodiments, the tricyclic aryl groups comprise at least one
heterocycle. In further or alternative embodiments, the bicyclic
aryl groups comprise at least one heterocycle. In further or
alternative embodiments, the monocyclic aryl group is a
heterocycle.
[0007] In another aspect are methods for making such compounds
having a diarylamine structure. In further or alternative
embodiments, such diarylamine compounds comprise at least one
heterocycle group. In further or alternative embodiments, such
heterocycle groups contain at least one nitrogen. In further or
alternative embodiments, such heterocycle groups are pyrimidines.
In further or alternative embodiments, such diarylamines further
comprise multicyclic aryl groups. In further or alternative
embodiments, such diarylamines further comprise at least one
tricyclic aryl groups. In further or alternative embodiments, such
diarylamines further comprise at least one bicyclic aryl groups. In
further or alternative embodiments, such diarylamines further
comprise at least one monocyclic aryl groups. In further or
alternative embodiments, the multicyclic aryl groups comprise at
least one heterocycle. In further or alternative embodiments, the
tricyclic aryl groups comprise at least one heterocycle. In further
or alternative embodiments, the bicyclic aryl groups comprise at
least one heterocycle. In further or alternative embodiments, the
monocyclic aryl group is a heterocycle.
[0008] In another aspect are compounds having the structure of
Formula (A) or Formula (B):
##STR00001##
[0009] wherein: [0010] Q.sub.1 is H, halogen, a group comprising a
non-aromatic tertiary amine, a group comprising a non-aromatic
secondary amine, or is an optionally substituted moiety selected
from the group consisting of: -L-alkyl, -L-cycloalkyl,
-L-heteroalkyl, -L-haloalkyl, -L-aryl, -L-heterocycloalkyl, and
-L-heteroaryl; wherein L is selected from a bond, --O--, --NH--,
--S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''YC(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y is optionally
substituted arylene or heteroarylene; [0011] each R.sub.1 is
independently selected from the group consisting of H, halogen, and
an optionally substituted moiety selected from -L.sub.1-alkyl,
-L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl, -L.sub.1-haloalkyl,
-L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and -L.sub.1-heteroaryl;
wherein L.sub.1 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y'C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y' is optionally
substituted arylene or heteroarylene; [0012] Q.sub.2 is selected
from the group consisting of H, halogen, and a group comprising an
optionally substituted moiety selected from -L.sub.6-alkyl,
-L.sub.6-cycloalkyl, -L.sub.6-heteroalkyl, -L.sub.6-haloalkyl,
-L.sub.6-aromatic carbocycle, -L.sub.6-heterocycloalkyl, and
-L.sub.6-aromatic heterocycle; wherein L.sub.6 is selected from a
bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y''C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y'' is optionally
substituted arylene or heteroarylene; [0013] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0014] any two
R.sub.1 groups together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0015] R.sub.5
is selected from the group consisting of H, and an optionally
substituted moiety selected from -L.sub.5-H, -L.sub.5-alkyl,
-L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl, -L.sub.5-haloalkyl,
-L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and -L.sub.5-heteroaryl,
wherein L.sub.5 is selected from a bond, --R'O--, --R'N(H)--,
--R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--, and --R'C(O)NH--;
[0016] each R' is independently selected from the group consisting
of a bond, alkylene, substituted alkylene, heteroalkylene,
substituted heteroalkylene, alkenylene, substituted alkenylene,
cycloalkylene, substituted cycloalkylene, heteroalkylene,
substituted heteroalkylene, heterocycloalkylene, substituted
heterocycloalkylene, arylene, substituted arylene, heteroarylene,
substituted heteroarylene, alkarylene, substituted alkarylene,
aralkylene, and substituted aralkylene; and [0017] any R.sub.1 and
R.sub.5 taken together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0018] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0019] In further or alternative embodiments, Q.sub.1 is selected
from the group consisting of H, halogen, and an optionally
substituted moiety selected from -L-alkyl, -L-cycloalkyl,
-L-heteroalkyl, -L-haloalkyl, -L-aryl, -L-heterocycloalkyl, and
-L-heteroaryl; wherein L is selected from a bond, --O--, --S--,
and, --C(O)O--; wherein said optional substituents are selected
from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, and
heteroaryl.
[0020] In further or alternative embodiments, Q.sub.1 is an
optionally substituted moiety selected from -L-alkyl,
-L-heteroalkyl, and -L-heterocycloalkyl; wherein L is selected from
a bond, --O--, --S--, and, --C(O)O--; wherein said optional
substituents are selected from halogen, OH, C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl,
haloaryl, and heteroaryl.
[0021] In further or alternative embodiments, Q.sub.1 is -L-R,
wherein R is a group comprising a tertiary amine and L is
optionally substituted and selected from a bond, --O--, --S--, and,
--C(O)O--;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl.
[0022] In further or alternative embodiments, Q.sub.2 is an
optionally substituted moiety selected from, -L.sub.6-cycloalkyl,
-L.sub.6-aromatic carbocycle, -L.sub.6-heterocycloalkyl, and
-L.sub.6-aromatic heterocycle; wherein L.sub.6 is selected from a
bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl.
[0023] In further or alternative embodiments, Q.sub.2 is selected
from the group consisting of an optionally substituted cycloalkyl,
optionally substituted aromatic carbocycle, optionally substituted
heterocycloalkyl, and optionally substituted aromatic heterocycle;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl.
[0024] In another aspect are compounds having the structure of
Formula (1) or Formula (46):
##STR00002##
[0025] wherein: [0026] Ar is a group comprising a moiety selected
from an optionally substituted five-membered aromatic heterocycle,
an optionally substituted five-membered aromatic carbocycle, an
optionally substituted six-membered aromatic heterocycle, and a
substituted, optionally further substituted six-membered aromatic
carbocycle; [0027] Q is a group comprising a non-aromatic tertiary
amine or a non-aromatic secondary amine, with the proviso that Q is
not --NR.sub.aR.sub.b or --SO.sub.2NR.sub.aR.sub.b; wherein each of
R.sub.a and R.sub.b is independently H or C.sub.1-6alkyl optionally
substituted by mono- or di-alkyl (C.sub.1-6) amino; [0028] each
R.sub.1 is independently selected from the group consisting of H,
halogen, and an optionally substituted moiety selected from
-L.sub.1-alkyl, -L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl,
-L.sub.1-haloalkyl, -L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and
-L.sub.1-heteroaryl; wherein L.sub.1 is selected from a bond,
--O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; [0029] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0030] or any
two adjacent R.sub.1 groups together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0031] R.sub.5 is selected from the group consisting of H, and an
optionally substituted moiety selected from -L.sub.5-H,
-L.sub.5-alkyl, -L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl,
-L.sub.5-haloalkyl, -L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and
-L.sub.5-heteroaryl; wherein L.sub.5 is selected from a bond,
--R'O--, --R'N(H)--, --R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--,
and --R'C(O)NH--; [0032] each R' is independently selected from the
group consisting of a bond, alkylene, substituted alkylene,
heteroalkylene, substituted heteroalkylene, alkenylene, substituted
alkenylene, cycloalkylene, substituted cycloalkylene,
heteroalkylene, substituted heteroalkylene, heterocycloalkylene,
substituted heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted
alkarylene, aralkylene, and substituted aralkylene; and [0033] any
R.sub.1 and R.sub.5 taken together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0034] or a pharmaceutically acceptable salt, pharmaceutically
acceptable N-oxide, pharmaceutically active metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable
solvate thereof.
[0035] In further or alternative embodiments are compounds having
the structure of Formula (1) or Formula (46):
##STR00003##
[0036] wherein: [0037] Ar is a group comprising a moiety selected
from an optionally substituted five-membered aromatic heterocycle,
an optionally substituted five-membered aromatic carbocycle, an
optionally substituted six-membered aromatic heterocycle, and a
substituted, optionally further substituted phenyl; [0038] Q is a
group comprising a non-aromatic tertiary amine or a non-aromatic
secondary amine, with the proviso that Q is not --NR.sub.aR.sub.b
or --SO.sub.2NR.sub.aR.sub.b; wherein each of R.sub.a and R.sub.b
is independently H or C.sub.1-6alkyl optionally substituted by
mono- or di-alkyl (C.sub.1-6) amino; [0039] each R.sub.1 is
independently selected from the group consisting of H, halogen, and
an optionally substituted moiety selected from -L.sub.1-alkyl,
-L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl, -L.sub.1-haloalkyl,
-L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and -L.sub.1-heteroaryl;
wherein L.sub.1 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; [0040] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0041] or any
two adjacent R.sub.1 groups together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0042] R.sub.5 is selected from the group consisting of hydrogen
and C.sub.1-6alkyl; or a pharmaceutically acceptable salt,
pharmaceutically acceptable N-oxide, pharmaceutically active
metabolite, pharmaceutically acceptable prodrug, or
pharmaceutically acceptable solvate thereof.
[0043] In further or alternative embodiments, the Ar is a group
comprising a substituted, optionally further substituted
six-membered aromatic heterocycle. In further or alternative
embodiments, said optional substituents are selected from halogen,
OH, halogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl.
[0044] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00004## ##STR00005## ##STR00006##
[0045] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) or Formula (46) is selected
from the group consisting of
##STR00007## ##STR00008## ##STR00009## ##STR00010## ##STR00011##
##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016##
##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021##
##STR00022## ##STR00023## ##STR00024## ##STR00025## ##STR00026##
##STR00027##
[0046] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00028## ##STR00029## ##STR00030## ##STR00031##
##STR00032##
[0047] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00033##
[0048] In further or alternative embodiments, the compound is
selected from the group consisting of: tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzamido)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzylamino)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzylamino-
)acetate,
2,2'-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl-
azanediyl)diethanol,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylic acid, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)a-
cetate, methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate,
N-(4-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-
-amine,
1-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl)pipe-
ridine-4-carboxylic acid,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine-
, tert-butyl
2-(4-(2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-5-yl)benzamido)aceta-
te, tert-butyl
2-(4-(2-(4-(2-(4-carbamoylpiperidin-1-yl)ethoxy)phenylamino)pyrimidin-5-y-
l)benzamido)acetate,
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)phenyl
acetate, ethyl
2-(2-(diethylamino)ethoxy)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate, 4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
5-(4-methoxyphenyl)-N-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)pyri-
midin-2-amine, methyl
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzoate,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(3-fluoro-4-methoxyphenyl)pyrimidi-
n-2-amine,
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)benzoic acid, methyl
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate,
N-(3-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-4-ca-
rboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine--
3-carboxamide, tert-butyl
3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propanoate,
5-(4-methoxyphenyl)-N-(4-(piperazin-1-ylmethyl)phenyl)pyrimidin-2-amine,
1-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)eth-
anone,
(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl-
)(tetrahydrofuran-2-yl)methanone,
1-(3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propyl)pyrrol-
idin-2-one,
(S)-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)-
methanol,
(R)--N-(4-((2-(methoxymethyl)pyrrolidin-1-yl)methyl)phenyl)-5-(4-
-methoxyphenyl)pyrimidin-2-amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-3-ol,
methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)cyclopent-
anecarboxylate,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)-2-methylpiperazine-1-
-carboxylic acid,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)pro-
panoic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-3-carboxyl-
ic acid, ethyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)ace-
tate,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-y-
l)acetic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidine-3-carboxy-
lic acid, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
morpholine-4-carboxylate,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
3-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino-
)phenyl 4-methylpiperazine-1-carboxylate, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazine-1-carboxyl-
ate,
4-(5-(4-((2-tert-butoxy-2-oxoethylamino)methylphenyl)pyrimidin-2-ylam-
ino)phenyl 4-methylpiperazine-1-carboxylate,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin-
-1-yl)ethanone,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1,4-dicarb-
oxamide, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate,
4-hydroxy-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine--
1-carboxamide,
N-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xamide,
furan-2-yl(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)-
piperazin-1-yl)methanone,
5-(4-methoxyphenyl)-N-(4-(2-(piperazin-1-yl)ethyl)phenyl)pyrimidin-2-amin-
e,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-N,4-dimethylpipera-
zine-1-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carbo-
xamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazine-1-carbo-
xylate,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetic acid, methyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetate,
(3-(hydroxymethyl)piperidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-
-2-ylamino)phenyl)methanone,
(3-hydroxypyrrolidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phen-
yl)methanone,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-4-carboxa-
mide,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin--
1-yl)propanoic acid,
(S)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)pyrrolidine-2--
carboxylic acid,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethylamino)cyclohexaneca-
rboxylic acid,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(3-(2-oxopyrrolidin-1-yl)pro-
pyl)benzamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxa-
mide,
N-(3-carbamoylphenyl)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
amide,
1,4'-bipiperidin-1'-yl(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)ph-
enyl)methanone,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)pip-
eridin-1-yl)methanone,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(2-(pyridin-2-yl)ethyl)benza-
mide,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyr-
azol-4-yl)benzamide,
(4-(furan-2-carbonyl)piperazin-1-yl)(3-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)phenyl)methanone,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol--
4-yl)benzamide,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(1-methylpiperidin-4-
-yl)piperazin-1-yl)methanone,
1-(4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperazin-1-yl)et-
hanone,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-
-yl)piperidin-1-yl)methanone,
1,4'-bipiperidin-1'-yl(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)m-
ethanone,
1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine--
3-carboxamide,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-(1-methylpiperidin-
-4-yl)piperazine-1-carboxamide, methyl
4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenylcarbamoyl)piperazine-1-
-carboxylate,
(R)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-c-
arboxylic acid,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne,
4-acetyl-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperazin-
e-1-carboxamide, and
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne.
[0049] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00034##
[0050] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00035##
wherein R.sub.A is selected from --NH.sub.2, --NEt.sub.2, and
--NH(CH.sub.2).sub.nOH; and n is 1 to 6.
[0051] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00036##
wherein R.sub.B is selected from the group consisting of
##STR00037##
[0052] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00038##
wherein R.sub.C is at 2, 3, or 4 position of the piperidine ring;
and R.sub.C is selected from the group consisting of --C(O)NHEt,
--C(O)NEt.sub.2, c-butyl, c-pentyl, --C(O)NH-thiazole, oxazole,
thiazole, --S(O).sub.2NH.sub.2, --S(O).sub.2NHEt, and
--S(O).sub.2NEt.sub.2.
[0053] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00039##
wherein each R.sub.D is independently selected from
--(CH.sub.2).sub.kOH or --(CH.sub.2).sub.kCO.sub.2H; and k is 1 to
6.
[0054] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00040##
wherein R.sub.E is at 2, 3, or 4 position of the piperidine ring;
and R.sub.E is selected from the group consisting of
--C(O)NH.sub.2, --C(O)NHEt, and --C(O)NEt.sub.2.
[0055] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00041##
wherein R.sub.F is thiazole, pyrazole, or isoxazole.
[0056] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048##
[0057] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00049##
[0058] In further or alternative embodiments, R.sub.5 is H. In
further or alternative embodiments, each R.sub.1 is H. In further
or alternative embodiments, each R.sub.1 is H and R.sub.5 is H. In
further or alternative embodiments, Q is a group comprising a
non-aromatic tertiary amine.
[0059] In a further or alternative embodiment of this aspect,
compounds having the structure of Formula (1) are selected from
Formula (2), Formula (3), or Formula (44):
##STR00050##
[0060] wherein: [0061] M is selected from the group consisting of
H, OH, SH, NO.sub.2, CN, NR''.sub.2, and an optionally substituted
moiety selected from -L.sub.7-alkyl, -L.sub.7-cycloalkyl,
-L.sub.7-heteroalkyl, -L.sub.7-haloalkyl, -L.sub.7-aryl,
-L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl; wherein L.sub.7
is selected from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--, --OC(O)--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR''Y.sup.1C(O)O--, and
--C(O)NR''O--; W is C.sub.1-6alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (2);
[0062] each R'' is independently H, OH, halogen, C.sub.1-6alkyl,
substituted C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0063] each X
is independently selected from N or CR.sub.2, provided that at
least one but no more than 2 X groups are N; [0064] each R.sub.2 is
independently selected from the group consisting of H, OH, halogen,
and an optionally substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl
and halo-C.sub.1-6alkoxy; [0065] or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; [0066] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0067] In further or alternative embodiments, L.sub.7 is selected
from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --OC(O)--,
--CH.sub.2NHCH.sub.2C(O)O--, --CH.sub.2NH(CH.sub.2).sub.2O--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--. In further or alternative embodiments, L.sub.2 is
selected from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--. In further or alternative
embodiments, each R.sub.1 is H. In further or alternative
embodiments, each R.sub.2 is H. In further or alternative
embodiments, R.sub.5 is H. In further or alternative embodiments,
each R.sub.1 is H, each R.sub.2 is H, and R.sub.5 is H.
[0068] In a further or alternative embodiment of this aspect,
compounds having the structure of Formula (46) are selected from
Formula (47), Formula (48), or Formula (49):
##STR00051##
[0069] wherein: [0070] M is selected from the group consisting of
H, OH, SH, NO.sub.2, CN, NR''.sub.2, and an optionally substituted
moiety selected from -L.sub.7-alkyl, -L.sub.7-cycloalkyl,
-L.sub.7-heteroalkyl, -L.sub.7-haloalkyl, -L.sub.7-aryl,
-L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl; wherein L.sub.7
is selected from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--, --OC(O)--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR''Y.sup.1C(O)O--, and
--C(O)NR''O--; W is C.sub.1-6alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (47);
[0071] each R'' is independently H, OH, halogen, C.sub.1-6alkyl,
substituted C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0072] each X
is independently selected from N or CR.sub.2, provided that at
least one but no more than 2 X groups are N; [0073] each R.sub.2 is
independently selected from the group consisting of H, OH, halogen,
and an optionally substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl
and halo-C.sub.1-6alkoxy; [0074] or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; or a pharmaceutically
acceptable salt, pharmaceutically acceptable N-oxide,
pharmaceutically active metabolite, pharmaceutically acceptable
prodrug, or pharmaceutically acceptable solvate thereof.
[0075] In further or alternative embodiments, L.sub.7 is selected
from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --OC(O)--,
--CH.sub.2NHCH.sub.2C(O)O--, --CH.sub.2NH(CH.sub.2).sub.2O--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--. In further or alternative embodiments, L.sub.2 is
selected from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR'').sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--. In further or alternative
embodiments, each R.sub.1 is H. In further or alternative
embodiments, each R.sub.2 is H. In further or alternative
embodiments, R.sub.5 is H. In further or alternative embodiments,
each R.sub.1 is H, each R.sub.2 is H, and R.sub.5 is H.
[0076] In a further or alternative embodiment of this aspect, are
compounds having the structure of Formula (1) or Formula (46) in
which the Ar group is a 5-membered carbocyclic bearing up to four
substituents. In further or alternative embodiments, compounds
having the structure of Formula (1) are selected from Formula (4),
Formula (5), or Formula (6):
##STR00052##
[0077] wherein: [0078] each R.sub.2 is independently selected from
the group consisting of H, OH, halogen, and an optionally
substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl
and halo-C.sub.1-6alkoxy; [0079] each R'' is independently H, OH,
halogen, C.sub.1-6alkyl, substituted C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl,
haloaryl, or heteroaryl; [0080] or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 7-membered
heterocyclic, cycloalkyl, or aryl ring; [0081] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0082] In further or alternative embodiments, L.sub.2 is selected
from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--. In further or alternative
embodiments, each R.sub.1 is H. In further or alternative
embodiments, R.sub.5 is H. In further or alternative embodiments,
each R.sub.1 is H and R.sub.5 is H. In further or alternative
embodiments of Formulas (4), (5), or (6), Q is at the meta position
corresponding to Formula (46).
[0083] In a further or alternative embodiment of this aspect,
compounds having the structure of Formula (1) are selected from the
group consisting of:
##STR00053## ##STR00054## ##STR00055##
[0084] wherein; [0085] each R.sub.2 is independently selected from
the group consisting of H, OH, halogen, and an optionally
substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR'''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl
and halo-C.sub.1-6alkoxy; [0086] each R'' is independently H, OH,
halogen, C.sub.1-6alkyl, substituted C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl,
haloaryl, or heteroaryl; [0087] or any two adjacent R.sub.2 groups
together may form an optionally substituted 6 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; [0088] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0089] In further or alternative embodiments, L.sub.2 is selected
from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--. In further or alternative
embodiments, each R.sub.1 is H. In further or alternative
embodiments, R.sub.5 is H. In further or alternative embodiments,
each R.sub.1 is H and R.sub.5 is H. In further or alternative
embodiments of Formulas (7)-(22), or (53), Q is at the meta
position corresponding to Formula (46).
[0090] In further or alternative embodiments of this aspect, Q is
selected from the group consisting of
##STR00056## ##STR00057## ##STR00058## ##STR00059## ##STR00060##
##STR00061## ##STR00062## ##STR00063## ##STR00064## ##STR00065##
##STR00066## ##STR00067## ##STR00068## ##STR00069## ##STR00070##
##STR00071## ##STR00072## ##STR00073## ##STR00074## ##STR00075##
##STR00076##
[0091] In further or alternative embodiments of this aspect, Q is
selected from the group consisting of
##STR00077##
[0092] In further or alternative embodiments of this aspect, Q is
selected from the group consisting of
##STR00078##
wherein R.sub.A is selected from --NH.sub.2, --NEt.sub.2, and
--NH(CH.sub.2).sub.nOH; and n is 1 to 6.
[0093] In further or alternative embodiments of this aspect, Q
is
##STR00079##
wherein R.sub.B is selected from the group consisting of
##STR00080##
--CH.sub.2OH, --CH.sub.2CH.sub.2OH, and
--CH.sub.2CH.sub.2CH.sub.2OH.
[0094] In further or alternative embodiments of this aspect, Q
is
##STR00081##
wherein R.sub.C is at 2, 3, or 4 position of the piperidine ring;
and R.sub.C is selected from the group consisting of --C(O)NHEt,
--C(O)NEt.sub.2, c-butyl, c-pentyl, --C(O)NH-thiazole, oxazole,
thiazole, --S(O).sub.2NH.sub.2, --S(O).sub.2NHEt, and
--S(O).sub.2NEt.sub.2.
[0095] In further or alternative embodiments of this aspect, Q is
selected from the group consisting of
##STR00082##
wherein each R.sub.D is independently selected from
--(CH.sub.2).sub.kOH or --(CH.sub.2).sub.kCO.sub.2H; and k is 1 to
6.
[0096] In further or alternative embodiments of this aspect, Q
is
##STR00083##
wherein R.sub.E is at 2, 3, or 4 position of the piperidine ring;
and R.sub.E is selected from the group consisting of
--C(O)NH.sub.2, --C(O)NBEt, and --C(O)NEt.sub.2.
[0097] In further or alternative embodiments of this aspect, Q is
selected from the group consisting of
##STR00084##
wherein R.sub.F is thiazole, pyrazole, or isoxazole.
[0098] In further or alternative embodiments of this aspect, Q is
selected from the group consisting of
##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089##
##STR00090## ##STR00091##
[0099] In further or alternative embodiments of this aspect, Q is
selected from the group consisting of
##STR00092##
[0100] In further or alternative embodiments, R.sub.5 is H. In
further or alternative embodiments, each R.sub.1 is H. In further
or alternative embodiments, each R.sub.1 is H and R.sub.5 is H. In
further or alternative embodiments, Q is a group comprising a
non-aromatic tertiary amine.
[0101] In a further or alternative embodiment of this aspect,
compounds having the structure of Formula (1) are selected from
Formula (23), Formula (24), or Formula (45):
##STR00093##
[0102] wherein: [0103] M is selected from the group consisting of
H, OH, SH, NO.sub.2, CN, NR''.sub.2, and an optionally substituted
moiety selected from -L.sub.7-alkyl, -L.sub.7-cycloalkyl,
-L.sub.7-heteroalkyl, -L.sub.7-haloalkyl, -L.sub.7-aryl,
-L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl; wherein L.sub.7
is selected from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--, --OC(O)--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR''Y.sup.1C(O)O--, and
--C(O)NR''O--; W is C.sub.1-6alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (23);
[0104] each R'' is independently H, OH, halogen, C.sub.1-6alkyl,
substituted C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0105] each X
is independently selected from N or CR.sub.2, provided that at
least one but no more than 2 X groups are N; [0106] each R.sub.2 is
independently selected from the group consisting of H, OH, halogen,
and an optionally substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
and halo-C.sub.1-6alkoxy; [0107] or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; [0108] each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -Z, -L.sub.3-Z, -L.sub.3-H, -L.sub.3-alkyl,
-L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl, -L.sub.3-haloalkyl,
-L.sub.3-aryl, -L.sub.3-heterocycloalkyl, and -L.sub.3-heteroaryl;
wherein L.sub.3 is selected from a bond, --C(S)--, --C(O)O--,
--C(O)NR'''--, --(CR''.sub.2).sub.1-6--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, --CR'''.sub.2S(O)NR'''--,
--CR'''.sub.2C(O)NR'''--, --(CR'''.sub.2).sub.1-6NR'''--,
--(CR'''.sub.2).sub.1-6O--, --(CR'''.sub.2).sub.1-6C(O)O--,
--Y.sup.2C(O)O--, and an optionally substituted C.sub.1-6alkylene;
[0109] wherein said optional substituents are selected from
halogen, --OH, .dbd.O, --Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halogen or OH substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--C(O)NR'''.sub.2, --C(O)R.sub.6, or --C(O)OR.sub.6; [0110] Y.sup.2
is an optionally substituted cycloalkyl ring or optionally
substituted non-aromatic heterocyclic ring; [0111] wherein said
optional substituents are selected from C.sub.1-6alkyl, halogen,
--OH, .dbd.O, and --CN. [0112] Y.sup.3 is optionally substituted
aryl, optionally substituted heteroaryl, optionally substituted
cycloalkyl, or optionally substituted non-aromatic heterocycle;
[0113] wherein said optional substituents are selected from
C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN. [0114] Z is --H,
--OH, --CN, --COOR''', --NR'''.sub.2, or --C.ident.CR'''; [0115]
each R''' is independently H, alkyl, or substituted alkyl; [0116]
or two R''' together may form a 3-6 membered cycloalkyl or
heterocyclic ring; [0117] or R.sub.3 and R.sub.4 taken together
with the N atom to which they are attached may form an optionally
substituted 3 to 8-membered heterocyclic ring; [0118] wherein said
optional substituents are selected from halogen, --OH, .dbd.O,
--Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen or OH
substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6Y.sup.4,
--(CR'''.sub.2).sub.1-6OR.sub.6, --C(O)NR'''R.sub.6,
--C(O)OR.sub.6, --OR.sub.6, --NR'''C(O)OR.sub.6,
--NR'''C(O)R.sub.6, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR'''C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR.sub.7R.sub.8, --S(O).sub.2NR'''.sub.2,
--C(O)R.sub.6, --OC(O)R.sub.6, --NR.sub.7R.sub.9,
--(CR'''.sub.2).sub.1-6C(O)NR.sub.7R.sub.8, --S(O).sub.2R.sub.A, or
--C(O)R.sub.A; [0119] Y.sup.4 is aryl, heteroaryl, cycloalkyl, or
non-aromatic heterocycle; [0120] R.sub.A is selected from
--NH.sub.2, --NEt.sub.2, and --NH(CH.sub.2).sub.1-6OH; [0121]
R.sub.6 is H, alkyl, substituted alkyl, cycloalkyl, non-aromatic
heterocycle, aryl, or heteroaryl; [0122] each of R.sub.7 and
R.sub.8 is independently H, OH, halogen, C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, or halo-C.sub.1-6alkoxy;
[0123] or R.sub.7 and R.sub.8 taken together with the N atom to
which they are attached may form a 3 to 6-membered heterocyclic
ring; [0124] T.sub.1 is an optionally substituted moiety selected
from -L.sub.4-, -alkylene-L.sub.4-, -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --NR'''C(O)--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NR'''--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR'''(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6C(O)--,
--CR''.sub.2NR'''CR''.sub.2C(O)O--, --C(O)NR'''NR'''C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6--, --CR''.sub.2C(O)--, and
--S(O)NH--; [0125] wherein said optional substituents are selected
from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, and
heteroaryl; [0126] or a pharmaceutically acceptable salt,
pharmaceutically acceptable N-oxide, pharmaceutically active
metabolite, pharmaceutically acceptable prodrug, or
pharmaceutically acceptable solvate thereof.
[0127] In further or alternative embodiments, L.sub.7 is selected
from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --OC(O)--,
--CH.sub.2NHCH.sub.2C(O)O--, --CH.sub.2NH(CH.sub.2).sub.2O--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--. In further or alternative embodiments, L.sub.2 is
selected from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--.
[0128] In further or alternative embodiments, each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -L.sub.3-alkyl, -L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl,
-L.sub.3-haloalkyl, -L.sub.3-aryl, -L.sub.3-heterocycloalkyl, and
-L.sub.3-heteroaryl; [0129] wherein L.sub.3 is selected from a
bond, --C(S)--, --C(O)O--, --C(O)NH--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, and --CR'''.sub.2S(O)NH--; wherein said
optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl; [0130] or
R.sub.3 and R.sub.4 together may form an optionally substituted 3
to 8-membered heterocyclic ring; wherein said optional substituents
are selected from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl,
heteroaryl.
[0131] In further or alternative embodiments, T.sub.1 is an
optionally substituted moiety selected from -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--.
[0132] In further or alternative embodiments, each R.sub.1 is H. In
further or alternative embodiments, each R.sub.2 is H. In further
or alternative embodiments, R.sub.5 is H. In further or alternative
embodiments, each R.sub.1 is H, each R.sub.2 is H, and R.sub.5 is
H.
[0133] In a further or alternative embodiment of this aspect,
compounds having the structure of Formula (46) are selected from
Formula (50), Formula (51), or Formula (52):
##STR00094##
[0134] wherein: [0135] M is selected from the group consisting of
H, OH, SH, NO.sub.2, CN, NR''.sub.2, and an optionally substituted
moiety selected from -L.sub.7-alkyl, -L.sub.7-cycloalkyl,
-L.sub.7-heteroalkyl, -L.sub.7-haloalkyl, -L.sub.7-aryl,
-L.sub.7-heterocycloalkyl, and -L.sub.7-heteroaryl; wherein L.sub.7
is selected from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--, --OC(O)--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''Y.sup.1C(O)O--,
--C(O)NR''NR''C(O)O--, --S(O)NH--, --C(O)NR''CR''.sub.2C(O)W--,
--CR''.sub.2NR''WO--, --CR''.sub.2NR'Y.sup.1C(O)O--, and
--C(O)NR''O--; W is C.sub.1-6alkylene; Y.sup.1 is optionally
substituted arylene or optionally substituted heteroarylene;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl and
halo-C.sub.1-6alkoxy; provided that M is not H in Formula (50);
[0136] each R'' is independently H, OH, halogen, C.sub.1-6alkyl,
substituted C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0137] each X
is independently selected from N or CR.sub.2, provided that at
least one but no more than 2 X groups are N; [0138] each R.sub.2 is
independently selected from the group consisting of H, OH, halogen,
and an optionally substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR'''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
and halo-C.sub.1-6alkoxy; [0139] or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; [0140] each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -Z, -L.sub.3-Z, -L.sub.3-H, -L.sub.3-alkyl,
-L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl, -L.sub.3-haloalkyl,
-L.sub.3-aryl, -L.sub.1-heterocycloalkyl, and -L.sub.3-heteroaryl;
wherein L.sub.3 is selected from a bond, --C(S)--, --C(O)O--,
--C(O)NR'''--, --(CR''.sub.2).sub.1-6--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, --CR'''.sub.2S(O)NR'''--,
--CR'''.sub.2C(O)NR'''--, --(CR'''.sub.2).sub.1-6NR'''--,
--(CR'''.sub.2).sub.1-6O--, --(CR'''.sub.2).sub.1-6C(O)O--,
--Y.sup.2C(O)O--, and an optionally substituted C.sub.1-6alkylene;
[0141] wherein said optional substituents are selected from
halogen, --OH, .dbd.O, --Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halogen or OH substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--C(O)NR'''.sub.2, --C(O)R.sub.6, or --C(O)OR.sub.6; [0142] Y.sup.2
is an optionally substituted cycloalkyl ring or optionally
substituted non-aromatic heterocyclic ring; [0143] wherein said
optional substituents are selected from C.sub.1-6alkyl, halogen,
--OH, .dbd.O, and --CN. [0144] Y.sup.3 is optionally substituted
aryl, optionally substituted heteroaryl, optionally substituted
cycloalkyl, or optionally substituted non-aromatic heterocycle;
[0145] wherein said optional substituents are selected from
C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN. [0146] Z is --H,
--OH, --CN, --COOR''', --NR'''.sub.2, or --C.ident.CR'''; [0147]
each R''' is independently H, alkyl, or substituted alkyl; [0148]
or two R''' together may form a 3-6 membered cycloalkyl or
heterocyclic ring; [0149] or R.sub.3 and R.sub.4 taken together
with the N atom to which they are attached may form an optionally
substituted 3 to 8-membered heterocyclic ring; [0150] wherein said
optional substituents are selected from halogen, --OH, .dbd.O,
--Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen or OH
substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6Y.sup.4,
--(CR'''.sub.2).sub.1-6OR.sub.6, --C(O)NR'''R.sub.6,
--C(O)OR.sub.6, --OR.sub.6, --NR'''C(O)OR.sub.6,
--NR'''C(O)R.sub.6, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR'''C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR.sub.7R.sub.8, --S(O).sub.2NR'''.sub.2,
--C(O)R.sub.6, --OC(O)R.sub.6, --NR.sub.7R.sub.8,
--(CR'''.sub.2).sub.1-6C(O)NR.sub.7R.sub.8, --S(O).sub.2R.sub.A, or
--C(O)R.sub.A; [0151] Y.sup.4 is aryl, heteroaryl, cycloalkyl, or
non-aromatic heterocycle; [0152] R.sub.A is selected from
--NH.sub.2, --NEt.sub.2, and --NH(CH.sub.2).sub.1-6OH; [0153]
R.sub.6 is H, alkyl, substituted alkyl, cycloalkyl, non-aromatic
heterocycle, aryl, or heteroaryl; [0154] each of R.sub.7 and
R.sub.8 is independently H, OH, halogen, C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, or halo-C.sub.1-6alkoxy;
[0155] or R.sub.7 and R.sub.8 taken together with the N atom to
which they are attached may form a 3 to 6-membered heterocyclic
ring; [0156] T.sub.1 is an optionally substituted moiety selected
from -L.sub.4-, -alkylene-L.sub.4-, -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --NR'''C(O)--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NR'''--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR'''(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6C(O)--,
--CR''.sub.2NR'''CR''.sub.2C(O)O--, --C(O)NR'''NR'''C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6--, --CR''.sub.2C(O)--, and
--S(O)NH--; [0157] wherein said optional substituents are selected
from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, and
heteroaryl; or a pharmaceutically acceptable salt, pharmaceutically
acceptable N-oxide, pharmaceutically active metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable
solvate thereof.
[0158] In further or alternative embodiments, L.sub.7 is selected
from a bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --OC(O)--,
--CH.sub.2NHCH.sub.2C(O)O--, --CH.sub.2NH(CH.sub.2).sub.2O--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--. In further or alternative embodiments, L.sub.2 is
selected from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--.
[0159] In further or alternative embodiments, each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -L.sub.3-alkyl, -L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl,
-L.sub.3-haloalkyl, -L.sub.3-aryl, -L.sub.3-heterocycloalkyl, and
-L.sub.3-heteroaryl; [0160] wherein L.sub.3 is selected from a
bond, --C(S)--, --C(O)O--, --C(O)NH--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, and --CR'''.sub.2S(O)NH--; wherein said
optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl; [0161] or
R.sub.3 and R.sub.4 together may form an optionally substituted 3
to 8-membered heterocyclic ring; wherein said optional substituents
are selected from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl,
heteroaryl.
[0162] In further or alternative embodiments, T.sub.1 is an
optionally substituted moiety selected from -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--.
[0163] In further or alternative embodiments, each R.sub.1 is H. In
further or alternative embodiments, each R.sub.2 is H. In further
or alternative embodiments, R.sub.5 is H. In further or alternative
embodiments, each R.sub.1 is H, each R.sub.2 is H, and R.sub.5 is
H.
[0164] In a further or alternative embodiment of this aspect,
compounds having the structure of Formula (1) are selected from
Formula (25), Formula (26), or Formula (27):
##STR00095##
[0165] wherein; [0166] each R.sub.2 is independently selected from
the group consisting of H, OH, halogen, and an optionally
substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl
and halo-C.sub.1-6alkoxy; [0167] each R'' is independently H, OH,
halogen, C.sub.1-6alkyl, substituted C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl,
haloaryl, or heteroaryl; [0168] or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; [0169] each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -Z, -L.sub.3-Z, -L.sub.3-H, -L.sub.3-alkyl,
-L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl, -L.sub.3-haloalkyl,
-L.sub.3-aryl, -L.sub.3-heterocycloalkyl, and -L.sub.3-heteroaryl;
wherein L.sub.3 is selected from a bond, --C(S)--, --C(O)O--,
--C(O)NR'''--, --CR'''.sub.2S(O)--, --CR'''.sub.2S(O).sub.2--,
--CR'''.sub.2S(O)NR'''--, --CR'''.sub.2C(O)NR'''--,
--(CR'''.sub.2).sub.1-6NR'''--, --(CR'''.sub.2).sub.1-6O--,
--(CR'''.sub.2).sub.1-6C(O)O--, --Y.sup.2C(O)O--, and an optionally
substituted C.sub.1-6alkylene; [0170] wherein said optional
substituents are selected from halogen, --OH, .dbd.O, --Y.sup.3,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen or OH substituted
C.sub.1-6alkyl, halogen or OH substituted C.sub.1-6alkoxy,
--(CR'''.sub.2).sub.1-6C(O)OR.sub.6, --C(O)NR'''.sub.2,
--C(O)R.sub.6, or --C(O)OR.sub.6;
[0171] In further or alternative embodiments, L.sub.2 is selected
from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--.
[0172] In further or alternative embodiments, each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -L.sub.3-alkyl, -L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl, -L
-haloalkyl, -L.sub.3-aryl, -L.sub.3-heterocycloalkyl, and
-L.sub.3-heteroaryl; [0173] wherein L.sub.3 is selected from a
bond, --C(S)--, --C(O)O--, --C(O)NH--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, and --CR'''.sub.2S(O)NH--; wherein said
optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl; [0174] or
R.sub.3 and R.sub.4 together may form an optionally substituted 3
to 8-membered heterocyclic ring; wherein said optional substituents
are selected from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl,
heteroaryl.
[0175] In further or alternative embodiments, T.sub.1 is an
optionally substituted moiety selected from -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--.
[0176] In further or alternative embodiments, each R.sub.1 is H. In
further or alternative embodiments, R.sub.5 is H. In further or
alternative embodiments, each R.sub.1 is H and R.sub.5 is H. In
further or alternative embodiments of Formulas (25), (26), or (27),
-T.sub.1NR.sub.3R.sub.4 is at the meta position corresponding to
Formula (46).
[0177] In a further or alternative embodiment of this aspect, the
compounds having the structure of Formula (1) are selected from the
group consisting of:
##STR00096## ##STR00097## ##STR00098##
[0178] wherein; [0179] each R.sub.2 is independently selected from
the group consisting of H, OH, halogen, and an optionally
substituted moiety selected from -L.sub.2-alkyl,
-L.sub.2-cycloalkyl, -L.sub.2-heteroalkyl, -L.sub.2-haloalkyl,
-L.sub.2-aryl, -L.sub.2-heterocycloalkyl, and -L.sub.2-heteroaryl;
wherein L.sub.2 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl
and halo-C.sub.1-6alkoxy; [0180] each R'' is independently H, OH,
halogen, C.sub.1-6alkyl, substituted C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl,
haloaryl, or heteroaryl; [0181] or any two adjacent R.sub.2 groups
together may form an optionally substituted 5 to 8-membered
heterocyclic, cycloalkyl, or aryl ring; [0182] each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -Z, -L.sub.3-Z, -L.sub.3-H, -L.sub.3-alkyl,
-L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl, -L.sub.3-haloalkyl,
-L.sub.3-aryl, -L.sub.3-heterocycloalkyl, and -L.sub.3-heteroaryl;
wherein L.sub.3 is selected from a bond, --C(S)--, --C(O)O--,
--C(O)NR'''--, --(CR''.sub.2).sub.1-6--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, --CR'''.sub.2S(O)NR'''--,
--CR'''.sub.2C(O)NR'''--, --(CR'''.sub.2).sub.1-6NR'''--,
--(CR'''.sub.2).sub.1-6O--, --(CR'''.sub.2).sub.1-6C(O)O--,
--Y.sup.2C(O)O--, and an optionally substituted C.sub.1-6alkylene;
[0183] wherein said optional substituents are selected from
halogen, --OH, .dbd.O, --Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halogen or OH substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--C(O)NR'''.sub.2, --C(O)R.sub.6, or --C(O)OR.sub.6; [0184] Y.sup.2
is an optionally substituted cycloalkyl ring or optionally
substituted non-aromatic heterocyclic ring; [0185] wherein said
optional substituents are selected from C.sub.1-6alkyl, halogen,
--OH, .dbd.O, and CN. [0186] Y.sup.3 is optionally substituted
aryl, optionally substituted heteroaryl, optionally substituted
cycloalkyl, or optionally substituted non-aromatic heterocycle;
[0187] wherein said optional substituents are selected from
C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN. [0188] Z is --H,
--OH, --CN, --COOR''', --NR'''.sub.2, or --C.ident.CR'''; [0189]
each R''' is independently H, alkyl, or substituted alkyl; [0190]
or two R''' together may form a 3-6 membered cycloalkyl or
heterocyclic ring; [0191] or R.sub.3 and R.sub.4 taken together
with the N atom to which they are attached may form an optionally
substituted 3 to 8-membered heterocyclic ring; [0192] wherein said
optional substituents are selected from halogen, --OH, .dbd.O,
--Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen or OH
substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6Y.sup.4,
--(CR'''.sub.2).sub.1-6OR.sub.6, --C(O)NR'''R.sub.6,
--C(O)OR.sub.6, --OR.sub.6, --NR'''C(O)OR.sub.6,
--NR'''C(O)R.sub.6, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR'''C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR.sub.7R.sub.8, --S(O).sub.2NR'''.sub.2,
--C(O)R.sub.6, --OC(O)R.sub.6, --NR.sub.7R.sub.8,
--(CR'''.sub.2).sub.1-6C(O)NR.sub.7R.sub.8, --S(O).sub.2R.sub.A, or
--C(O)R.sub.A; [0193] Y.sup.4 is aryl, heteroaryl, cycloalkyl, or
non-aromatic heterocycle; [0194] R.sub.A is selected from
--NH.sub.2, --NEt.sub.2, and --NH(CH.sub.2).sub.1-6OH; [0195]
R.sub.6 is H, alkyl, substituted alkyl, cycloalkyl, non-aromatic
heterocycle, aryl, or heteroaryl; [0196] each of R.sub.7 and
R.sub.8 is independently H, OH, halogen, C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, or halo-C.sub.1-6alkoxy;
[0197] or R.sub.7 and R.sub.8 taken together with the N atom to
which they are attached may form a 3 to 6-membered heterocyclic
ring; [0198] T.sub.1 is an optionally substituted moiety selected
from -L.sub.4-, -alkylene-L.sub.4-, -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --NR'''C(O)--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NR'''--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR'''(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6C(O)--,
--CR'''.sub.2NR'''CR'.sub.2C(O)O--, --C(O)NR'''NR'''C(O)O--,
--C(O)NR'''(CR'''.sub.2).sub.16--, --CR''.sub.2C(O)--, and
--S(O)NH--; [0199] wherein said optional substituents are selected
from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, and
heteroaryl; [0200] or a pharmaceutically acceptable salt,
pharmaceutically acceptable N-oxide, pharmaceutically active
metabolite, pharmaceutically acceptable prodrug, or
pharmaceutically acceptable solvate thereof.
[0201] In further or alternative embodiments, L.sub.2 is selected
from a bond, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.16C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--.
[0202] In further or alternative embodiments, each of R.sub.3 and
R.sub.4 is independently an optionally substituted moiety selected
from -L.sub.3-alkyl, -L.sub.3-cycloalkyl, -L.sub.3-heteroalkyl,
-L.sub.3-haloalkyl, -L.sub.3-aryl, -L.sub.3-heterocycloalkyl, and
-L.sub.3-heteroaryl; [0203] wherein L.sub.3 is selected from a
bond, --C(S)--, --C(O)O--, --C(O)NH--, --CR'''.sub.2S(O)--,
--CR'''.sub.2S(O).sub.2--, and --CR'''.sub.2S(O)NH--; wherein said
optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl; [0204] or
R.sub.3 and R.sub.4 together may form an optionally substituted 3
to 8-membered heterocyclic ring; wherein said optional substituents
are selected from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl,
heteroaryl.
[0205] In further or alternative embodiments, T.sub.1 is an
optionally substituted moiety selected from -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --C(O)--, --C(S)--,
--C(O)O--, --C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--.
[0206] In further or alternative embodiments, each R.sub.1 is H. In
further or alternative embodiments, R.sub.5 is H. In further or
alternative embodiments, each R.sub.1 is H and R.sub.5 is H. In
further or alternative embodiments of Formulas (28)-(43), or (54),
-T.sub.1NR.sub.3R.sub.4 is at the meta position corresponding to
Formula (46).
[0207] In another aspect is a method for modulating the activity of
a c-kit kinase receptor comprising contacting the c-kit kinase
receptor with a compound having the structure of Formula (A) or
Formula (B):
##STR00099##
[0208] wherein: [0209] Q.sub.1 is H, halogen, a group comprising a
non-aromatic tertiary amine, a group comprising a non-aromatic
secondary amine, or is an optionally substituted moiety selected
from the group consisting of: -L-alkyl, -L-cycloalkyl,
-L-heteroalkyl, -L-haloalkyl, -L-aryl, -L-heterocycloalkyl, and
-L-heteroaryl; wherein L is selected from a bond, --O--, --NH--,
--S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''YC(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y is optionally
substituted arylene or heteroarylene; [0210] each R.sub.1 is
independently selected from the group consisting of H, halogen, and
an optionally substituted moiety selected from -L.sub.1-alkyl,
-L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl, -L.sub.1-haloalkyl,
-L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and -L.sub.1-heteroaryl;
wherein L.sub.1 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y'C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y' is optionally
substituted arylene or heteroarylene; [0211] Q.sub.2 is selected
from the group consisting of H, halogen, and a group comprising an
optionally substituted moiety selected from -L.sub.6-alkyl,
-L.sub.6-cycloalkyl, -L.sub.6-heteroalkyl, -L.sub.6-haloalkyl,
-L.sub.6-aromatic carbocycle, -L.sub.6-heterocycloalkyl, and
-L.sub.6-aromatic heterocycle; wherein L.sub.6 is selected from a
bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y''C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y'' is optionally
substituted arylene or heteroarylene; [0212] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0213] any two
R.sub.1 groups together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0214] R.sub.5
is selected from the group consisting of H, and an optionally
substituted moiety selected from -L.sub.5-H, -L.sub.5-alkyl,
-L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl, -L.sub.5-haloalkyl,
-L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and -L.sub.5-heteroaryl,
wherein L.sub.5 is selected from a bond, --R'O--, --R'N(H)--,
--R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--, and --R'C(O)NH--;
[0215] each R' is independently selected from the group consisting
of a bond, alkylene, substituted alkylene, heteroalkylene,
substituted heteroalkylene, alkenylene, substituted alkenylene,
cycloalkylene, substituted cycloalkylene, heteroalkylene,
substituted heteroalkylene, heterocycloalkylene, substituted
heterocycloalkylene, arylene, substituted arylene, heteroarylene,
substituted heteroarylene, alkarylene, substituted alkarylene,
aralkylene, and substituted aralkylene; and [0216] any R.sub.1 and
R.sub.5 taken together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0217] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0218] In further or alternative embodiments, Q.sub.1 is selected
from the group consisting of H, halogen, and an optionally
substituted moiety selected from -L-alkyl, -L-cycloalkyl,
-L-heteroalkyl, -L-haloalkyl, -L-aryl, -L-heterocycloalkyl, and
-L-heteroaryl; wherein L is selected from a bond, --O--, --S--,
and, --C(O)O--; wherein said optional substituents are selected
from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, and
heteroaryl.
[0219] In further or alternative embodiments, Q.sub.1 is an
optionally substituted moiety selected from -L-alkyl,
-L-heteroalkyl, and -L-heterocycloalkyl; wherein L is selected from
a bond, --O--, --S--, and, --C(O)O--; wherein said optional
substituents are selected from halogen, OH, C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl,
haloaryl, and heteroaryl.
[0220] In further or alternative embodiments, Q.sub.1 is -L-R,
wherein R is a group comprising a tertiary amine and L is
optionally substituted and selected from a bond, --O--, --S--, and,
--C(O)O--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl.
[0221] In further or alternative embodiments, Q.sub.2 is an
optionally substituted moiety selected from, -L.sub.6-cycloalkyl,
-L.sub.6-aromatic carbocycle, -L.sub.6-heterocycloalkyl, and
-L.sub.6-aromatic heterocycle; wherein L.sub.6 is selected from a
bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NH(CR''.sub.2).sub.1-6C(O)O--, --C(O)NR''NR''C(O)O--, and
--S(O)NH--; wherein said optional substituents are selected from
halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl.
[0222] In further or alternative embodiments, Q.sub.2 is selected
from the group consisting of an optionally substituted cycloalkyl,
optionally substituted aromatic carbocycle, optionally substituted
heterocycloalkyl, and optionally substituted aromatic heterocycle;
wherein said optional substituents are selected from halogen, OH,
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, and heteroaryl.
[0223] In a further or alternative embodiment of this aspect, the
compound of Formula (A) or Formula (B) is a compound having the
structure of Formula (1) or Formula (46):
##STR00100##
[0224] wherein: [0225] Ar is a group comprising a moiety selected
from an optionally substituted five-membered aromatic heterocycle,
an optionally substituted five-membered aromatic carbocycle, an
optionally substituted six-membered aromatic heterocycle, and a
substituted, optionally further substituted six-membered aromatic
carbocycle; [0226] Q is a group comprising a non-aromatic tertiary
amine or a non-aromatic secondary amine, with the proviso that Q is
not --NR.sub.aR.sub.b or --SO.sub.2NR.sub.aR.sub.b; wherein each of
R.sub.a and R.sub.b is independently H or C.sub.1-6alkyl optionally
substituted by mono- or di-alkyl (C.sub.1-6) amino; [0227] each
R.sub.1 is independently selected from the group consisting of H,
halogen, and an optionally substituted moiety selected from
-L.sub.1-alkyl, -L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl,
-L.sub.1-haloalkyl, -L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and
-L.sub.1-heteroaryl; wherein L.sub.1 is selected from a bond, O--,
--NH--, --S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; [0228] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0229] or any
two adjacent R.sub.1 groups together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0230] R.sub.5 is selected from the group consisting of H, and an
optionally substituted moiety selected from -L.sub.5-H,
-L.sub.5-alkyl, -L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl,
-L.sub.5-haloalkyl, -L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and
-L.sub.5-heteroaryl; wherein L.sub.5 is selected from a bond,
--R'O--, --R'N(H)--, --R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--,
and --R'C(O)NH--; [0231] each R' is independently selected from the
group consisting of a bond, alkylene, substituted alkylene,
heteroalkylene, substituted heteroalkylene, alkenylene, substituted
alkenylene, cycloalkylene, substituted cycloalkylene,
heteroalkylene, substituted heteroalkylene, heterocycloalkylene,
substituted heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted
alkarylene, aralkylene, and substituted aralkylene; and [0232] any
R.sub.1 and R.sub.5 taken together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0233] or a pharmaceutically acceptable salt, pharmaceutically
acceptable N-oxide, pharmaceutically active metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable
solvate thereof.
[0234] In further or alternative embodiments, the compound of
Formula (A) or Formula (B), directly contacts the c-kit kinase
receptor. In further or alternative embodiments, the contacting
occurs in vitro. In further or alternative embodiments, the
contacting occurs in vivo.
[0235] In further or alternative embodiments, the Ar is a group
comprising a substituted, optionally further substituted
six-membered aromatic heterocycle. In further or alternative
embodiments, said optional substituents are selected from halogen,
OH, halogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl. In further or
alternative embodiments, the compound is the compound of any of
Formula (1) to Formula (54) in various embodiments described
above.
[0236] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00101## ##STR00102## ##STR00103## ##STR00104##
[0237] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00105## ##STR00106## ##STR00107## ##STR00108## ##STR00109##
##STR00110## ##STR00111## ##STR00112## ##STR00113## ##STR00114##
##STR00115## ##STR00116## ##STR00117## ##STR00118## ##STR00119##
##STR00120## ##STR00121## ##STR00122## ##STR00123## ##STR00124##
##STR00125## ##STR00126##
[0238] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00127## ##STR00128## ##STR00129## ##STR00130##
##STR00131##
[0239] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00132##
[0240] In further or alternative embodiments, the compound is
selected from the group consisting of: tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzamido)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzylamino)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-(5-yl)benzylamin-
o)acetate,
2,2'-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethy-
lazanediyl)diethanol,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylic acid, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)a-
cetate, methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate,
N-(4-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-
-amine,
1-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl)pipe-
ridine-4-carboxylic acid,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine-
, tert-butyl
2-(4-(2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-5-yl)benzamido)aceta-
te, tert-butyl
2-(4-(2-(4-(2-(4-carbamoylpiperidin-1-yl)ethoxy)phenylamino)pyrimidin-5-y-
l)benzamido)acetate,
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)phenyl
acetate, ethyl
2-(2-(diethylamino)ethoxy)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate, 4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
5-(4-methoxyphenyl)-N-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)pyri-
midin-2-amine, methyl
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzoate,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(3-fluoro-4-methoxyphenyl)pyrimidi-
n-2-amine,
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)benzoic acid, methyl
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate,
N-(3-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-4-ca-
rboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine--
3-carboxamide, tert-butyl
3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propanoate,
5-(4-methoxyphenyl)-N-(4-(piperazin-1-ylmethyl)phenyl)pyrimidin-2-amine,
1-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)eth-
anone,
(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl-
)(tetrahydrofuran-2-yl)methanone,
1-(3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propyl)pyrrol-
idin-2-one,
(S)-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)-
methanol,
(R)--N-(4-((2-(methoxymethyl)pyrrolidin-1-yl)methyl)phenyl)-5-(4-
-methoxyphenyl)pyrimidin-2-amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-3-ol,
methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)cyclopent-
anecarboxylate,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)-2-methylpiperazine-1-
-carboxylic acid,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)pro-
panoic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-3-carboxyl-
ic acid, ethyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)ace-
tate,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-y-
l)acetic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidine-3-carboxy-
lic acid, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
morpholine-4-carboxylate,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
3-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino-
)phenyl 4-methylpiperazine-1-carboxylate, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazine-1-carboxyl-
ate,
4-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-yla-
mino)phenyl 4-methylpiperazine-1-carboxylate,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin-
-1-yl)ethanone,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1,4-dicarb-
oxamide, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate,
4-hydroxy-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine--
1-carboxamide,
N-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xamide,
furan-2-yl(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)-
piperazin-1-yl)methanone,
5-(4-methoxyphenyl)-N-(4-(2-(piperazin-1-yl)ethyl)phenyl)pyrimidin-2-amin-
e,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-N,4-dimethylpipera-
zine-1-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carbo-
xamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazine-1-carbo-
xylate,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetic acid, methyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetate,
(3-(hydroxymethyl)piperidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-
-2-ylamino)phenyl)methanone,
(3-hydroxypyrrolidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phen-
yl)methanone,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-4-carboxa-
mide,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin--
1-yl)propanoic acid,
(S)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)pyrrolidine-2--
carboxylic acid,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethylamino)cyclohexaneca-
rboxylic acid,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(3-(2-oxopyrrolidin-1-yl)pro-
pyl)benzamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxa-
mide,
N-(3-carbamoylphenyl)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
amide,
1,4'-bipiperidin-1'-yl(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)ph-
enyl)methanone,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)pip-
eridin-1-yl)methanone,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(2-(pyridin-2-yl)ethyl)benza-
mide,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyr-
azol-4-yl)benzamide,
(4-(furan-2-carbonyl)piperazin-1-yl)(3-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)phenyl)methanone,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol--
4-yl)benzamide,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(1-methylpiperidin-4-
-yl)piperazin-1-yl)methanone,
1-(4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperazin-1-yl)et-
hanone,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-
-yl)piperidin-1-yl)methanone,
1,4'-bipiperidin-1'-yl(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)m-
ethanone,
1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine--
3-carboxamide,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-(1-methylpiperidin-
-4-yl)piperazine-1-carboxamide, methyl
4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenylcarbamoyl)piperazine-1-
-carboxylate,
(R)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-c-
arboxylic acid,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne,
4-acetyl-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperazin-
e-1-carboxamide, and
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne.
[0241] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00133##
[0242] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00134##
wherein R.sub.A is selected from --NH.sub.2, --NEt.sub.2, and
--NH(CH.sub.2).sub.nOH; and n is 1 to 6.
[0243] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00135##
wherein R.sub.B is selected from the group consisting of
##STR00136##
[0244] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00137##
wherein R.sub.C is at 2, 3, or 4 position of the piperidine ring;
and R.sub.C is selected from the group consisting of --C(O)NHEt,
--C(O)NEt.sub.2, c-butyl, c-pentyl, --C(O)NH-thiazole, oxazole,
thiazole, --S(O).sub.2NH.sub.2, --S(O).sub.2NHEt, and
--S(O).sub.2NEt.sub.2.
[0245] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00138##
wherein each R.sub.D is independently selected from
--(CH.sub.2).sub.kOH or --(CH.sub.2).sub.kCO.sub.2H; and k is 1 to
6.
[0246] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00139##
wherein R.sub.E is at 2, 3, or 4 position of the piperidine ring;
and R.sub.E is selected from the group consisting of
--C(O)NH.sub.2, --C(O)NHEt, and --C(O)NEt.sub.2.
[0247] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00140##
wherein R.sub.F is thiazole, pyrazole, or isoxazole.
[0248] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00141## ##STR00142## ##STR00143## ##STR00144## ##STR00145##
##STR00146##
[0249] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00147##
[0250] In another aspect is pharmaceutical compositions comprising
at least one compound having the structure of Formula (1) or
Formula (46):
##STR00148##
[0251] wherein: [0252] Ar is a group comprising a moiety selected
from an optionally substituted five-membered aromatic heterocycle,
an optionally substituted five-membered aromatic carbocycle, an
optionally substituted six-membered aromatic heterocycle, and a
substituted, optionally further substituted six-membered aromatic
carbocycle; [0253] Q is a group comprising a non-aromatic tertiary
amine or a non-aromatic secondary amine, with the proviso that Q is
not --NR.sub.aR.sub.b or --SO.sub.2NR.sub.aR.sub.b; wherein each of
R.sub.a and R.sub.b is independently H or C.sub.1-6alkyl optionally
substituted by mono- or di-alkyl (C.sub.1-6) amino; [0254] each
R.sub.1 is independently selected from the group consisting of H,
halogen, and an optionally substituted moiety selected from
-L.sub.1-alkyl, -L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl,
-L.sub.1-haloalkyl, -L.sub.1-aryl, -L.sub.3-heterocycloalkyl, and
-L.sub.1-heteroaryl; wherein L.sub.1 is selected from a bond,
--O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; [0255] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0256] or any
two adjacent R.sub.1 groups together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0257] R.sub.5 is selected from the group consisting of H, and an
optionally substituted moiety selected from -L.sub.5-H,
-L.sub.5-alkyl, -L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl,
-L.sub.5-haloalkyl, -L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and
-L.sub.5-heteroaryl; wherein L.sub.5 is selected from a bond,
--R'O--, --R'N(H)--, --R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--,
and --R'C(O)NH--; [0258] each R' is independently selected from the
group consisting of a bond, alkylene, substituted alkylene,
heteroalkylene, substituted heteroalkylene, alkenylene, substituted
alkenylene, cycloalkylene, substituted cycloalkylene,
heteroalkylene, substituted heteroalkylene, heterocycloalkylene,
substituted heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted
alkarylene, aralkylene, and substituted aralkylene; and [0259] any
R.sub.1 and R.sub.5 taken together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0260] or a pharmaceutically acceptable salt, pharmaceutically
acceptable N-oxide, pharmaceutically active metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable
solvate thereof, in admixture with one or more suitable
excipients.
[0261] In further or alternative embodiments, the one or more
excipients are suitable for parenteral administration. In further
or alternative embodiments, the one or more excipients are suitable
for oral administration.
[0262] In further or alternative embodiments, the Ar is a group
comprising a substituted, optionally further substituted
six-membered aromatic heterocycle. In further or alternative
embodiments, said optional substituents are selected from halogen,
OH, halogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl. In further or
alternative embodiments, the compound is the compound of any of
Formula (1) to Formula (54) in various embodiments described
above.
[0263] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00149## ##STR00150## ##STR00151## ##STR00152##
[0264] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157##
##STR00158## ##STR00159## ##STR00160## ##STR00161## ##STR00162##
##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167##
##STR00168## ##STR00169## ##STR00170## ##STR00171## ##STR00172##
##STR00173## ##STR00174##
[0265] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00175## ##STR00176## ##STR00177## ##STR00178##
##STR00179##
[0266] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00180##
[0267] In further or alternative embodiments, the compound is
selected from the group consisting of: tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzamido)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzylamino)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzylamino-
)acetate,
2,2'-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl-
azanediyl)diethanol,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylic acid, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)a-
cetate, methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate,
N-(4-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-
-amine,
1-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl)pipe-
ridine-4-carboxylic acid,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine-
, tert-butyl
2-(4-(2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-5-yl)benzamido)aceta-
te, tert-butyl
2-(4-(2-(4-(2-(4-carbamoylpiperidin-1-yl)ethoxy)phenylamino)pyrimidin-5-y-
l)benzamido)acetate,
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)phenyl
acetate, ethyl
2-(2-(diethylamino)ethoxy)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate, 4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
5-(4-methoxyphenyl)-N-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)pyri-
midin-2-amine, methyl
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzoate,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(3-fluoro-4-methoxyphenyl)pyrimidi-
n-2-amine,
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)benzoic acid, methyl
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate,
N-(3-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
anine,
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-4-ca-
rboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine--
3-carboxamide, tert-butyl
3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propanoate,
5-(4-methoxyphenyl)-N-(4-(piperazin-1-ylmethyl)phenyl)pyrimidin-2-amine,
1-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)eth-
anone,
(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl-
)(tetrahydrofuran-2-yl)methanone,
1-(3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propyl)pyrrol-
idin-2-one,
(S)-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)-
methanol,
(R)--N-(4-((2-(methoxymethyl)pyrrolidin-1-yl)methyl)phenyl)-5-(4-
-methoxyphenyl)pyrimidin-2-amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-3-ol,
methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)cyclopent-
anecarboxylate,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)-2-methylpiperazine-1-
-carboxylic acid,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)pro-
panoic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-3-carboxyl-
ic acid, ethyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)ace-
tate,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-y-
l)acetic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidine-3-carboxy-
lic acid, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
morpholine-4-carboxylate,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
3-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino-
)phenyl 4-methylpiperazine-1-carboxylate, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazine-1-carboxyl-
ate,
4-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-yla-
mino)phenyl 4-methylpiperazine-1-carboxylate,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin-
-1-yl)ethanone,
N1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1,4-dicar-
boxamide, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate,
4-hydroxy-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine--
1-carboxamide,
N-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xamide,
furan-2-yl(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)-
piperazin-1-yl)methanone,
5-(4-methoxyphenyl)-N-(4-(2-(piperazin-1-yl)ethyl)phenyl)pyrimidin-2-amin-
e,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-N,4-dimethylpipera-
zine-1-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carbo-
xamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazine-1-carbo-
xylate,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetic acid, methyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetate,
(3-(hydroxymethyl)piperidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-
-2-ylamino)phenyl)methanone,
(3-hydroxypyrrolidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phen-
yl)methanone,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-4-carboxa-
mide,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin--
1-yl)propanoic acid,
(S)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)pyrrolidine-2--
carboxylic acid,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethylamino)cyclohexaneca-
rboxylic acid,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(3-(2-oxopyrrolidin-1-yl)pro-
pyl)benzamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxa-
mide,
N-(3-carbamoylphenyl)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
amide,
1,4'-bipiperidin-1'-yl(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)ph-
enyl)methanone,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)pip-
eridin-1-yl)methanone,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(2-(pyridin-2-yl)ethyl)benza-
mide,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyr-
azol-4-yl)benzamide,
(4-(furan-2-carbonyl)piperazin-1-yl)(3-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)phenyl)methanone,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol--
4-yl)benzamide,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(1-methylpiperidin-4-
-yl)piperazin-1-yl)methanone,
1-(4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperazin-1-yl)et-
hanone,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-
-yl)piperidin-1-yl)methanone,
1,4'-bipiperidin-1'-yl(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)m-
ethanone,
1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine--
3-carboxamide,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-(1-methylpiperidin-
-4-yl)piperazine-1-carboxamide, methyl
4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenylcarbamoyl)piperazine-1-
-carboxylate,
(R)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-c-
arboxylic acid,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne,
4-acetyl-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperazin-
e-1-carboxamide, and
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne.
[0268] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00181##
[0269] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00182##
wherein R.sub.A is selected from --NH.sub.2, --NEt.sub.2, and
--NH(CH.sub.2).sub.nOH; and n is 1 to 6.
[0270] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00183##
wherein R.sub.B is selected from the group consisting of
##STR00184##
[0271] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00185##
wherein R.sub.C is at 2, 3, or 4 position of the piperidine ring;
and R.sub.C is selected from the group consisting of --C(O)NHEt,
--C(O)NEt.sub.2, c-butyl, c-pentyl, --C(O)NH-thiazole, oxazole,
thiazole, --S(O).sub.2NH.sub.2, --S(O).sub.2NHEt, and
--S(O).sub.2NEt.sub.2.
[0272] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00186##
wherein each R.sub.D is independently selected from
--(CH.sub.2).sub.kOH or --(CH.sub.2).sub.kCO.sub.2H; and k is 1 to
6.
[0273] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00187##
wherein R.sub.E is at 2, 3, or 4 position of the piperidine ring;
and R.sub.E is selected from the group consisting of
--C(O)NH.sub.2, --C(O)NHEt, and --C(O)NEt.sub.2.
[0274] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00188##
wherein R.sub.F is thiazole, pyrazole, or isoxazole.
[0275] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00189## ##STR00190## ##STR00191## ##STR00192## ##STR00193##
##STR00194## [0276] Y.sup.2 is an optionally substituted cycloalkyl
ring or optionally substituted non-aromatic heterocyclic ring;
[0277] wherein said optional substituents are selected from
C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN. [0278] Y.sup.3 is
optionally substituted aryl, optionally substituted heteroaryl,
optionally substituted cycloalkyl, or optionally substituted
non-aromatic heterocycle; [0279] wherein said optional substituents
are selected from C.sub.1-6alkyl, halogen, --OH, .dbd.O, and --CN.
[0280] Z is --H, --OH, --CN, --COOR''', --NR'''.sub.2, or
--C.ident.CR'''; [0281] each R''' is independently H, alkyl, or
substituted alkyl; [0282] or two R''' together may form a 3-6
membered cycloalkyl or heterocyclic ring; [0283] or R.sub.3 and
R.sub.4 taken together with the N atom to which they are attached
may form an optionally substituted 3 to 8-membered heterocyclic
ring; [0284] wherein said optional substituents are selected from
halogen, --OH, .dbd.O, --Y.sup.3, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halogen or OH substituted C.sub.1-6alkyl, halogen or OH substituted
C.sub.1-6alkoxy, --(CR'''.sub.2).sub.1-6Y.sup.4,
--(CR'''.sub.2).sub.1-6OR.sub.6, --C(O)NR'''R.sub.6,
--C(O)OR.sub.6, --OR.sub.6, --NR'''C(O)OR.sub.6,
--NR'''C(O)R.sub.6, --(CR'''.sub.2).sub.1-6C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR'''C(O)OR.sub.6,
--(CR'''.sub.2).sub.1-6NR.sub.7R.sub.8, --S(O).sub.2NR'''.sub.2,
--C(O)R.sub.6, --OC(O)R.sub.6, --NR.sub.7R.sub.8,
--(CR'''.sub.2).sub.1-6C(O)NR.sub.7R.sub.8, --S(O).sub.2R.sub.A, or
--C(O)R.sub.A; [0285] Y.sup.4 is aryl, heteroaryl, cycloalkyl, or
non-aromatic heterocycle; [0286] R.sub.A is selected from
--NH.sub.2, --NEt.sub.2, and --NH(CH.sub.2).sub.1-6OH; [0287]
R.sub.6 is H, alkyl, substituted alkyl, cycloalkyl, non-aromatic
heterocycle, aryl, or heteroaryl; [0288] each of R.sub.7 and
R.sub.8 is independently H, OH, halogen, C.sub.1-6alkyl,
C.sub.1-6alkoxy, halo-C.sub.1-6alkyl, or halo-C.sub.1-6alkoxy;
[0289] or R.sub.7 and R.sub.8 taken together with the N atom to
which they are attached may form a 3 to 6-membered heterocyclic
ring; [0290] T.sub.1 is an optionally substituted moiety selected
from -L.sub.4-, -alkylene-L.sub.4-, -L.sub.4-alkylene-,
-L.sub.4-cycloalkylene-, -L.sub.4-heteroalkylene-,
-L.sub.4-haloalkylene-, -L.sub.4-arylene-, -L.sub.4-heteroarylene-,
and -L.sub.4-heterocycloalkylene-; wherein L.sub.4 is selected from
a bond, --O--, --NH--, --S--, --CR''.sub.2--, --NR'''C(O)--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NR'''--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR'''(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6C(O)--,
--CR''.sub.2NR'''CR''.sub.2C(O)O--, --C(O)NR'''NR'''C(O)O--,
--C(O)NR'''(CR''.sub.2).sub.1-6--, --CR''.sub.2C(O)--, and
--S(O)NH--; [0291] wherein said optional substituents are selected
from halogen, OH, C.sub.1-6alkyl, C.sub.1-6alkoxy,
halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, aryl, haloaryl, and
heteroaryl; or a pharmaceutically acceptable salt, pharmaceutically
acceptable N-oxide, pharmaceutically active metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable
solvate thereof.
[0292] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00195##
[0293] In another aspect are methods of treating a disease or
condition in animals in which modulation of c-kit receptor
activities can prevent, inhibit or ameliorate the pathology and/or
symptomology of the disease or condition, which methods comprise
administering to the animal a therapeutically effective amount of a
compound having the structure of Formula (A) or Formula (B):
##STR00196##
[0294] wherein; [0295] Q.sub.1 is H, halogen, a group comprising a
non-aromatic tertiary amine, a group comprising a non-aromatic
secondary amine, or is an optionally substituted moiety selected
from the group consisting of: -L-alkyl, -L-cycloalkyl,
-L-heteroalkyl, -L-haloalkyl, -L-aryl, -L-heterocycloalkyl, and
-L-heteroaryl; wherein L is selected from a bond, --O--, --NH--,
--S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''YC(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y is optionally
substituted arylene or heteroarylene; [0296] each R.sub.1 is
independently selected from the group consisting of H, halogen, and
an optionally substituted moiety selected from -L.sub.1-alkyl,
-L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl, -L.sub.1-haloalkyl,
-L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and -L.sub.1-heteroaryl;
wherein L.sub.1 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y'C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y' is optionally
substituted arylene or heteroarylene; [0297] Q.sub.2 is selected
from the group consisting of H, halogen, and a group comprising an
optionally substituted moiety selected from -L.sub.6-alkyl,
-L.sub.6-cycloalkyl, -L.sub.6-heteroalkyl, -L.sub.6-haloalkyl,
-L.sub.6-aromatic carbocycle, -L.sub.6-heterocycloalkyl, and
-L.sub.1-aromatic heterocycle; wherein L.sub.6 is selected from a
bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y''C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y'' is optionally
substituted arylene or heteroarylene; [0298] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0299] any two
R.sub.1 groups together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0300] R.sub.5
is selected from the group consisting of H, and an optionally
substituted moiety selected from -L.sub.5-H, -L.sub.5-alkyl,
-L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl, -L.sub.5-haloalkyl,
-L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and -L.sub.5-heteroaryl,
wherein L.sub.5 is selected from a bond, --R'O--, --R'N(H)--,
--R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--, and --R'C(O)NH--;
[0301] each R' is independently selected from the group consisting
of a bond, alkylene, substituted alkylene, heteroalkylene,
substituted heteroalkylene, alkenylene, substituted alkenylene,
cycloalkylene, substituted cycloalkylene, heteroalkylene,
substituted heteroalkylene, heterocycloalkylene, substituted
heterocycloalkylene, arylene, substituted arylene, heteroarylene,
substituted heteroarylene, alkarylene, substituted alkarylene,
aralkylene, and substituted aralkylene; and [0302] any R.sub.1 and
R.sub.5 taken together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0303] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0304] In a further or alternative embodiment of this aspect,
compounds of Formula (A) or Formula (B) are compounds having the
structure of Formula (1) or Formula (46):
##STR00197##
[0305] wherein: [0306] Ar is a group comprising a moiety selected
from an optionally substituted five-membered aromatic heterocycle,
an optionally substituted five-membered aromatic carbocycle, an
optionally substituted six-membered aromatic heterocycle, and a
substituted, optionally further substituted six-membered aromatic
carbocycle; [0307] Q is a group comprising a non-aromatic tertiary
amine or a non-aromatic secondary amine, with the proviso that Q is
not --NR.sub.aR.sub.b or --SO.sub.2NR.sub.aR.sub.b; wherein each of
R.sub.a and R.sub.b is independently H or C.sub.1-6alkyl optionally
substituted by mono- or di-alkyl (C.sub.1-6) amino; [0308] each
R.sub.1 is independently selected from the group consisting of H,
halogen, and an optionally substituted moiety selected from
-L.sub.1-alkyl, -L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl,
-L.sub.1-haloalkyl, -L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and
-L.sub.1-heteroaryl; wherein L.sub.1 is selected from a bond,
--O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; [0309] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0310] or any
two adjacent R.sub.1 groups together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0311] R.sub.5 is selected from the group consisting of H, and an
optionally substituted moiety selected from -L.sub.5-H,
-L.sub.5-alkyl, -L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl,
-L.sub.5-haloalkyl, -L.sub.5-aryl, -L.sub.1-heterocycloalkyl, and
-L.sub.5-heteroaryl; wherein L.sub.5 is selected from a bond,
--R'O--, --R'N(H)--, --R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--,
and --R'C(O)NH--; [0312] each R' is independently selected from the
group consisting of a bond, alkylene, substituted alkylene,
heteroalkylene, substituted heteroalkylene, alkenylene, substituted
alkenylene, cycloalkylene, substituted cycloalkylene,
heteroalkylene, substituted heteroalkylene, heterocycloalkylene,
substituted heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted
alkarylene, aralkylene, and substituted aralkylene; and [0313] any
R.sub.1 and R.sub.5 taken together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0314] or a pharmaceutically acceptable salt, pharmaceutically
acceptable N-oxide, pharmaceutically active metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable
solvate thereof.
[0315] In a further or alternative embodiment of this aspect, the
method further comprises administration of a therapeutically
effective amount of a second substance, wherein the second
substance is used in the treatment of a disease or condition
selected from the group consisting of a neoplastic disease, an
allergy disease, an inflammatory disease, an autoimmune disease, a
graft-versus-host disease, a metabolic syndrome, a CNS related
disorders, a neurodegenerative disease, a pain condition, a
substance abuse disorder, a prion disease, a cancer, a heart
disease, a fibrotic disease, idiopathic pulmonary arterial
hypertension (IPAH), and primary pulmonary hypertension (PPH).
[0316] In further or alternative embodiments, the second substance
is selected from the group consisting of a bronchodilator, an
anti-inflammatory agent, a leukotriene antagonist, and an IgE
blocker. In further or alternative embodiments, the compound of
Formula (A) or Formula (B) is administered prior to the second
substance. In further or alternative embodiments, the compound of
Formula (A) or Formula (B) is administered prior to the second
substance. In further or alternative embodiments, the compound of
Formula (A) or Formula (B) is administered with the second
substance. In further or alternative embodiments, the compound of
Formula (A) or Formula (B) is administered after the second
substance. In further or alternative embodiments, the compound of
Formula (A) or Formula (B) and the second substance are
administered in the same pharmaceutical composition.
[0317] In further or alternative embodiments, the Ar is a group
comprising a substituted, optionally further substituted
six-membered aromatic heterocycle. In further or alternative
embodiments, said optional substituents are selected from halogen,
OH, halogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl. In further or
alternative embodiments, the compound is the compound of any of
Formula (1) to Formula (54) in various embodiments described
above.
[0318] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00198## ##STR00199## ##STR00200##
[0319] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00201## ##STR00202## ##STR00203## ##STR00204## ##STR00205##
##STR00206## ##STR00207## ##STR00208## ##STR00209## ##STR00210##
##STR00211## ##STR00212## ##STR00213## ##STR00214## ##STR00215##
##STR00216## ##STR00217## ##STR00218## ##STR00219## ##STR00220##
##STR00221## ##STR00222##
[0320] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00223## ##STR00224## ##STR00225## ##STR00226##
##STR00227##
[0321] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00228##
[0322] In further or alternative embodiments, the compound is
selected from the group consisting of: tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzamido)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzylamino)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzylamino-
)acetate,
2,2'-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl-
azanediyl)diethanol,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylic acid, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)a-
cetate, methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate,
N-(4-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-
-amine,
1-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl)pipe-
ridine-4-carboxylic acid,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine-
, tert-butyl
2-(4-(2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-5-yl)benzamido)aceta-
te, tert-butyl
2-(4-(2-(4-(2-(4-carbamoylpiperidin-1-yl)ethoxy)phenylamino)pyrimidin-5-y-
l)benzamido)acetate,
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)phenyl
acetate, ethyl
2-(2-(diethylamino)ethoxy)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate, 4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
5-(4-methoxyphenyl)-N-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)pyri-
midin-2-amine, methyl
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzoate,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(3-fluoro-4-methoxyphenyl)pyrimidi-
n-2-amine,
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)benzoic acid, methyl
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate,
N-(3-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-4-ca-
rboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine--
3-carboxamide, tert-butyl
3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propanoate,
5-(4-methoxyphenyl)-N-(4-(piperazin-1-ylmethyl)phenyl)pyrimidin-2-amine,
1-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)eth-
anone,
(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl-
)(tetrahydrofuran-2-yl)methanone,
1-(3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propyl)pyrrol-
idin-2-one,
(S)-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)-
methanol,
(R)--N-(4-((2-(methoxymethyl)pyrrolidin-1-yl)methyl)phenyl)-5-(4-
-methoxyphenyl)pyrimidin-2-amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-3-ol,
methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)cyclopent-
anecarboxylate,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)-2-methylpiperazine-1-
-carboxylic acid,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)pro-
panoic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-3-carboxyl-
ic acid, ethyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)ace-
tate,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-y-
l)acetic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidine-3-carboxy-
lic acid, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
morpholine-4-carboxylate,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
3-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino-
)phenyl 4-methylpiperazine-1-carboxylate, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazine-1-carboxyl-
ate,
4-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-yla-
mino)phenyl 4-methylpiperazine-1-carboxylate,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin-
-1-yl)ethanone,
N1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1,4-dicar-
boxamide, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate,
4-hydroxy-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine--
1-carboxamide,
N-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xamide,
furan-2-yl(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)-
piperazin-1-yl)methanone,
5-(4-methoxyphenyl)-N-(4-(2-(piperazin-1-yl)ethyl)phenyl)pyrimidin-2-amin-
e,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-N,4-dimethylpipera-
zine-1-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carbo-
xamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazine-1-carbo-
xylate,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetic acid, methyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetate,
(3-(hydroxymethyl)piperidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-
-2-ylamino)phenyl)methanone,
(3-hydroxypyrrolidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phen-
yl)methanone,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-4-carboxa-
mide,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin--
1-yl)propanoic acid,
(S)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)pyrrolidine-2--
carboxylic acid,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethylamino)cyclohexaneca-
rboxylic acid,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(3-(2-oxopyrrolidin-1-yl)pro-
pyl)benzamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxa-
mide,
N-(3-carbamoylphenyl)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
amide,
1,4'-bipiperidin-1'-yl(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)ph-
enyl)methanone,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)pip-
eridin-1-yl)methanone,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(2-(pyridin-2-yl)ethyl)benza-
mide,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyr-
azol-4-yl)benzamide,
(4-(furan-2-carbonyl)piperazin-1-yl)(3-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)phenyl)methanone,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol--
4-yl)benzamide,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(1-methylpiperidin-4-
-yl)piperazin-1-yl)methanone,
1-(4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperazin-1-yl)et-
hanone,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-
-yl)piperidin-1-yl)methanone,
1,4'-bipiperidin-1'-yl(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)m-
ethanone,
1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine--
3-carboxamide,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-(1-methylpiperidin-
-4-yl)piperazine-1-carboxamide, methyl
4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenylcarbamoyl)piperazine-1-
-carboxylate,
(R)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-c-
arboxylic acid,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne,
4-acetyl-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperazin-
e-1-carboxamide, and
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne.
[0323] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00229##
[0324] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00230##
wherein R.sub.A is selected from --NH.sub.2, --NEt.sub.2, and
--NH(CH.sub.2).sub.nOH; and n is 1 to 6.
[0325] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00231##
wherein R.sub.B is selected from the group consisting of
##STR00232##
[0326] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00233##
wherein R.sub.C is at 2, 3, or 4 position of the piperidine ring;
and R.sub.C is selected from the group consisting of --C(O)NHEt,
--C(O)NEt.sub.2, c-butyl, c-pentyl, --C(O)NH-thiazole, oxazole,
thiazole, --S(O).sub.2NH.sub.2, --S(O).sub.2NHEt, and
--S(O).sub.2NEt.sub.2.
[0327] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00234##
wherein each R.sub.D is independently selected from
--(CH.sub.2).sub.kOH or --(CH.sub.2).sub.kCO.sub.2H; and k is 1 to
6.
[0328] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00235##
wherein R.sub.E is at 2, 3, or 4 position of the piperidine ring;
and R.sub.E is selected from the group consisting of
--C(O)NH.sub.2, --C(O)NHEt, and --C(O)NEt.sub.2.
[0329] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00236##
wherein R.sub.F is thiazole, pyrazole, or isoxazole.
[0330] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00237## ##STR00238## ##STR00239## ##STR00240## ##STR00241##
##STR00242##
[0331] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00243##
[0332] In another aspect are methods of using compounds having the
structure of Formula (A) or Formula (B) in the manufacture of a
medicament for treating a disease or condition in an animal in
which c-kit receptor activity contributes to the pathology and/or
symptomology of the disease or condition:
##STR00244##
[0333] wherein; [0334] Q.sub.1 is H, halogen, a group comprising a
non-aromatic tertiary amine, a group comprising a non-aromatic
secondary amine, or is an optionally substituted moiety selected
from the group consisting of: -L-alkyl, -L-cycloalkyl,
-L-heteroalkyl, -L-haloalkyl, -L-aryl, -L-heterocycloalkyl, and
-L-heteroaryl; wherein L is selected from a bond, --O--, --NH--,
--S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''YC(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y is optionally
substituted arylene or heteroarylene; [0335] each R.sub.1 is
independently selected from the group consisting of H, halogen, and
an optionally substituted moiety selected from -L.sub.1-alkyl,
-L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl, -L.sub.1-haloalkyl,
-L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and -L.sub.1-heteroaryl;
wherein L.sub.1 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y'C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y' is optionally
substituted arylene or heteroarylene; [0336] Q.sub.2 is selected
from the group consisting of H, halogen, and a group comprising an
optionally substituted moiety selected from -L.sub.6-alkyl,
-L.sub.6-cycloalkyl, -L.sub.6-heteroalkyl, -L.sub.6-haloalkyl,
-L.sub.6-aromatic carbocycle, -L.sub.6-heterocycloalkyl, and
-L.sub.6-aromatic heterocycle; wherein L.sub.6 is selected from a
bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y''C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y'' is optionally
substituted arylene or heteroarylene; [0337] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0338] any two
R.sub.1 groups together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0339] R.sub.5
is selected from the group consisting of H, and an optionally
substituted moiety selected from -L.sub.5-H, -L.sub.5-alkyl,
-L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl, -L.sub.5-haloalkyl,
-L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and -L.sub.5-heteroaryl,
wherein L.sub.5 is selected from a bond, --R'O--, --R'N(H)--,
--R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--, and --R'C(O)NH--;
[0340] each R' is independently selected from the group consisting
of a bond, alkylene, substituted alkylene, heteroalkylene,
substituted heteroalkylene, alkenylene, substituted alkenylene,
cycloalkylene, substituted cycloalkylene, heteroalkylene,
substituted heteroalkylene, heterocycloalkylene, substituted
heterocycloalkylene, arylene, substituted arylene, heteroarylene,
substituted heteroarylene, alkarylene, substituted alkarylene,
aralkylene, and substituted aralkylene; and [0341] any R.sub.1 and
R.sub.5 taken together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0342] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0343] In a further or alternative embodiment of this aspect,
compounds of Formula (A) or Formula (B) are compounds having the
structure of Formula (1) or Formula (46):
##STR00245##
[0344] wherein: [0345] Ar is a group comprising a moiety selected
from an optionally substituted five-membered aromatic heterocycle,
an optionally substituted five-membered aromatic carbocycle, an
optionally substituted six-membered aromatic heterocycle, and a
substituted, optionally further substituted six-membered aromatic
carbocycle; [0346] Q is a group comprising a non-aromatic tertiary
amine or a non-aromatic secondary amine, with the proviso that Q is
not --NR.sub.aR.sub.b or --SO.sub.2NR.sub.aR.sub.b; wherein each of
R.sub.a and R.sub.b is independently H or C.sub.1-6alkyl optionally
substituted by mono- or di-alkyl (C.sub.1-6) amino; [0347] each
R.sub.1 is independently selected from the group consisting of H,
halogen, and an optionally substituted moiety selected from
-L.sub.1-alkyl, -L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl,
-L.sub.1-haloalkyl, -L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and
-L.sub.1-heteroaryl; wherein L.sub.1 is selected from a bond,
--O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--,
--S(O)--, --S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; [0348] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl;
##STR00246## ##STR00247##
[0349] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00248## ##STR00249## ##STR00250## [0350] or any two adjacent
R.sub.1 groups together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0351] R.sub.5
is selected from the group consisting of H, and an optionally
substituted moiety selected from -L.sub.5-H, -L.sub.5-alkyl,
-L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl, -L.sub.5-haloalkyl,
-L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and -L.sub.5-heteroaryl;
wherein L.sub.5 is selected from a bond, --R'O--, --R'N(H)--,
--R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--, and --R'C(O)NH--;
[0352] each R' is independently selected from the group consisting
of a bond, alkylene, substituted alkylene, heteroalkylene,
substituted heteroalkylene, alkenylene, substituted alkenylene,
cycloalkylene, substituted cycloalkylene, heteroalkylene,
substituted heteroalkylene, heterocycloalkylene, substituted
heterocycloalkylene, arylene, substituted arylene, heteroarylene,
substituted heteroarylene, alkarylene, substituted alkarylene,
aralkylene, and substituted aralkylene; and [0353] any R.sub.1 and
R.sub.5 taken together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0354] or a
pharmaceutically acceptable salt, pharmaceutically acceptable
N-oxide, pharmaceutically active metabolite, pharmaceutically
acceptable prodrug, or pharmaceutically acceptable solvate
thereof.
[0355] In further or alternative embodiments, the Ar is a group
comprising a substituted, optionally further substituted
six-membered aromatic heterocycle. In further or alternative
embodiments, said optional substituents are selected from halogen,
OH, halogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl. In further or
alternative embodiments, the compound is the compound of any of
Formula (1) to Formula (54) in various embodiments described
above.
[0356] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00251## ##STR00252## ##STR00253##
##STR00254## ##STR00255## ##STR00256## ##STR00257## ##STR00258##
##STR00259## ##STR00260## ##STR00261## ##STR00262## ##STR00263##
##STR00264## ##STR00265## ##STR00266## ##STR00267## ##STR00268##
##STR00269## ##STR00270## ##STR00271## ##STR00272##
##STR00273##
[0357] In further or alternative embodiments, Q is selected from
the group consisting of
##STR00274## ##STR00275## ##STR00276## ##STR00277##
##STR00278##
[0358] In further or alternative embodiments, Ar is selected from
the group consisting of
##STR00279##
[0359] In further or alternative embodiments, the compound is
selected from the group consisting of: tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzamido)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzylamino)acetate, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzylamino-
)acetate,
2,2'-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl-
azanediyl)diethanol,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylic acid, tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)a-
cetate, methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate,
N-(4-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-
-amine,
1-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl)pipe-
ridine-4-carboxylic acid,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine-
, tert-butyl
2-(4-(2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-5-yl)benzamido)aceta-
te, tert-butyl
2-(4-(2-(4-(2-(4-carbamoylpiperidin-1-yl)ethoxy)phenylamino)pyrimidin-5-y-
l)benzamido)acetate,
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)phenyl
acetate, ethyl
2-(2-(diethylamino)ethoxy)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate, 4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
5-(4-methoxyphenyl)-N-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)pyri-
midin-2-amine, methyl
4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzoate,
N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(3-fluoro-4-methoxyphenyl)pyrimidi-
n-2-amine,
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)benzoic acid, methyl
2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
oate,
N-(3-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-4-ca-
rboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine--
3-carboxamide, tert-butyl
3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propanoate,
5-(4-methoxyphenyl)-N-(4-(piperazin-1-ylmethyl)phenyl)pyrimidin-2-amine,
1-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)eth-
anone,
(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl-
)(tetrahydrofuran-2-yl)methanone,
1-(3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propyl)pyrrol-
idin-2-one,
(S)-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)-
methanol,
(R)--N-(4-((2-(methoxymethyl)pyrrolidin-1-yl)methyl)phenyl)-5-(4-
-methoxyphenyl)pyrimidin-2-amine,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-3-ol,
methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)cyclopent-
anecarboxylate,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)-2-methylpiperazine-1-
-carboxylic acid,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)pro-
panoic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-3-carboxyl-
ic acid, ethyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)ace-
tate,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-y-
l)acetic acid,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidine-3-carboxy-
lic acid, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
morpholine-4-carboxylate,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate,
3-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino-
)phenyl 4-methylpiperazine-1-carboxylate, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazine-1-carboxyl-
ate,
4-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-yla-
mino)phenyl 4-methylpiperazine-1-carboxylate,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin-
-1-yl)ethanone,
N1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1,4-dicar-
boxamide, 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate,
4-hydroxy-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine--
1-carboxamide,
N-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-
-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xamide,
furan-2-yl(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)-
piperazin-1-yl)methanone,
5-(4-methoxyphenyl)-N-(4-(2-(piperazin-1-yl)ethyl)phenyl)pyrimidin-2-amin-
e,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-N,4-dimethylpipera-
zine-1-carboxamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carbo-
xamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid, methyl
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazine-1-carbo-
xylate,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine--
3-carboxylic acid,
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetic acid, methyl
2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)-
acetate,
(3-(hydroxymethyl)piperidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-
-2-ylamino)phenyl)methanone,
(3-hydroxypyrrolidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phen-
yl)methanone,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-4-carboxa-
mide,
3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin--
1-yl)propanoic acid,
(S)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)pyrrolidine-2--
carboxylic acid,
4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethylamino)cyclohexaneca-
rboxylic acid,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(3-(2-oxopyrrolidin-1-yl)pro-
pyl)benzamide,
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxa-
mide,
N-(3-carbamoylphenyl)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benz-
amide,
1,4'-bipiperidin-1'-yl(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)ph-
enyl)methanone,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)pip-
eridin-1-yl)methanone,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(2-(pyridin-2-yl)ethyl)benza-
mide,
4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyr-
azol-4-yl)benzamide,
(4-(furan-2-carbonyl)piperazin-1-yl)(3-(5-(4-methoxyphenyl)pyrimidin-2-yl-
amino)phenyl)methanone,
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol--
4-yl)benzamide,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(1-methylpiperidin-4-
-yl)piperazin-1-yl)methanone,
1-(4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperazin-1-yl)et-
hanone,
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-
-yl)piperidin-1-yl)methanone,
1,4'-bipiperidin-1'-yl(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)m-
ethanone,
1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine--
3-carboxamide,
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-(1-methylpiperidin-
-4-yl)piperazine-1-carboxamide, methyl
4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenylcarbamoyl)piperazine-1-
-carboxylate,
(R)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-c-
arboxylic acid,
(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne,
4-acetyl-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperazin-
e-1-carboxamide, and
(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methano-
ne.
[0360] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00280##
[0361] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00281##
wherein R.sub.A is selected from --NH.sub.2, --NEt.sub.2, and
--NH(CH.sub.2).sub.nOH; and n is 1 to 6.
[0362] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00282##
wherein R.sub.B is selected from the group consisting of
##STR00283##
[0363] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00284##
wherein R.sub.C is at 2, 3, or 4 position of the piperidine ring;
and R.sub.C is selected from the group consisting of --C(O)NHEt,
--C(O)NEt.sub.2, c-butyl, c-pentyl, --C(O)NH-thiazole, oxazole,
thiazole, --S(O).sub.2NH.sub.2, --S(O).sub.2NHEt, and
--S(O).sub.2NEt.sub.2.
[0364] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00285##
wherein each R.sub.D is independently selected from
--(CH.sub.2).sub.kOH or --(CH.sub.2).sub.kCO.sub.2H; and k is 1 to
6.
[0365] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is
##STR00286##
wherein R.sub.E is at 2, 3, or 4 position of the piperidine ring;
and R.sub.E is selected from the group consisting of
--C(O)NH.sub.2, --C(O)NHEt, and --C(O)NEt.sub.2.
[0366] In further or alternative embodiments, Q of the compound
having the structure of Formula (1) is selected from the group
consisting of
##STR00287##
wherein R.sub.F is thiazole, pyrazole, or isoxazole.
[0367] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00288## ##STR00289## ##STR00290## ##STR00291##
##STR00292##
[0368] In further or alternative embodiments, Q of the compound
having the structure of Formula (46) is selected from the group
consisting of
##STR00293##
[0369] In further or alternative embodiments, the disease is a
neoplastic disease. In further or alternative embodiments, the
disease is a neoplastic diseases selected from the group consisting
of mastocytosis, canine mastocytoma, human gastrointestinal stromal
tumor, small cell lung cancer, non-small cell lung cancer, acute
myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic
syndrome, chronic myelogenous leukemia, colorectal carcinomas,
gastric carcinomas, gastrointestinal stromal tumors, testicular
cancers, glioblastomas, and astrocytomas.
[0370] In further or alternative embodiments, the disease is an
allergy disease. In further or alternative embodiments, the disease
is an allergic disease selected from the group consisting of
asthma, allergic rhinitis, allergic sinusitis, anaphylactic
syndrome, urticaria, angioedema, atopic dermatitis, allergic
contact dermatitis, erythema nodosum, erythema multiforme,
cutaneous necrotizing venulitis and insect bite skin inflammation
and blood sucking parasitic infestation.
[0371] In further or alternative embodiments, the disease is an
inflammatory disease. In further or alternative embodiments, the
disease is an inflammatory diseases selected from the group
consisting of rheumatoid arthritis, conjunctivitis, rheumatoid
spondylitis, osteoarthritis, gouty arthritis and other arthritic
conditions.
[0372] In further or alternative embodiments, the disease is an
autoimmune disease. In further or alternative embodiments, the
disease is an autoimmune disease selected from the group consisting
of multiple sclerosis, psoriasis, intestine inflammatory disease,
ulcerative colitis, Crohn's disease, rheumatoid arthritis and
polyarthritis, local and systemic scleroderma, systemic lupus
erythematosus, discoid lupus erythematosus, cutaneous lupus,
dermatomyositis, polymyositis, Sjogren's syndrome, nodular
panarteritis, autoimmune enteropathy, and proliferative
glomerulonephritis.
[0373] In further or alternative embodiments, the disease is a
graft-versus-host disease. In further or alternative embodiments,
the disease is organ transplantation graft rejection. In further or
alternative embodiments, the organ transplantation is kidney
transplantation, pancreas transplantation, liver transplantation,
heart transplantation, lung transplantation, or bone marrow
transplantation.
[0374] In further or alternative embodiments, the disease is a
metabolic syndrome. In further or alternative embodiments, the
disease is a metabolic syndrome selected from type I diabetes, type
II diabetes, or obesity.
[0375] In further or alternative embodiments, the condition is a
CNS related disorder. In further or alternative embodiments, the
disease is a CNS related disorders selected from the group
consisting of depression, dysthymic disorder, cyclothymic disorder,
bipolar depression, severe or "melancholic" depression, atypical
depression, refractory depression, seasonal depression, anorexia,
bulimia, premenstrual syndrome and post-menopause syndrome, as
mental slowing and loss of concentration, pessimistic worry,
agitation, self-deprecation and decreased libido, as anxiety
disorders including anxiety associated with hyperventilation and
cardiac arrhythmias, phobic disorders, obsessive-compulsive
disorder, posttraumatic stress disorder, acute stress disorder, and
generalized anxiety disorder, as psychiatric disorders such as
panic attacks, including psychosis, delusional disorders,
conversion disorders, phobias, mania, delirium, dissociative
episodes including dissociative amnesia, dissociative fugue and
dissociative suicidal behavior, self-neglect, violent or aggressive
behavior, trauma, borderline personality, and acute psychosis as
schizophrenia including paranoid schizophrenia, disorganized
schizophrenia, catatonic schizophrenia, and undifferentiated
schizophrenia.
[0376] In further or alternative embodiments, the disease is a
neurodegenerative disease. In further or alternative embodiments,
the disease is a neurodegenerative disease selected from the group
consisting of Alzheimer's disease, Parkinson's disease,
Huntington's disease, the prion diseases, Motor Neuron Disease
(MND), and Amyotrophic Lateral Sclerosis (ALS).
[0377] In further or alternative embodiments, the condition is
pain. In further or alternative embodiments, the type of pain is
selected from the group consisting of acute pain, postoperative
pain, chronic pain, nociceptive pain, cancer pain, neuropathic
pain, and psychogenic pain syndromes.
[0378] In further or alternative embodiments, the condition is a
substance use disorder. In further or alternative embodiments, the
condition is a substance use disorder selected from the group
consisting of drug addiction, drug abuse, drug habituation, drug
dependence, withdrawal syndrome and overdose.
[0379] In further or alternative embodiments, the disease is a
prion disease.
[0380] In further or alternative embodiments, the disease is
cancer. In further or alternative embodiments, the disease is
cancer selected from the group consisting of melanoma,
gastrointestinal stromal tumor (GIST), small cell lung cancer, and
other solid tumors.
[0381] In further or alternative embodiments, the disease is heart
disease.
[0382] In further or alternative embodiments, the disease is a
fibrotic disease. In further or alternative embodiments, the
disease is a fibrotic disease selected from the group consisting of
hepatitis C(HCV), liver fibrosis, nonalcoholic steatohepatitis
(NASH), cirrhosis in liver, pulmonary fibrosis, and bone marrow
fibrosis.
[0383] In further or alternative embodiments, the disease is
idiopathic pulmonary arterial hypertension (IPAH).
[0384] In further or alternative embodiments, the disease is
primary pulmonary hypertension (PPH).
[0385] In another aspect are methods for making the compounds
having the structure of Formula (1) comprising admixing a compound
of structure:
##STR00294##
with a compound having the structure:
##STR00295##
under suitable reaction conditions to yield a compound having the
structure of Formula (C):
##STR00296##
and further admixing the compound having the structure of Formula
(C) with a compound of structure: ArB(OH).sub.2, under suitable
reaction conditions.
[0386] In another aspect are methods for making the compounds
having the structure of Formula (1) comprising admixing a compound
of structure:
##STR00297##
with a compound having the structure:
##STR00298##
under suitable reaction conditions to yield a compound having the
structure of Formula (C)
##STR00299##
and further admixing the compound having the structure of Formula
(C) with a compound of structure: ArB(OH).sub.2, under suitable
reaction conditions.
[0387] Other objects, features and advantages of the methods and
compositions described herein will become apparent from the
following detailed description. It should be understood, however,
that the detailed description and the specific examples, while
indicating specific embodiments, are given by way of illustration
only, since various changes and modifications within the spirit and
scope of the invention will become apparent to those skilled in the
art from this detailed description.
[0388] These and other aspects of the present invention will become
evident upon reference to the following detailed description. In
addition, all patents and other references cited herein which
describe in more detail certain procedures or compositions, and are
incorporated by reference in their entirety.
DETAILED DESCRIPTION OF THE INVENTION
Certain Chemical Terminology
[0389] Unless otherwise stated, the following terms used in this
application, including the specification and claims, have the
definitions given below. It must be noted that, as used in the
specification and the appended claims, the singular forms "a," "an"
and "the" include plural referents unless the context clearly
dictates otherwise. Definition of standard chemistry terms may be
found in reference works, including Carey and Sundberg "ADVANCED
ORGANIC CHEMISTRY 4.sup.TH ED." Vols. A (2000) and B (2001), Plenum
Press, New York. Unless otherwise indicated, conventional methods
of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry,
recombinant DNA techniques and pharmacology, within the skill of
the art are employed.
[0390] The term "alkenyl group," as used herein, refers to a
hydrocarbon chain having one or more double bonds therein. The
double bond of an alkenyl group can be unconjugated or conjugated
to another unsaturated group. Suitable alkenyl groups include, but
are not limited to, (C.sub.2-C.sub.8)alkenyl groups, such as vinyl,
allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl,
hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl,
4-(2-methyl-3-butene)-pentenyl. The alkenyl moiety may be branched,
straight chain, or cyclic (in which case, it would also be known as
a "cycloalkenyl" group), and can be unsubstituted or
substituted.
[0391] The term "alkoxy" as used herein, includes --O-(alkyl),
where alkyl is as defined herein. By way of example only, C.sub.1-6
alkoxy includes, but is not limited to, methoxy, ethoxy, and the
like. An alkoxy group can be unsubstituted or substituted.
[0392] The term "alkyl," as used herein, refers to a hydrocarbon
group having from 1 to 10 carbon atoms and can include straight,
branched, cyclic, saturated and/or unsaturated features. Whenever
it appears herein, a numerical range such as "1 to 10" refers to
each integer in the given range; e.g., "1 to 10 carbon atoms" or
"C.sub.1 " or "(C.sub.1-C.sub.10)" means that the alkyl group may
consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up
to and including 10 carbon atoms, although the present definition
also covers the occurrence of the term "alkyl" where no numerical
range is designated. The alkyl moiety may be a "saturated alkyl"
group, which means that it does not contain any alkene or alkyne
moieties. Representative saturated alkyl groups include, but are
not limited to, methyl, ethyl, n-propyl, isopropyl,
2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl,
3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl,
2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,
2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,
2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl,
isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, and
n-hexyl, and longer alkyl groups, such as heptyl, and octyl. The
alkyl moiety may also be an "unsaturated alkyl" moiety, which means
that it contains at least one alkene or alkyne moiety. An "alkene"
moiety refers to a group consisting of at least two carbon atoms
and at least one carbon-carbon double bond, and an "alkyne" moiety
refers to a group consisting of at least two carbon atoms and at
least one carbon-carbon triple bond. Representative unsaturated
alkyl groups include, but are not limited to, ethenyl, propenyl,
butenyl and the like. An alkyl group can be unsubstituted or
substituted. Substituted alkyl groups include, but are not limited
to, halogen-substituted alkyl groups, such as, by way of example
only, trifluoromethyl, pentafluoroethyl, and the like.
[0393] The term "alkylamine," as used herein, refers to the
--N(alkyl).sub.xH.sub.y group, where x and y are selected from the
group x=1, y=1 and x=2, y=0. When x=2, the alkyl groups, taken
together, can optionally form a cyclic ring system and further when
x=2, the alkyl groups can be the same or different. An alkylamine
group can be unsubstituted or substituted.
[0394] The term "alkynyl" group, as used herein, refers to a
hydrocarbon chain having one or more triple bonds therein. The
triple bond of an alkynyl group can be unconjugated or conjugated
to another unsaturated group. Suitable alkynyl groups include, but
are not limited to, (C.sub.2-C.sub.6)alkynyl groups, such as
ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl,
4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl. The
alkynyl moiety may be branched or straight chain, and can be
unsubstituted or substituted.
[0395] The term "amide," as used herein, refers to a chemical
moiety with formula --C(O)NHR or --NHC(O)R, where R is selected
from the group consisting of alkyl, cycloalkyl, aryl, and
heterocyclic (bonded through a ring carbon). Amides can be formed
from any amine or carboxyl side chain on the compounds described
herein. The procedures and specific groups to make such amides are
known to those of skill in the art and can readily be found in
reference sources such as Greene and Wuts, Protective Groups in
Organic Synthesis, 3.sup.rd Ed., John Wiley & Sons, New York,
N.Y., 1999, which is incorporated herein by reference in its
entirety. An amide group can be unsubstituted or substituted.
[0396] The term "aromatic" or "aryl," as used herein, refers to a
closed ring structure which has at least one ring having a
conjugated pi electron system and includes both carbocyclic aryl
and heterocyclic aryl (or "heteroaryl" or "heteroaromatic") groups.
The carbocyclic or heterocyclic aromatic group may contain from 5
to 20 ring atoms. The term includes monocyclic or fused-ring
polycyclic (i.e., rings which share adjacent pairs of carbon atoms)
groups. An aromatic group can be unsubstituted or substituted.
[0397] The term "aryloxy," as used herein, includes --O-aryl group,
wherein aryl is as defined herein. An aryloxy group can be
unsubstituted or substituted.
[0398] The term "bond" or "single bond," as used herein, refers to
a covalent bond between two atoms, either of which may be part of a
larger moiety.
[0399] The terms "carbocyclic" or "cycloalkyl," as used herein,
refer to a compound which contains one or more covalently closed
ring structures, and that the atoms forming the backbone of the
ring are all carbon atoms. Such a group may have from 3 to 20 ring
carbon atoms and be saturated, partially unsaturated, or fully
unsaturated monocyclic, fused bicyclic, spirocyclic, bridged
polycyclic or polycyclic ring comprising carbon and hydrogen atoms.
Carbocyclic alkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and
cyclooctyl. A carbocyclic aromatic group includes, but is not
limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl,
azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties
such as, by way of example only, dibenzosuberenone, and
dibenzosuberone. A carbocyclic group can be unsubstituted or
substituted.
[0400] The term "ester," as used herein, refers to a chemical
moiety with formula --COOR, where R is selected from the group
consisting of alkyl, cycloalkyl, aryl, and heterocyclic (bonded
through a ring carbon). Any hydroxy or carboxyl side chain on the
compounds described herein can be esterified. The procedures and
specific groups to make such esters are known to those of skill in
the art and can readily be found in reference sources such as
Greene and Wuts, Protective Groups in Organic Synthesis, 3.sup.rd
Ed., John Wiley & Sons, New York, N.Y., 1999, which is
incorporated herein by reference in its entirety. An ester group
can be unsubstituted or substituted.
[0401] The terms "heteroalkyl" "heteroalkenyl" and "heteroalkynyl,"
as used herein, include optionally substituted alkyl, alkenyl and
alkynyl moieties and which have one or more skeletal chain atoms
selected from an atom other than carbon, e.g., oxygen, nitrogen,
sulfur, phosphorus or combinations thereof. A "heteroalkyl"
"heteroalkenyl" and "heteroalkynyl" group can be unsubstituted or
substituted.
[0402] The terms "heteroaryl" or, alternatively, "heteroaromatic,"
as used herein, refers to an aryl group that includes one or more
ring heteroatoms selected from nitrogen, oxygen, sulfur. By way of
example, an N-containing "heteroaromatic" or "heteroaryl" moiety
refers to an aromatic group in which at least one of the skeletal
atoms of the ring is a nitrogen atom. A polycyclic heteroaryl group
may be fused or non-fused. A heteroaryl group can be unsubstituted
or substituted.
[0403] The term "heterocyclic," as used herein, refers to ring
structures in which the ring backbone contains at least one atom
selected from nitrogen, oxygen, and sulfur. Examples of
heterocyclic aromatic groups include, but are not limited to,
acridinyl, benzo[1,3]dioxole, benzimidazolyl, benzindazolyl,
benzoisooxazolyl, benzokisazolyl, benzofuranyl, benzofurazanyl,
benzopyranyl, benzothiazolyl, benzo[b]thienyl, benzothiophenyl,
benzothiopyranyl, benzotriazolyl, benzoxazolyl, carbazolyl,
carbolinyl, cinnolinyl, furanyl, furazanyl, furopyridinyl, furyl,
imidazolyl, indazolyl, indolyl, indolidinyl, indolizinyl,
isobenzofuranyl, isoindolyl, isoxazolyl, isoquinolinyl,
isothiazolyl, naphthylidinyl, naphthyridinyl, oxadiazolyl,
oxazolyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiynyl,
thianthrenyl, phenathridinyl, phenathrolinyl, phthalazinyl,
pteridinyl, purinyl, puteridinyl, pyrazyl, pyrazolyl, pyridyl,
pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrimidyl,
pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrazolyl,
thiadiazolyl, thiazolyl, thienyl, triazinyl, (1,2,3,)- and
(1,2,4)-triazolyl and the like. In addition, a heterocyclic group
can be unsubstituted or substituted. Examples of non-aromatic
heterocyclic groups include, but are not limited to, are azepinyl,
azepan-2-onyl, azetidinyl, diazepinyl, dihydrofuranyl,
dihydropyranyl, dihydrothienyl, dioxanyl, dioxolanyl,
1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, dithianyl, dithiolanyl,
homopiperidinyl, imidazolinyl, imidazolidinyl, indolinyl, indolyl,
morpholinyl, oxazepinyl, oxepanyl, oxetanyl, oxylanyl, piperidino,
piperidyl, piperidinonyl, piperazinyl, pyranyl, pyrazolinyl,
pyrazolidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl,
quinolizinyl, thietanyl, tetrahydrofuranyl, tetrahydroquinolyl,
tetrahydrothienyl, tetrahydrothiopyranyl, tetrahydropyridinyl,
tetrahydropyranyl, thiazepinyl, thiepanyl, thiomorpholinyl,
thioranyl, thioxanyl and the like. The heterocyclic group may be
fused or non-fused. The terms referring to the groups also
encompass all possible tautomers.
[0404] The term "halogen," as used herein, means fluoro, chloro,
bromo or iodo. Preferred halogen groups are fluoro, chloro and
bromo.
[0405] The terms "haloalkyl," "haloalkenyl," "haloalkynyl" and
"haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures
that are substituted with one or more halogen groups or with
combinations thereof.
[0406] The term "membered ring," as used herein, can embrace any
cyclic structure. The term "membered" is meant to denote the number
of skeletal atoms that constitute the ring. Thus, for example,
cyclohexyl, pyridine, pyran and thiopyran are 6-membered rings and
cyclopentyl, pyrrole, furan, and thiophene are 5-membered
rings.
[0407] The term "moiety," as used herein, refers to a specific
segment or functional group of a molecule. Chemical moieties are
often recognized chemical entities embedded in or appended to a
molecule.
[0408] The term "protecting group," as used herein, refers to a
chemical moiety which blocks some or all reactive moieties and
prevent such groups from participating in chemical reactions until
the protective group is removed.
[0409] The term "reactant," as used herein, refers to a nucleophile
or electrophile used to create covalent linkages.
[0410] The term "sulfonyl" refers to the presence of a sulfur atom,
which is optionally linked to another moiety such as an alkyl
group, an aryl group, or a heterocyclic group. Aryl or alkyl
sulfonyl moieties have the formula --SO.sub.2R', wherein R' is
alkyl or aryl as defined herein, and include, but are not limited
to, methylsulfonyl, ethylsulfonyl and phenylsulfonyl groups. A
sulfonyl group can be unsubstituted or substituted. A
phenylsulfonyl is optionally substituted with 1 to 3 substituents
independently selected from halogen, alkyl, and alkoxy.
[0411] Unless otherwise indicated, when a substituent is deemed to
be "optionally substituted," it is meant that the substituent is a
group that may be substituted with one or more group(s)
individually and independently selected from, for example, alkenyl,
alkyl, alkoxy, alkylamine, alkylthio, alkynyl, amide, amino,
including mono- and di-substituted amino groups, aryl, aryloxy,
arylthio, carbonyl, carbocyclic, cyano, cycloalkyl, halogen,
heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl,
heterocyclic, hydroxy, isocyanato, isothiocyanato, mercapto, nitro,
O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido,
N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy,
perhaloalkyl, perfluoroalkyl, silyl, sulfonyl, thiocarbonyl,
thiocyanato, trihalomethanesulfonyl, and the protected compounds
thereof. The protecting groups that may form the protected
compounds of the above substituents are known to those of skill in
the art and may be found in references such as Greene and Wuts,
Protective Groups in Organic Synthesis, 3.sup.rd Ed., John Wiley
& Sons, New York, N.Y., 1999, and Kocienski, Protective Groups,
Thieme Verlag, New York, N.Y., 1994, which are incorporated herein
by reference in their entirety.
Certain Pharmaceutical Terminology
[0412] The term "acceptable" with respect to a formulation,
composition or ingredient, as used herein, means having no
persistent detrimental effect on the general health of the subject
being treated.
[0413] The term "agonist," as used herein, refers to a molecule
such as a compound, a drug, an enzyme activator or a hormone
modulator which enhances the activity of another molecule or the
activity of a receptor site.
[0414] The term "antagonist," as used herein, refers to a molecule
such as a compound, a drug, an enzyme inhibitor, or a hormone
modulator, which diminishes, or prevents the action of another
molecule or the activity of a receptor site.
[0415] The term "carrier," as used herein, refers to relatively
nontoxic chemical compounds or agents that facilitate the
incorporation of a compound into cells or tissues.
[0416] The terms "co-administration" or the like, as used herein,
are meant to encompass administration of the selected therapeutic
agents to a single patient, and are intended to include treatment
regimens in which the agents are administered by the same or
different route of administration or at the same or different
time.
[0417] The terms "effective amount" or "therapeutically effective
amount," as used herein, refer to a sufficient amount of an agent
or a compound being administered which will relieve to some extent
one or more of the symptoms of the disease or condition being
treated. The result can be reduction and/or alleviation of the
signs, symptoms, or causes of a disease, or any other desired
alteration of a biological system. For example, an "effective
amount" for therapeutic uses is the amount of the composition
comprising a compound as disclosed herein required to provide a
clinically significant decrease in a disease. An appropriate
"effective" amount in any individual case may be determined using
techniques, such as a dose escalation study.
[0418] The terms "enhance" or "enhancing," as used herein, means to
increase or prolong either in potency or duration a desired effect.
Thus, in regard to enhancing the effect of therapeutic agents, the
term "enhancing" refers to the ability to increase or prolong,
either in potency or duration, the effect of other therapeutic
agents on a system. An "enhancing-effective amount," as used
herein, refers to an amount adequate to enhance the effect of
another therapeutic agent in a desired system.
[0419] The terms "kit" and "article of manufacture" are used as
synonyms.
[0420] The term "metabolite," as used herein, refers to a
derivative of a compound which is formed when the compound is
metabolized.
[0421] The term "active metabolite," as used herein, refers to a
biologically active derivative of a compound that is formed when
the compound is metabolized.
[0422] The term "metabolized," as used herein, refers to the sum of
the processes (including, but not limited to, hydrolysis reactions
and reactions catalyzed by enzymes) by which a particular substance
is changed by an organism. Thus, enzymes may produce specific
structural alterations to a compound. For example, cytochrome P450
catalyzes a variety of oxidative and reductive reactions while
uridine diphosphate glucuronyltransferases catalyze the transfer of
an activated glucuronic-acid molecule to aromatic alcohols,
aliphatic alcohols, carboxylic acids, amines and free sulphydryl
groups. Further information on metabolism may be obtained from The
Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill
(1996).
[0423] The term "modulate," as used herein, means to interact with
a target either directly or indirectly so as to alter the activity
of the target, including, by way of example only, to enhance the
activity of the target, to inhibit the activity of the target, to
limit the activity of the target, or to extend the activity of the
target.
[0424] The term "modulator," as used herein, refers to a molecule
that interacts with a target either directly or indirectly. The
interactions include, but are not limited to, the interactions of
an agonist and an antagonist.
[0425] By "pharmaceutically acceptable," as used herein, refers a
material, such as a carrier or diluent, which does not abrogate the
biological activity or properties of the compound, and is
relatively nontoxic, i.e., the material may be administered to an
individual without causing undesirable biological effects or
interacting in a deleterious manner with any of the components of
the composition in which if is contained.
[0426] The term "pharmaceutically acceptable salt" of a compound,
as used herein, refers to a salt that is pharmaceutically
acceptable.
[0427] The term "pharmaceutical combination" as used herein, means
a product that results from the mixing or combining of more than
one active ingredient and includes both fixed and non-fixed
combinations of the active ingredients. The term "fixed
combination" means that the active ingredients, e.g. a compound of
Formula (A) or Formula (B) and a co-agent, are both administered to
a patient simultaneously in the form of a single entity or dosage.
The term "non-fixed combination" means that the active ingredients,
e.g. a compound of Formula (A) or Formula (B) and a co-agent, are
administered to a patient as separate entities either
simultaneously, concurrently or sequentially with no specific
intervening time limits, wherein such administration provides
effective levels of the two compounds in the body of the patient.
The latter also applies to cocktail therapy, e.g. the
administration of three or more active ingredients.
[0428] The term "pharmaceutical composition," as used herein,
refers to a mixture of an active compound with other chemical
components, such as carriers, stabilizers, diluents, dispersing
agents, suspending agents, thickening agents, and/or
excipients.
[0429] A "prodrug," as used herein, refers to a drug or compound in
which metabolic processes within the body converts the drug or
compound into a pharmacological active form.
[0430] The term "subject" or "patient" encompasses mammals and
non-mammals. Examples of mammals include, but are not limited to,
any member of the Mammalian class: humans, non-human primates such
as chimpanzees, and other apes and monkey species; farm animals
such as cattle, horses, sheep, goats, swine; domestic animals such
as rabbits, dogs, and cats; laboratory animals including rodents,
such as rats, mice and guinea pigs, and the like. Examples of
non-mammals include, but are not limited to, birds, fish and the
like. In one embodiment of the methods and compositions provided
herein, the mammal is a human.
[0431] The terms "treat," "treating" or "treatment," as used
herein, include alleviating, abating or ameliorating a disease or
condition symptoms, preventing additional symptoms, ameliorating or
preventing the underlying metabolic causes of symptoms, inhibiting
the disease or condition, e.g., arresting the development of the
disease or condition, relieving the disease or condition, causing
regression of the disease or condition, relieving a condition
caused by the disease or condition, or stopping the symptoms of the
disease or condition.
Illustrative Biological Activity
[0432] Presented herein are 5-substituted-2-aminopyrimidine
compounds which selectively modulate, regulate, and/or inhibit
signal transduction mediated by certain native and/or mutant
tyrosine kinases implicated in a variety of human and animal
diseases such as cell proliferative, metabolic, allergic, and
degenerative disorders. By way of example only, these compounds are
potent and selective c-kit inhibitors.
[0433] c-Kit Receptor
[0434] Mast cells are tissue elements derived from a particular
subset of hematopoietic stem cells that express CD34, c-kit and
CD13 antigens. Mast cells are characterized by their heterogeneity,
not only regarding tissue location and structure but also at the
functional and histochemical levels. Immature mast cell progenitors
circulate in the bloodstream and differentiate into various
tissues. These differentiation and proliferation processes are
under the influence of cytokines, one of utmost importance being
Stem Cell Factor (SCF), also termed Kit ligand, Steel factor or
Mast Cell Growth Factor. The Stem Cell Factor receptor is encoded
by the protooncogene, c-kit, which is expressed in hematopoietic
progenitor cells, mast cells, germ cells, interstitial cells of
Cajal (ICC), and some human tumors, and is also expressed by non
hematopoietic cells.
[0435] Tyrosine kinases are receptor type or non-receptor type
proteins, which transfer the terminal phosphate of ATP to tyrosine
residues of proteins thereby activating or inactivating signal
transduction pathways. The Stem Cell Factor receptor, c-kit, is a
Type III transmembrane receptor protein tyrosine kinase which
initiates cell growth and proliferation signal transduction
cascades in response to SCF binding. Ligation of c-kit receptor by
SCF induces its dimerization followed by its transphorilation,
leading to the recruitement and activation of various
intracytoplasmic substrates. These activated substrates induce
multiple intracellular signaling pathways responsible for cell
proliferation and activation. These proteins are known to be
involved in many cellular mechanisms, which in case of disruption,
lead to disorders such as abnormal cell proliferation and
migration, as well as inflammation.
[0436] The activity of the c-kit receptor protein tyrosine kinase
is regulated in normal cells, and the normal functional activity of
the c-kit gene product is essential for maintenance of normal
hematopoeisis, melanogenesis, genetogensis, and growth and
differentiation of mast cells. In addition to its importance in
normal cellular physiologic activities, c-kit plays a role in the
biological aspects of certain human cancers, and unregulated c-kit
kinase activity is implicated in the pathogenesis of human cancers,
and in certain tumors types. Proliferation of tumor cell growth
mediated by c-kit can occur by a specific mutation of the c-kit
polypeptide that results in ligand independent activation or by
autocrine stimulation of the receptor. In the former case,
mutations that cause constitutive activation of c-kit kinase
activity in the absence of SCF binding are implicated in malignant
human cancers, including germ cell tumors, mast cell tumors,
gastrointestinal stromal tumors, small-cell lung cancer, melanoma,
breast cancer, acute myelogenous leukemia, neuroblastoma and
mastocytosis.
[0437] Mast cells present in tissues of patients are implicated in
or contribute to the genesis of diseases such as autoimmune
diseases (multiple sclerosis, rheumatoid arthritis, inflammatory
bowel diseases (IBD)) allergic diseases (allergic sinusitis,
allergic rhinitis and asthma), tumor angiogenesis, inflammatory
diseases, and interstitial cystitis. In these diseases, mast cells
participate in the destruction of tissues by releasing a cocktail
of different proteases and mediators such as histamine, neutral
proteases, lipid-derived mediators (prostaglandins, thromboxanes
and leucotrienes), and various cytokines (IL-1, IL-2, IL-3, IL-4,
IL-5, IL-6, IL-8, TNF-A, GM-CSF, MIP-LA, MIP-1b, MIP-2 and
IFN-y).
[0438] Human are more and more afflicted in modern societies with
allergic disorders such as allergic sinusitis, allergic rhinitis
and asthma. For example, in the USA alone, it is estimated that
more than 87 million people are coping with some form of allergic
diseases. The financial burden of the treatments rises to a total
of several billion dollars and is due to the recurrence of these
diseases. Among these allergic diseases, we can cite allergic
rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria,
angioedema, atopic dermatitis, allergic contact dermatitis,
erythema nodosum, erythema multiforme, cutaneous necrotizing
venulitis and insect bite skin inflammation, but bronchial asthma
is the most prevalent and recurrent disease severely afflicting the
human population.
[0439] Asthma is characterized by airflow obstruction, bronchial
hyperresponsiveness and airway inflammation. Airway inflammation is
the major factor in the development and perpetuation of asthma. In
allergic asthma, which is the most frequent, especially in
children, and better studied form of the disease, allergens are
thought to initiate the inflammatory process by inducing a
T-lymphocyte mediated response (TH2) that results in the production
of allergen-specific IgE. IgE bind to its high-affinity receptor
FCERI on pulmonary mast cells triggering a type I (IgE-mediated)
immediate allergic response.
[0440] Mast cell activation induces diverse effector responses,
such as secretion of allergic mediators, proteases, chemokines such
as MCP-1 and RANTES, leukotrienes, prostaglandins, neurotrophins,
induction of cytokine gene transcription (IL-4, IL-5, IL-6, IL-13,
TNFA and GM-CSF). These mediators contribute to creating the
asthmatic phenotype by their effects on endothelial cells, smooth
muscle cells and fibroblasts and on extracellular matrix, and by
recruiting other inflammatory cells.
[0441] Different treatments are available to alleviate the symptoms
associated with allergic diseases. For instance, treatments for
severe allergic diseases such as asthma, include combination of
histamine H.sub.1-receptor antagonists with antagonists of
leukotriene receptors or 5-lipoxygenase inhibitors. However,
anti-histamine compounds have been found to be less effective and
do not provide a solution to the recurrence of asthma, and the
latter treatment only reduces inflammation symptoms associated with
allergic diseases and cannot be considered as a cure on the long
run. In response to this problem, interleukin-2 (IL-2) has been
used to suppress allergic disorders, but the induction of death by
apoptosis of a subpopulation of T lymphocytes has many side effects
limiting such therapy to the most severe forms of allergic
diseases.
[0442] Mast cells may play a role in asthma as suggested by the
humanized anti-IgE monoclonal antibody treatment. The rationale of
anti-IgE therapy is to specifically target IgE with the result of
inactivating free anti-IgE and halting further IgE production. In
addition, since IgE levels are a major regulator of the level of
expression of IgE receptor FceRI, one aim of this therapy is to
decrease FceRI expression on mast cells and basophils, and, as a
consequence, to decrease the capacity of these cells to be
activated. The capacity of the anti-IgE therapy to decrease FceRI
expression has been demonstrated on basophils. The decrease in
FceRI expression on basophils is associated with a decrease in the
capacity of basophils to secrete mediators upon activation. Even
though the effect of the anti-IgE therapy on pilmonary mast cells
has not been studied because these cells are difficult to harvest.
These trials have shown that the anti-IgE therapy is capable of
improving some of the parameters of asthma, for example
corticosteroid usage. Nevertheless, antibody based therapy is not
suitable to repeated treatment of the most recurrent forms of
allergic diseases. In addition, compositions comprising tryptase
inhibitors for treating mast-cell mediated conditions are may be
used, but decreasing the activity of free tryptase released by
activated mast cells is not sufficient to block chain reactions
caused by the others mast cells released factors. Therefore, there
is a need for alternative treatments of allergic diseases and/or
conditions which would be more effective on the long term and would
be well tolerated, especially in respect to repeated
administration.
[0443] Non-insulin-dependent diabetes mellitus (NLDDM), also known
as type II diabetes, is defined as a chronic disease appearing when
insulin is inefficient in promoting glucose uptake by cells,
resulting in increased levels of glucose in the blood. This disease
affects about 100 million people world-wide, 75% of which are obese
at the time of diagnosis.
[0444] Diminution in the ability of the cells to respond adequately
to insulin is often referred as insulin resistance. Excessive
weight and lack of physical activity are regarded as being
responsible for inducing insulin resistance. Over many years, the
failure of the glucose uptake regulation leads to the development
of Type II diabetes and the blood glucose level needs to be
regulated with medicinal products. Ultimately, unregulated blood
glucose level is responsible for blood vessels, kidney and eye
damages, as well as cardiovascular diseases. This tissue damages
contribute to mortality in diabetics.
[0445] Hypoglycemic agents such as sulfonylureas work by triggering
the pancreas to make more insulin, which lower blood glucose. The
side effects of sulfonylureas include hypoglycemia, renal and
hepatic disease, gastrointestinal disturbances, increased
cardiovascular mortality, dermatological reactions, drowsiness and
headache. Biguanides lower blood glucose levels by reducing
intestinal glucose absorption and hepatic glucose, but not by
stimulating insulin secretion. The major side effects of
biguanidine are lactic acidosis and increased cardiovascular
mortality. Alpha-glucosidase inhibitors decrease the absorption of
carbohydrates from the digestive tract, thereby lowering the
after-meal glucose level, but gastrointestinal side effects and
hypoglycemia are observed. Thiazolidinediones, such as
rosiglitazone are PPARgamma agonists and increase the cell's
sensitivity to insulin. However, they may be responsible for water
retention, liver diseases, cardiovascular diseases, red blood cell
abnormalities, and headache.
[0446] Because treatment of Type II diabetes requires long term
administration of compounds lowering blood glucose level, there is
still a great need for improved and safer methods. C-kit inhibitors
may also be used in the treatment of type II diabetes. Inhibition
of c-kit activity reduces cellular proliferation, depleting the
mast cells responsible for diseases and/or conditions, such as
allergic diseases, thereby suggesting a role for use of inhibitors
of c-kit in the treatment of c-kit dependent diseases and/or
conditions, such as diabetes. Described herein are diarylamine
compounds, pharmaceutical compositions and medicaments, which
include such diarylamine compounds or a pharmaceutically acceptable
salt or solvate thereof, that are potent and selective c-kit
inhibitors and which selectively modulate, regulate, and/or inhibit
signal transduction mediated by certain native and/or mutant
tyrosine kinases implicated in a variety of human and animal
diseases such as, by way of example only, diabetes.
[0447] Neurons propagate a signal in the form of an action
potential along its axon to other neurons or to effector cells.
Many positive or negative signals are exchanged between neurons and
are integrated to produce meaningful firing patterns. The
communication between two neurons is based on the action of
numerous neurotransmitters on specific receptors located at the
synapses. A disruption in the regulation of neurotransmission is
responsible for neurologic and psychiatric diseases. Furthermore,
the activity of neurotransmitters on their respective receptor is
normally time limited so that receptors can respond repeatedly to
the next waves of stimuli. In this regard, different mechanisms
abolish the action of neurotransmitters, for instance they can be
pumped back into the presynaptic nerve terminals by active
processes (reuptake), they can be destroyed by enzymes, or they
simply diffuse into the surrounding area.
[0448] Changes in neurotransmitter synthesis, storage, release, or
degradation or changes in the number and affinity of receptors can
affect neurotransmission and cause clinical disorders. Among
neurotransmitters, glutamate and aspartate are the major excitatory
neurotransmitters, whereas aminobutyric acid (GABA) is the major
inhibitory neurotransmitter in the brain. The first theory about
depression concerned the noradrenergic system (NS) (Shildkraut J.
et al. 1965, Am J. Psychiat. 12:, 509-522). At that time, it was
observed that tricyclic compounds (ADT) and monoamine-oxidase
inhibitors modified the level of noradrenaline. Later on, in 1978,
Sulser F. et al., Biochem Pharmacol. 27: 257-261 showed that these
antidepressants lead to a decrease in the number of post-synaptic
(3-Adrenergis receptors. Therefore, it was thought that depression
was due to the deregulation of the noradrenergic pre-synaptic
stimuli as well as the post-synaptic receptors (Siever L J. et AL.
(1985), Am. J. Psychiat. 142, 1017-1031).
[0449] In 1986, Rasmussen et al., Brain Res. 385: 395-400
demonstrated the presence of serotonin (5-hydroxytriptamin, 5-HT)
receptors in NA neurones. Treatments with ADT were shown to provoke
also a down-regulation of the 5-HT.sub.2 receptors in Sugrue M. F.
et al, 1981, Pharmacol. Ther. 13: 219-247. As a consequence, it
appears that the NA and 5-HT systems play a crucial role in the
regulation of mood and behaviour. In the nineties, research has
focused on the finding of specific serotonin re-uptake inhibitors
(SSRI), such as fluoxetin, parxetin or sertralin (Pinder R. M. et
al., 1993, Med. Res. Rev. 13: 259-325). Serotonin
(5-hydroxytryptamine, or 5-HT) levels are controlled by the uptake
of tryptophan and intraneuronal monoamine oxidase activity. In the
meantime, a decrease in the level of HVA, the main catabolic of
dopamin (DA), was observed in depressed patients (Kapur S. et al.,
1992, Biol. Psychiat. 32: 1-17). GABA was also shown to be involved
in the physiopathology of depression since (i) unpolar patients
display decreased level of GABA, (ii) some antidepressants induce
the release of GABA in vivo and (iii) agonists of GABA receptors
have antidepressant effects (Lloyd K. G. et al., 1989, Prog.
Neuro-Psycopharmacol. Biol. Psychiat. 13: 341-351).
[0450] More recently, it has been reported that other factors may
be involved in CNS disorders. For example, it has been observed
from 30 to 70% of patients afflicted with melancholia have high
level of plasmatic cortisol and escape to the test with
dexamethasone described in Caroll B. J. et al., 1981, Arch. Gen.
Psychiat. 38: 15. In addition, cortocosteroids modify (i) the
expression of serotoninergic receptors and (ii) the activity of
tryptophan hydroxylase, which is the key enzyme in the synthesis of
5-HT (Biegon A., 1990, Ann. NY Acad. Sci. 600: 427-431).
[0451] Regarding post-partum or post-menopause depression, repeated
administration of oestrogene induces a down-regulation of
dopaminergic D.sub.2 receptors (Munemura M. et al., 1989,
Endocrinology 124: 346-355 and Roy E. J. et al., 1990, Brain. Res.
Bull. 25: 221-227).
[0452] Other neurotransmitters include the well known
acetylcholine, norepinephrine which interacts with adrenergic
receptors and which is regulated by tyrosine hydroxylase and
monoamine oxidase, endorphins which are polypeptides that activate
many central neurons and interact with opioid receptors,
enkephalins, dynorphins, histamine, vasopressin, vasoactive
intestinal peptide, carnosine, bradykinin, cholecystokinin,
bombesin, somatostatin, corticotropin releasing factor,
neurotensin, and adenosine.
[0453] As mentioned above, any imbalance in these neurotransmitters
or any deregulation of associated receptors may lead to the
development of CNS disorders ranging from psychiatric diseases to
migraine, pain, memory loss and nerve cells degeneracy.
[0454] As of today, available treatments include selective
serotonin reuptake inhibitors (SSRIS) such as fluoxetine,
sertraline, paroxetine, and fluvoxamine. Other compounds include
nefaxodone which blocks the 5-HT.sub.2 receptor and inhibits
reuptake of 5-HT and norepinephrine, trazodone which is a
5-HT.sub.2 receptor blocker and a 1-noradrenergic blocker,
mirtazapine which blocks 2-adrenergic autoreceptors as well as
5-HT.sub.2, 5-HT.sub.3 and HI receptors, tricyclic compounds such
as imipramine and desipramine, tetracyclic compounds which increase
the level of free norepinephrine and of 5-HT, and monoamine oxidase
inhibitors (MAOI) which inhibit the oxidative deamination of
norepinephrine, dopamine, and 5-HT. We can also cite
lithium-antidepressants for treating bipolar disorder.
[0455] However, the above mentioned compounds display numerous side
effects such as tachycardia, sedation and weight gain. In addition,
these compounds are only effective in about 65% of depressed
patients, which implies a large population afflicted with the
so-called "refractory depression". In some cases, the life of
patients is in jeopardy at the extent that hospitalization and
electroconvulsive therapy is required, thus showing the seriousness
of these diseases.
[0456] Schizophrenia is also a serious mental disorder affecting
about 1% of western countries population. Antipsychotic
(neuroleptic) drugs available include chlorpromazine and
haloperidol which show affinity for the dopamine 2 receptor. But,
adverse side effects such as sedation, dystonia, tremors and
akathisia have been commonly observed and a significant percentage
of patients do not respond to the treatments.
[0457] Therefore, the problem is to find alternative solutions to
provide a relief and a cure for the numerous patients afflicted
with these diseases. The activation of mast cells by different
stimuli such as stress, trauma, infection as well as
neurotransmitters, may participate in the exacerbation of the
chemical imbalance causing CNS disorders. More specifically, mast
cell degranulation is stimulated by common neurotransmitters such
as neurotensin, somatostatin, substance P and acetylcholine, by
growth or survival factors, notably NGF, TGF.beta.L Mast cells
involved in the response to such stimulus can be brain mast cells
but also other mast cells releasing the content of their granules
in the blood stream that ultimately reach sensory, motor or brain
neurons. Brain mast cells staining is CTMC staining-like but they
show the secretory pattern of MMC, implying that they constitute a
particular subset of mast cells presenting specificities.
[0458] Following mast cells activation, released granules liberate
various factors capable of modulating and altering
neurotransmission and neurons survival. Among such factors,
serotonin is important since an increase of the level of free
serotonin has been observed in depressed patients. Alternatively,
the sudden burst of serotonin may be followed by a period of
serotonin shortage, leading to pain and migraine. As a consequence,
it is believed that mast cells exacerbate in autocrine or paracrine
manner the deregulation of neurotransmission. For example, anxiety
or stress-induced release of neurotransmitters such as serotonin
activates mast cells, which in turn release the content of their
granules, further contributing to the chemical imbalance in the
brain leading to CNS disorders.
[0459] Other mediators released by mast cells can be categorized
into vasoactive, nociceptive, proinflammatory and other
neurotransmitters. Taken together, these factors are able to induce
great disturbance in the activity of neurons, whether they are
sensory, motor, or CNS neurons.
[0460] In addition, patients afflicted with mastocytosis are more
incline to develop CNS disorders than the normal population. This
can be explained by the presence of activating mutations in the
c-kit receptor, which induce degranulation of mast cells and a
burst of factors contributing to chemical imbalance and
neurotransmission alteration.
[0461] In some cases, activated mast cells can also participate in
the destruction of neuronal tissues by releasing a cocktail of
different proteases and mediators categorized into three groups:
preformed granule-associated mediators (histamine, proteoglycans,
and neutral proteases), lipid-derived mediators (prostaglandins,
thromboxanes and leucotrienes), and various cytokines (IL-1, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-8, TNF-A, GM-CSF, MIP-LA, MIP-1b, MIP-2
and IFN-y). The liberation by activated mast cells of mediators
(TNF-A, histamine, leukotrienes, prostaglandines etc.) as well as
proteases may i) induce inflammation and vasodilatation and ii)
participate in the neuronal tissue destruction process.
[0462] Inhibition of c-kit activity reduces cellular proliferation,
depleting the mast cells responsible for diseases and/or
conditions, such as allergic diseases, thereby suggesting a role
for use of inhibitors of c-kit in the treatment of c-kit dependent
diseases and/or conditions, such as CNS disorders. Described herein
are diarylamine compounds, pharmaceutical compositions and
medicaments, which include such diarylamine compounds or a
pharmaceutically acceptable salt or solvate thereof, that are
potent and selective c-kit inhibitors and which selectively
modulate, regulate, and/or inhibit signal transduction mediated by
certain native and/or mutant tyrosine kinases implicated in a
variety of human and animal diseases such as, by way of example
only, CNS disorders.
[0463] Drug dependence is the result of a phenomenon called
tolerance, which is the need to increase the dose of the drug to
maintain its full effect, and of physical dependence, which is the
habituation of the body to a drug. When the intake of a drug is
discontinued, individual may experience unpleasant withdrawal
syndrome. This syndrome is difficult to qualify or quantify but it
can be illustrated by a strong feeling of unmet satisfaction.
[0464] This episode has been described by former drug addicted
individuals as "a strong scream and complaint emanating from the
body", which indicates the seriousness and the difficulties
encountered by these individuals. In addition, it must be
emphasized that drug addiction is accompanied with or may follow
psychiatric disorders such as anxiety, depression, and
schizophrenia.
[0465] Drugs leading to dependence can be classified into two
types. One type is responsible for psychologic dependence such as
cocaine, marijuana, amphetamine, and hallucinogens. The other type
is more prone to physical dependence, but one must not rule out
psychologic dependence, and is exemplified by drugs such as heroin,
alcohol and nicotine.
[0466] Of course, any drug that acts on the CNS may involve a risk
of dependence. For example, one of the side effects of
benzodiazepine derivatives is dependence. In animal models, it has
been observed that administration of drugs such as opioids,
cocaine, amphetamine, nicotine, and benzodiazepines is associated
with enhanced dopaminergic transmission. The problem is that the
increased level of DA may be followed by a down regulation of DA
receptors. This might explain in part the observed withdrawal
symptoms that are sometimes associated with depression, mood
disorders, insomnia and other unwanted dependence disorders.
[0467] Drug addiction may be responsible for, or arise from, job
pressure or familial problems resulting in anxiety or depression.
At the extreme of the spectrum, it can result in hospitalization
for overdose, withdrawal episodes and associated substance use
disorders.
[0468] Finally, anxyolitics such as benzodiazepines are being
consumed more and more, therefore, it is urgent to find solutions
for preventing and managing drug dependence and withdrawal
symptoms. The socioeconomic consequences of reliable solutions will
have a huge impact in modern societies since addiction is often
accompanied not only with susceptibility to HIV infection and
hepatitis. Consequently, research programs aimed at developing
compounds capable of alleviating drug dependence and withdrawal
symptoms must be encouraged and considered as a top priority.
[0469] Substance abuse and drug addiction introduce changes in
neurotransmitter synthesis, storage, release, or in the number and
affinity of receptors. This can affect neurotransmission and cause
drug dependence and withdrawal symptoms. Among neurotransmitters,
example include, but are not limited to, glutamate and aspartate,
which are the major excitatory neurotransmitters, aminobutyric acid
(GABA), which is the major inhibitory neurotransmitter in the brain
and shown to be involved in the physiopathology of depression,;
serotinin (5-HT); dopamine (DA), which was observed in depressed
patients; acetylcholine, norepinephrine which interacts with
adrenergic receptors and which is regulated by tyrosine hydroxylase
and monoamine oxidase; endorphins, which are polypeptides that
activate many central neurons and interact with opioid receptors,
and others neurotransmitters such as enkephalins, dynorphins,
histamine, vasopressin, vasoactive intestinal peptide, carnosine,
bradykinin, cholecystokinin, bombesin, somatostatin, corticotropin
releasing factor, neurotensin, and adenosine. As mentioned above,
any imbalance in these neurotransmitters or any deregulation of
associated receptors due to drug intake may lead to the development
of drug dependence and withdrawal symptoms.
[0470] It has been identified that mast cells are involved in or
contribute to drug dependence and withdrawal symptoms. The
activation of mast cells by different drugs, including, but not
limited to, salicylic derivatives, morphine derivatives, opioids,
heroin, amphetamines, alcohol, nicotine, analgesics, anesthetics,
and anxyolitics results in the degranulation of mast cells, which
participate in the exacerbation of the chemical imbalance
responsible for drug habituation and withdrawal syndrome. In
addition, following mast cells activation, released granules
liberate various factors capable of modulating and altering
neurotransmission. Among such factors, is morphine which is bound
or stored in mast cells granules. Also tobacco smoke induces the
release of mediators from canine mast cells and modulates
prostaglandin production leading to asthma. In addition, patients
afflicted with mastocytosis are more incline to develop substance
use disorders than the normal population. This can be explained by
the presence of activating mutations in the c-kit receptor, which
inducedegranulation of mast cells and a burst of factors
contributing to chemical imbalance and neurotransmission
alteration.
[0471] Presently, there is no treatment providing relief and help
to individuals to withdraw from their addiction are available.
C-kit inhibitors may be used for treating substance abuse
disorders, particularly drug addiction, drug abuse, drug
habituation, drug dependence, withdrawal syndrome and overdose,
comprising administering a compound capable of depleting mast cells
to a human in need of such treatment.
[0472] Inhibition of c-kit activity reduces cellular proliferation,
depleting the mast cells responsible for diseases and/or
conditions, such as drug dependency, thereby suggesting a role for
use of inhibitors of c-kit in the treatment of c-kit dependent
diseases and/or conditions, such as drug dependency. Described
herein are diarylamine compounds, pharmaceutical compositions and
medicaments, which include such diarylamine compounds or a
pharmaceutically acceptable salt or solvate thereof, that are
potent and selective c-kit inhibitors and which selectively
modulate, regulate, and/or inhibit signal transduction mediated by
certain native and/or mutant tyrosine kinases implicated in a
variety of human and animal diseases such as, by way of example
only, drug dependency.
[0473] Described herein are diarylamine compounds, pharmaceutical
compositions and medicaments, which include such diarylamine
compounds or a pharmaceutically acceptable salt or solvate thereof,
for treating a disease and/or condition in an animal in which c-kit
receptor activity contributes to the pathology and/or symptomology
of the disease or condition. Such diseases and/or conditions
include, but are not limited to, (i) neoplastic diseases, such as,
but not limited to mastocytosis, canine mastocytoma, human
gastrointestinal stromal tumor, small cell lung cancer, non-small
cell lung cancer, acute myelocytic leukemia, acute lymphocytic
leukemia, myelodysplastic syndrome, chronic myelogenous leukemia,
colorectal carcinomas, gastric carcinomas, gastrointestinal stromal
tumors, testicular cancers, glioblastomas, and astrocytomas; (ii)
allergy diseases, such as, but not limited to, asthma, allergic
rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria,
angioedema, atopic dermatitis, allergic contact dermatitis,
erythema nodosum, erythema multiforme, cutaneous necrotizing
venulitis and insect bite skin inflammation and blood sucking
parasitic infestation; (iii) inflammatory diseases, such as, but
not limited to, rheumatoid arthritis, conjunctivitis, rheumatoid
spondylitis, osteoarthritis, gouty arthritis and other arthritic
conditions; (iv) autoimmune diseases, such as, but not limited to,
multiple sclerosis, psoriasis, intestine inflammatory disease,
ulcerative colitis, Crohn's disease, rheumatoid arthritis and
polyarthritis, local and systemic scleroderma, systemic lupus
erythematosus, discoid lupus erythematosus, cutaneous lupus,
dermatomyositis, polymyositis, Sjogren's syndrome, nodular
panarteritis, autoimmune enteropathy, and proliferative
glomerulonephritis; (v) graft-versus-host diseases, such as, but
not limited to, organ transplantation graft rejection (including,
but not limited to, kidney transplantation, pancreas
transplantation, liver transplantation, heart transplantation, lung
transplantation, and bone marrow transplantation); (vi) metabolic
syndromes, such as, but not limited to, type I diabetes, type II
diabetes, or obesity; (vii) CNS related disorders, such, as, but
not limited to, depression, dysthymic disorder, cyclothymic
disorder, bipolar depression, severe or "melancholic" depression,
atypical depression, refractory depression, seasonal depression,
anorexia, bulimia, premenstrual syndrome and post-menopause
syndrome, as mental slowing and loss of concentration, pessimistic
worry, agitation, self-deprecation and decreased libido, as anxiety
disorders including anxiety associated with hyperventilation and
cardiac arrhythmias, phobic disorders, obsessive-compulsive
disorder, posttraumatic stress disorder, acute stress disorder, and
generalized anxiety disorder, as psychiatric disorders such as
panic attacks, including psychosis, delusional disorders,
conversion disorders, phobias, mania, delirium, dissociative
episodes including dissociative amnesia, dissociative fugue and
dissociative suicidal behavior, self-neglect, violent or aggressive
behavior, trauma, borderline personality, and acute psychosis as
schizophrenia including paranoid schizophrenia, disorganized
schizophrenia, catatonic schizophrenia, and undifferentiated
schizophrenia; (viii) neurodegenerative diseases, such as, but not
limited to, Alzheimer's disease, Parkinson's disease, Huntington's
disease, the prion diseases, Motor Neuron Disease (MND), and
Amyotrophic Lateral Sclerosis (ALS), (ix) pain, such as, but not
limited to, acute pain, postoperative pain, chronic pain,
nociceptive pain, cancer pain, neuropathic pain, and psychogenic
pain syndromes; (x) substance use disorders, such as, but not
limited to, drug addiction, drug abuse, drug habituation, drug
dependence, withdrawal syndrome and overdose; (xi) prion diseases;
(xii) cancers, such as, but not limited to, melanoma,
gastrointestinal stromal tumor (GIST), small-cell lung cancer, germ
cell tumors, mast cell tumors, breast cancer, acute myelogenous
leukemia, neuroblastoma, mastocytosis, and other solid tumors;
(xiii) heart diseases; (xiv) fibrotic diseases, such as, but not
limited to, hepatitis C (HCV), liver fibrosis, nonalcoholic
steatohepatitis (NASH), cirrhosis in liver, pulmonary fibrosis, and
bone marrow fibrosis; (xv) idiopathic pulmonary arterial
hypertension (IPAH); and (xvi) primary pulmonary hypertension
(PPH).
Compounds
[0474] Compounds having the structure of Formula (A) or Formula
(B), pharmaceutically acceptable salts, pharmaceutically acceptable
N-oxides, pharmaceutically active metabolites, pharmaceutically
acceptable prodrugs, and pharmaceutically acceptable solvates
thereof, modulate the activity of c-kit receptors; and, as such,
are useful for treating diseases or conditions in which aberrant
c-kit receptor activity contributes to the pathology and/or
symptoms of a disease or condition:
##STR00300##
[0475] wherein: [0476] Q.sub.1 is H, halogen, a group comprising a
non-aromatic tertiary amine, a group comprising a non-aromatic
secondary amine, or is an optionally substituted moiety selected
from the group consisting of: -L-alkyl, -L-cycloalkyl,
-L-heteroalkyl, -L-haloalkyl, -L-aryl, -L-heterocycloalkyl, and
-L-heteroaryl; wherein L is selected from a bond, --O--, --NH--,
--S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --OC(O)--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''YC(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y is optionally
substituted arylene or heteroarylene; [0477] each R.sub.1 is
independently selected from the group consisting of H, halogen, and
an optionally substituted moiety selected from -L.sub.1-alkyl,
-L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl, -L.sub.1-haloalkyl,
-L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and -L.sub.1-heteroaryl;
wherein L.sub.1 is selected from a bond, --O--, --NH--, --S--,
--C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y'C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y' is optionally
substituted arylene or heteroarylene; [0478] Q.sub.2 is selected
from the group consisting of H, halogen, and a group comprising an
optionally substituted moiety selected from -L.sub.6-alkyl,
-L.sub.6-cycloalkyl, -L.sub.6-heteroalkyl, -L.sub.6-haloalkyl,
-L.sub.6-aromatic carbocycle, -L.sub.6-heterocycloalkyl, and
-L.sub.6-aromatic heterocycle; wherein L.sub.6 is selected from a
bond, --O--, --NH--, --S--, --C(O)--, --C(S)--, --C(O)O--,
--C(O)NH--, --S(O)--, --S(O).sub.2--,
--C(O)NR''(CR''.sub.2).sub.1-6C(O)O--, --OC(O)--,
--CR''.sub.2NR''CR''.sub.2C(O)O--, --C(O)--NR''Y''C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; and Y'' is optionally
substituted arylene or heteroarylene; [0479] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, haloaryl, or heteroaryl; [0480] any two
R.sub.1 groups together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring; [0481] R.sub.5
is selected from the group consisting of H, and an optionally
substituted moiety selected from -L.sub.5-H, -L.sub.5-alkyl,
-L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl, -L.sub.5-haloalkyl,
-L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and -L.sub.5-heteroaryl,
wherein L.sub.5 is selected from a bond, --R'O--, --R'N(H)--,
--R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--, and --R'C(O)NH--;
[0482] each R' is independently selected from the group consisting
of a bond, alkylene, substituted alkylene, heteroalkylene,
substituted heteroalkylene, alkenylene, substituted alkenylene,
cycloalkylene, substituted cycloalkylene, heteroalkylene,
substituted heteroalkylene, heterocycloalkylene, substituted
heterocycloalkylene, arylene, substituted arylene, heteroarylene,
substituted heteroarylene, alkarylene, substituted alkarylene,
aralkylene, and substituted aralkylene; and [0483] any R.sub.1 and
R.sub.5 taken together may form an optionally substituted 5 to
8-membered heterocyclic, cycloalkyl, or aryl ring.
[0484] Compounds having the structure of Formula (A) or Formula (B)
include compounds having the structure of Formula (1) or Formula
(46) and pharmaceutically acceptable salts, pharmaceutically
acceptable N-oxides, pharmaceutically active metabolites,
pharmaceutically acceptable prodrugs, and pharmaceutically
acceptable solvates thereof. Such compounds also modulate the
activity of c-kit receptors and, as such, are useful for treating
diseases or conditions in which aberrant c-kit receptor activity
contributes to the pathology and/or symptoms of a disease or
condition:
##STR00301##
[0485] wherein: [0486] Ar is a group comprising a moiety selected
from an optionally substituted five-membered aromatic heterocycle,
an optionally substituted five-membered aromatic carbocycle, an
optionally substituted six-membered aromatic heterocycle, and a
substituted, optionally further substituted six-membered aromatic
carbocycle; [0487] Q is a group comprising a non-aromatic tertiary
amine or a non-aromatic secondary amine, with the proviso that Q is
not --NR.sub.aR.sub.b or --SO.sub.2NR.sub.aR.sub.b; wherein each of
R.sub.a and R.sub.b is independently H or C.sub.1-6alkyl optionally
substituted by mono- or di-alkyl (C.sub.1-6) amino; [0488] each
R.sub.1 is independently selected from the group consisting of H,
halogen, and an optionally substituted moiety selected from
-L.sub.1-alkyl, -L.sub.1-cycloalkyl, -L.sub.1-heteroalkyl,
-L.sub.1-haloalkyl, -L.sub.1-aryl, -L.sub.1-heterocycloalkyl, and
-L-heteroaryl; wherein L.sub.1 is selected from a bond, --O--,
--NH--, --S--, --C(O)--, --C(S)--, --C(O)O--, --C(O)NH--, --S(O)--,
--S(O).sub.2--, --C(O)NH(CR''.sub.2).sub.1-6C(O)O--,
--C(O)NR''NR''C(O)O--, and --S(O)NH--; [0489] each R'' is
independently H, OH, halogen, C.sub.1-6alkyl, substituted
C.sub.1-6alkyl, C.sub.1-6alkoxy, halo-C.sub.1-6alkyl,
halo-C.sub.1-6alkoxy, aryl, halo aryl, or heteroaryl; [0490] or any
two adjacent R.sub.1 groups together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;
[0491] R.sub.5 is selected from the group consisting of H, and an
optionally substituted moiety selected from -L.sub.5-H,
-L.sub.5-alkyl, -L.sub.5-cycloalkyl, -L.sub.5-heteroalkyl,
-L.sub.5-haloalkyl, -L.sub.5-aryl, -L.sub.5-heterocycloalkyl, and
-L.sub.5-heteroaryl; wherein L.sub.5 is selected from a bond,
--R'O--, --R'N(H)--, --R'S--, --R'C(O)--, --R'C(S)--, --R'C(O)O--,
and --R'C(O)NH--; [0492] each R' is independently selected from the
group consisting of a bond, alkylene, substituted alkylene,
heteroalkylene, substituted heteroalkylene, alkenylene, substituted
alkenylene, cycloalkylene, substituted cycloalkylene,
heteroalkylene, substituted heteroalkylene, heterocycloalkylene,
substituted heterocycloalkylene, arylene, substituted arylene,
heteroarylene, substituted heteroarylene, alkarylene, substituted
alkarylene, aralkylene, and substituted aralkylene; and [0493] any
R.sub.1 and R.sub.5 taken together may form an optionally
substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl
ring.
[0494] Table 1 shows exemplary, non-limiting examples of compounds
which have the structure of Formula (A) or Formula (B), and which
modulate the activity of c-kit receptors.
TABLE-US-00001 TABLE 1 Examplary compounds which modulate the
activiry of c-kit receptors. MS # Structure [M + 1].sup.+ 1
##STR00302## 520.4 2 ##STR00303## 582.4 3 ##STR00304## 536.4 4
##STR00305## 520.4 5 ##STR00306## 538.3 6 ##STR00307## 542.3 7
##STR00308## 498.3 8 ##STR00309## 572.3 9 ##STR00310## 600.4 10
##STR00311## 570.5 11 ##STR00312## 574.4 12 ##STR00313## 492.4 13
##STR00314## 568.4 14 ##STR00315## 520.4 15 ##STR00316## 582.4 16
##STR00317## 536.4 17 ##STR00318## 520.4 18 ##STR00319## 524.5 19
##STR00320## 506.5 20 ##STR00321## 521.2 21 ##STR00322## 425.1 22
##STR00323## 433.2 23 ##STR00324## 520.5 24 ##STR00325## 447.2 25
##STR00326## 377.2 26 ##STR00327## 627.0 27 ##STR00328## 534.5 28
##STR00329## 631.6 29 ##STR00330## 421.2 30 ##STR00331## 425.5 31
##STR00332## 423.1 32 ##STR00333## 423.4 33 ##STR00334## 492.3 34
##STR00335## 552.2 35 ##STR00336## 552.1 36 ##STR00337## 379.2 37
##STR00338## 453.1 38 ##STR00339## 550.2 39 ##STR00340## 534.2 40
##STR00341## 504.3 41 ##STR00342## 391.2 42 ##STR00343## 391.2 43
##STR00344## 395.2 44 ##STR00345## 377.4 45 ##STR00346## 421.2 46
##STR00347## 605.1 47 ##STR00348## 517.5 48 ##STR00349## 580.3 49
##STR00350## 449.2 50 ##STR00351## 550.1 51 ##STR00352## 379.2 52
##STR00353## 393.4 53 ##STR00354## 534.2 54 ##STR00355## 534.5 55
##STR00356## 522.2 56 ##STR00357## 638.0 57 ##STR00358## 494.3 58
##STR00359## 463.1 59 ##STR00360## 506.2 60 ##STR00361## 582.6 61
##STR00362## 575.1 62 ##STR00363## 575.1 63 ##STR00364## 562.2 64
##STR00365## 548.6 65 ##STR00366## 423.1 66 ##STR00367## 391.3 67
##STR00368## 534.2 68 ##STR00369## 631.0 69 ##STR00370## 365.2 70
##STR00371## 477.0 71 ##STR00372## 592.0 72 ##STR00373## 453.1 73
##STR00374## 448.3 74 ##STR00375## 421.1 75 ##STR00376## 548.5 76
##STR00377## 494.1 77 ##STR00378## 621.0 78 ##STR00379## 591.1 79
##STR00380## 532.3 80 ##STR00381## 448.3 81 ##STR00382## 421.2 82
##STR00383## 590.1 83 ##STR00384## 465.5 84 ##STR00385## 364.2 85
##STR00386## 464.3 86 ##STR00387## 560.2 87 ##STR00388## 580.1 88
##STR00389## 560.5 89 ##STR00390## 407.2 90 ##STR00391## 647.0 91
##STR00392## 604.0 92 ##STR00393## 435.0 93 ##STR00394## 407.2 94
##STR00395## 548.1 95 ##STR00396## 506.2 96 ##STR00397## 425.2 97
##STR00398## 575.1 98 ##STR00399## 611.0 99 ##STR00400## 604.1 100
##STR00401## 558.1 101 ##STR00402## 519.2 102 ##STR00403## 484.3
103 ##STR00404## 518.3 104 ##STR00405## 549.2 105 ##STR00406##
406.4 106 ##STR00407## 619.0 107 ##STR00408## 516.2 108
##STR00409## 422.3 109 ##STR00410## 389.2 110 ##STR00411## 433.3
111 ##STR00412## 420.4 112 ##STR00413## 431.1 113 ##STR00414##
608.0 114 ##STR00415## 646.0 115 ##STR00416## 428.1 116
##STR00417## 349.1 117 ##STR00418## 647.0 118 ##STR00419## 500.3
119 ##STR00420## 547.1 120 ##STR00421## 504.3 121 ##STR00422##
485.2 122 ##STR00423## 608.3
123 ##STR00424## 505.3 124 ##STR00425## 582.3 125 ##STR00426##
562.5 126 ##STR00427## 647.4 127 ##STR00428## 610.0 128
##STR00429## 369.1 129 ##STR00430## 406.4 130 ##STR00431## 409.4
131 ##STR00432## 394.2 132 ##STR00433## 421.2 133 ##STR00434##
508.2 134 ##STR00435## 411.2 135 ##STR00436## 492.4 136
##STR00437## 568.4 137 ##STR00438## 542.3 138 ##STR00439## 471.3
139 ##STR00440## 408.3 140 ##STR00441## 465.0 141 ##STR00442##
520.3 142 ##STR00443## 383.1 143 ##STR00444## 407.1 144
##STR00445## 420.3 145 ##STR00446## 406.2 146 ##STR00447## 448.3
147 ##STR00448## 617.5 148 ##STR00449## 549.4 149 ##STR00450##
558.3 150 ##STR00451## 632.4 151 ##STR00452## 618.4 152
##STR00453## 675.5 153 ##STR00454## 633.4 154 ##STR00455## 393.2
155 ##STR00456## 451.3 156 ##STR00457## 437.2 157 ##STR00458##
377.3 158 ##STR00459## 409.2 159 ##STR00460## 441.2 160
##STR00461## 432.3 161 ##STR00462## 403.0 162 ##STR00463## 444.3
163 ##STR00464## 420.0 164 ##STR00465## 418.5 165 ##STR00466##
361.3 166 ##STR00467## 405.2 167 ##STR00468## 447.3 168
##STR00469## 470.0 169 ##STR00470## 418.2 170 ##STR00471## 346.2
171 ##STR00472## 435.0 172 ##STR00473## 376.0 173 ##STR00474##
407.2 174 ##STR00475## 462.0 175 ##STR00476## 418.3 176
##STR00477## 474.3 177 ##STR00478## 391.3 178 ##STR00479## 432.3
179 ##STR00480## 389.4 180 ##STR00481## 476.3 181 ##STR00482##
419.0 182 ##STR00483## 391.0 183 ##STR00484## 476.3 184
##STR00485## 432.3 185 ##STR00486## 405.3 186 ##STR00487## 377.3
187 ##STR00488## 405.3 188 ##STR00489## 433.0 189 ##STR00490##
419.0 190 ##STR00491## 434.3 191 ##STR00492## 461.3 192
##STR00493## 476.3 193 ##STR00494## 347.3 194 ##STR00495## 448.3
195 ##STR00496## 405.0 196 ##STR00497## 433.0 197 ##STR00498##
446.2 198 ##STR00499## 431.2 199 ##STR00500## 419.2 200
##STR00501## 389.2 201 ##STR00502## 488.3 202 ##STR00503## 419.2
203 ##STR00504## 518.3 204 ##STR00505## 601.3 205 ##STR00506##
434.0 206 ##STR00507## 533.0 207 ##STR00508## 533.1 208
##STR00509## 478.3 209 ##STR00510## 478.2 210 ##STR00511## 420.5
211 ##STR00512## 407.2 212 ##STR00513## 365.2 213 ##STR00514##
434.3 214 ##STR00515## 418.3 215 ##STR00516## 419.3 216
##STR00517## 419.1 217 ##STR00518## 390.5 218 ##STR00519## 406.2
219 ##STR00520## 404.2 220 ##STR00521## 420.2 221 ##STR00522##
418.6 222 ##STR00523## 413.5 223 ##STR00524## 392.5 224
##STR00525## 447.6 225 ##STR00526## 447.2 226 ##STR00527## 416.2
227 ##STR00528## 434.2 228 ##STR00529## 307.1 229 ##STR00530##
433.2 230 ##STR00531## 390.3 231 ##STR00532## 432.4 232
##STR00533## 488.4 233 ##STR00534## 432.3 234 ##STR00535## 461.4
235 ##STR00536## 484.4 236 ##STR00537## 432.3 237 ##STR00538##
404.2 238 ##STR00539## 432.4 239 ##STR00540## 417.4 240
##STR00541## 434.4 241 ##STR00542## 405.4 242 ##STR00543## 419.2
243 ##STR00544## 375.3 244 ##STR00545## 418.4 245 ##STR00546##
375.3 246 ##STR00547## 405.1 247 ##STR00548## 391.4 248
##STR00549## 419.3
249 ##STR00550## 447.3 250 ##STR00551## 445.3 251 ##STR00552##
477.2 252 ##STR00553## 437.2 253 ##STR00554## 447.3 254
##STR00555## 469.3 255 ##STR00556## 461.3 256 ##STR00557## 435.2
257 ##STR00558## 437.2 258 ##STR00559## 432.2 259 ##STR00560##
473.5 260 ##STR00561## 447.2 261 ##STR00562## 433.5 262
##STR00563## 461.3 263 ##STR00564## 475.3 264 ##STR00565## 448.2
265 ##STR00566## 490.4 266 ##STR00567## 476.3 267 ##STR00568##
490.3 268 ##STR00569## 473.3 269 ##STR00570## 433.2 270
##STR00571## 462.3 271 ##STR00572## 421.2 272 ##STR00573## 419.1
273 ##STR00574## 435.2 274 ##STR00575## 435.2 275 ##STR00576##
461.1 276 ##STR00577## 447.2 277 ##STR00578## 433.2 278
##STR00579## 445.2 279 ##STR00580## 491.2 280 ##STR00581## 447.2
281 ##STR00582## 447.2 282 ##STR00583## 533.2 283 ##STR00584##
465.2 284 ##STR00585## 451.2 285 ##STR00586## 431.2 286
##STR00587## 499.2 287 ##STR00588## 419.2 288 ##STR00589## 419.2
289 ##STR00590## 403.3 290 ##STR00591## 432.2 291 ##STR00592##
419.2 292 ##STR00593## 490.2 293 ##STR00594## 391.2 294
##STR00595## 375.2 295 ##STR00596## 488.3 296 ##STR00597## 419.2
297 ##STR00598## 391.2 298 ##STR00599## 379.3 299 ##STR00600##
405.1 300 ##STR00601## 419.2 301 ##STR00602## 401.2 302
##STR00603## 367.1 303 ##STR00604## 441.2 304 ##STR00605## 375.2
305 ##STR00606## 419.2 306 ##STR00607## 448.3 307 ##STR00608##
415.2 308 ##STR00609## 403.2 309 ##STR00610## 484.3 310
##STR00611## 446.2 311 ##STR00612## 432.3 312 ##STR00613## 418.3
313 ##STR00614## 379.2 314 ##STR00615## 392.2 315 ##STR00616##
389.2 316 ##STR00617## 432.2 317 ##STR00618## 398.2 318
##STR00619## 440.2 319 ##STR00620## 467.2 320 ##STR00621## 405.2
321 ##STR00622## 377.2 322 ##STR00623## 441.2 323 ##STR00624##
440.2 324 ##STR00625## 425.2 325 ##STR00626## 429.3 326
##STR00627## 491.2 327 ##STR00628## 486.3 328 ##STR00629## 482.2
329 ##STR00630## 472.4 330 ##STR00631## 393.1 331 ##STR00632##
426.3 332 ##STR00633## 365.2 333 ##STR00634## 405.2 334
##STR00635## 405.2 335 ##STR00636## 401.2 336 ##STR00637## 405.2
337 ##STR00638## 458.4 338 ##STR00639## 403.2 339 ##STR00640##
421.2 340 ##STR00641## 389.2 341 ##STR00642## 458.4 342
##STR00643## 426.2 343 ##STR00644## 432.2 344 ##STR00645## 378.2
345 ##STR00646## 403.2 346 ##STR00647## 432.2 347 ##STR00648##
458.5 348 ##STR00649## 419.5 349 ##STR00650## 464.2 350
##STR00651## 417.3 351 ##STR00652## 429.2 352 ##STR00653## 435.3
353 ##STR00654## 393.2 354 ##STR00655## 478.3 355 ##STR00656##
421.3 356 ##STR00657## 447.3 357 ##STR00658## 379.2 358
##STR00659## 405.2 359 ##STR00660## 367.2 360 ##STR00661## 385.2
361 ##STR00662## 448.3 362 ##STR00663## 415.3 363 ##STR00664##
484.3 364 ##STR00665## 446.3 365 ##STR00666## 432.3 366
##STR00667## 418.3 367 ##STR00668## 379.2 368 ##STR00669## 392.3
369 ##STR00670## 432.2 370 ##STR00671## 398.2 371 ##STR00672##
467.3 372 ##STR00673## 429.2 373 ##STR00674## 491.3
374 ##STR00675## 486.3 375 ##STR00676## 482.5 376 ##STR00677##
472.3 377 ##STR00678## 426.3 378 ##STR00679## 365.2 379
##STR00680## 405.3 380 ##STR00681## 405.3 381 ##STR00682## 458.2
382 ##STR00683## 432.2 383 ##STR00684## 405.3 384 ##STR00685##
405.2 385 ##STR00686## 389.3 386 ##STR00687## 458.4 387
##STR00688## 426.3 388 ##STR00689## 432.3 389 ##STR00690## 403.3
390 ##STR00691## 432.3 391 ##STR00692## 432.3 392 ##STR00693##
458.3 393 ##STR00694## 419.3 394 ##STR00695## 429.5 395
##STR00696## 393.3 396 ##STR00697## 392.1 397 ##STR00698## 403.6
398 ##STR00699## 501.6 399 ##STR00700## 487.3 400 ##STR00701##
503.3 401 ##STR00702## 474.6 402 ##STR00703## 475.5 403
##STR00704## 501.5 404 ##STR00705## 440.3 405 ##STR00706## 486.6
406 ##STR00707## 453.1 407 ##STR00708## 426.3 408 ##STR00709##
460.4 409 ##STR00710## 440.7 410 ##STR00711## 432.5 411
##STR00712## 375.5 412 ##STR00713## 391.3 413 ##STR00714## 390.1
414 ##STR00715## 404.2 415 ##STR00716## 391.2 416 ##STR00717##
390.1 417 ##STR00718## 404.2 418 ##STR00719## 391.2 419
##STR00720## 432.2 420 ##STR00721## 462.2 421 ##STR00722## 448.2
422 ##STR00723## 483.2 423 ##STR00724## 458.2 424 ##STR00725##
433.2 425 ##STR00726## 475.2 426 ##STR00727## 490.2 427
##STR00728## 447.2 428 ##STR00729## 462.2 429 ##STR00730## 448.2
430 ##STR00731## 407.1 431 ##STR00732## 375.1 432 ##STR00733##
433.3 433 ##STR00734## 447.2 434 ##STR00735## 502.4 435
##STR00736## 463.2 436 ##STR00737## 505.3 437 ##STR00738## 445.2
438 ##STR00739## 391.2 439 ##STR00740## 391.2
Synthesis of the Compounds
[0495] Compounds of Formula (A) or Formula (B) and compounds having
the structures described in the prior section may be synthesized
using standard synthetic techniques known to those of skill in the
art or using methods known in the art in combination with methods
described herein. In additions, solvents, temperatures and other
reaction conditions presented herein may vary according to the
practice and knowledge of those of skill in the art.
[0496] The starting material used for the synthesis of the
compounds of Formula (A) or Formula (B) and compounds having the
structures described in the prior section as described herein can
be obtained from commercial sources, such as Aldrich Chemical Co.
(Milwaukee, Wis.), Sigma Chemical Co. (St. Louis, Mo.), or the
starting materials can be synthesized. The compounds described
herein, and other related compounds having different substituents
can be synthesized using techniques and materials known to those of
skill in the art, such as described, for example, in March,
ADVANCED ORGANIC CHEMISTRY 4.sup.th Ed., (Wiley 1992); Carey and
Sundberg, ADVANCED ORGANIC CHEMISTRY 4.sup.th Ed., Vols. A and B
(Plenum 2000, 2001), and Green and Wuts, PROTECTVE GROUPS IN
ORGANIC SYNTHESIS 3.sup.rd Ed., (Wiley 1999) (all of which are
incorporated by reference in their entirety). General methods for
the preparation of compound as disclosed herein may be derived from
known reactions in the field, and the reactions may be modified by
the use of appropriate reagents and conditions, as would be
recognized by the skilled person, for the introduction of the
various moieties found in the formulae as provided herein. As a
guide the following synthetic methods may be utilized.
Formation of Covalent Linkages by Reaction of an Electrophile with
a Nucleophile
[0497] The compounds described herein can be modified using various
electrophiles or nucleophiles to form new functional groups or
substituents. Table 2 entitled "Examples of Covalent Linkages and
Precursors Thereof" lists selected examples of covalent linkages
and precursor functional groups which yield and can be used as
guidance toward the variety of electrophiles and nucleophiles
combinations available. Precursor functional groups are shown as
electrophilic groups and nucleophilic groups.
TABLE-US-00002 TABLE 2 Examples of Covalent Linkages and Precursors
Thereof Covalent Linkage Product Electrophile Nucleophile
Carboxamides Activated esters amines/anilines Carboxamides acyl
azides amines/anilines Carboxamides acyl halides amines/anilines
Esters acyl halides alcohols/phenols Esters acyl nitriles
alcohols/phenols Carboxamides acyl nitriles amines/anilines Imines
Aldehydes amines/anilines Hydrazones aldehydes or ketones
Hydrazines Oximes aldehydes or ketones Hydroxylamines Alkyl amines
alkyl halides amines/anilines Esters alkyl halides carboxylic acids
Thioethers alkyl halides Thiols Ethers alkyl halides
alcohols/phenols Thioethers alkyl sulfonates Thiols Esters alkyl
sulfonates carboxylic acids Ethers alkyl sulfonates
alcohols/phenols Esters Anhydrides alcohols/phenols Carboxamides
Anhydrides amines/anilines Thiophenols aryl halides Thiols Aryl
amines aryl halides Amines Thioethers Azindines Thiols Boronate
esters Boronates Glycols Carboxamides carboxylic acids
amines/anilines Esters carboxylic acids Alcohols hydrazines
Hydrazides carboxylic acids N-acylureas or Anhydrides carbodiimides
carboxylic acids Esters diazoalkanes carboxylic acids Thioethers
Epoxides Thiols Thioethers haloacetamides Thiols Ammotriazines
halotriazines amines/anilines Triazinyl ethers halotriazines
alcohols/phenols Amidines imido esters amines/anilines Ureas
Isocyanates amines/anilines Urethanes Isocyanates alcohols/phenols
Thioureas isothiocyanates amines/anilines Thioethers Maleimides
Thiols Phosphite esters phosphoramidites Alcohols Silyl ethers
silyl halides Alcohols Alkyl amines sulfonate esters
amines/anilines Thioethers sulfonate esters Thiols Esters sulfonate
esters carboxylic acids Ethers sulfonate esters Alcohols
Sulfonamides sulfonyl halides amines/anilines Sulfonate esters
sulfonyl halides phenols/alcohols
Use of Protecting Groups
[0498] In the reactions described, it may be necessary to protect
reactive functional groups, for example hydroxy, amino, imino, thio
or carboxy groups, where these are desired in the final product, to
avoid their unwanted participation in the reactions. Protecting
groups are used to block some or all reactive moieties and prevent
such groups from participating in chemical reactions until the
protective group is removed. It is preferred that each protective
group be removable by a different means. Protective groups that are
cleaved under totally disparate reaction conditions fulfill the
requirement of differential removal. Protective groups' can be
removed by acid, base, and hydrogenolysis. Groups such as trityl,
dimethoxytrityl, acetal and t-butyldimethylsilyl are acid labile
and may be used to protect carboxy and hydroxy reactive moieties in
the presence of amino groups protected with Cbz groups, which are
removable by hydrogenolysis, and Fmoc groups, which are base
labile. Carboxylic acid and hydroxy reactive moieties may be
blocked with base labile groups such as, but not limited to,
methyl, ethyl, and acetyl in the presence of amines blocked with
acid labile groups such as t-butyl carbamate or with carbamates
that are both acid and base stable but hydrolytically
removable.
[0499] Carboxylic acid and hydroxy reactive moieties may also be
blocked with hydrolytically removable protective groups such as the
benzyl group, while amine groups capable of hydrogen bonding with
acids may be blocked with base labile groups such as Fmoc.
Carboxylic acid reactive moieties may be protected by conversion to
simple ester compounds as exemplified herein, or they may be
blocked with oxidatively-removable protective groups such as
2,4-dimethoxybenzyl, while co-existing amino groups may be blocked
with fluoride labile silyl carbamates.
[0500] Allyl blocking groups are useful in then presence of acid-
and base-protecting groups since the former are stable and can be
subsequently removed by metal or pi-acid catalysts. For example, an
allyl-blocked carboxylic acid can be deprotected with a
Pd.sub.0-catalyzed reaction in the presence of acid labile t-butyl
carbamate or base-labile acetate amine protecting groups. Yet
another form of protecting group is a resin to which a compound or
intermediate may be attached. As long as the residue is attached to
the resin, that functional group is blocked and cannot react. Once
released from the resin, the functional group is available to
react.
[0501] Typically blocking/protecting groups may be selected
from:
##STR00741##
[0502] Other protecting groups, plus a detailed description of
techniques applicable to the creation of protecting groups and
their removal are described in Greene and Wuts, Protective Groups
in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York,
N.Y., 1999, and Kocienski, Protective Groups, Thieme Verlag, New
York, N.Y., 1994, which are incorporated herein by reference in
their entirety.
[0503] Compounds of Formula (1) can be synthesized according to
reaction scheme 1a, wherein amine compounds (A) react with
dihalogen compounds (B) to give diaryl compounds (C). Arylation of
compounds (C) yield compounds (1).
##STR00742##
Arylation, by way of example only, may be accomplished by reaction
of the halogen functionality with an aryl derivatized boronic acid
in the presence of tetrakis(triphenylphosphino) palladium.
[0504] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 1b, wherein halogen compounds (D)
react with amine compounds (E) to give diaryl compounds of (C).
Arylation of compounds (C) yield compounds (1).
##STR00743##
[0505] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 1c, wherein halogen compounds (B)
react with amine compounds (a'') to give diaryl compounds (c'').
Arylation of compounds (c'') yield compounds (1-C), and subsequent
amination affords compounds (1).
##STR00744##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted). Amination, by way
of example only, may be accomplished by reaction of the halogen
functionality with an appropriate amine.
[0506] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 1d, wherein halogen compounds (d'')
react with amine compounds (E) to give diaryl compounds (c'').
Arylation of compounds (c'') yield compounds (1-C), and subsequent
amination affords compounds (1).
##STR00745##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted).
[0507] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 1e, wherein dihalogen compounds (B)
are arylated to give compounds (b''). Compounds (b'') are then
reacted with amine compounds (A) to yield compounds (1).
##STR00746##
Arylation, by way of example only, may be accomplished by reaction
of the halogen functionality with an aryl derivatized boronic acid
in the presence of tetrakis(triphenylphosphino) palladium.
[0508] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme if, wherein compounds (E) are arylated
to give compounds (e''). Compounds (e'') are then reacted with
amine compounds (D) to yield compounds (1);
##STR00747##
Arylation, by way of example only, may be accomplished by reaction
of the halogen functionality with an aryl derivatized boronic acid
in the presence of tetrakis(triphenylphosphino) palladium.
[0509] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 1g, wherein dihalogen compounds (B)
are arylated giving compounds (b''), which then react with amine
compounds (a'') to give compounds (1-C). Subsequent amination of
compounds (1-C) affords compounds (1).
##STR00748##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted). Arylation, by way
of example only, may be accomplished by reaction of the halogen
functionality with an aryl derivatized boronic acid in the presence
of tetrakis(triphenylphosphino) palladium. Amination, by way of
example only, may be accomplished by reaction of the halogen
functionality with an appropriate amine.
[0510] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 1 h, wherein halogen compounds (E) are
arylated giving compounds (e''), which then react with amine
compounds (d'') to give compounds (1-C). Subsequent amination of
compounds (1-C) affords compounds (1).
##STR00749##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted). Arylation, by way
of example only, may be accomplished by reaction of the halogen
functionality with an aryl derivatized boronic acid in the presence
of tetrakis(triphenylphosphino) palladium. Amination, by way of
example only, may be accomplished by reaction of the halogen
functionality with an appropriate amine.
[0511] Similarly, compounds of Formula (1) can be synthesized
according to reaction scheme 2a, wherein substituted amine
compounds (F) react with dihalogen compounds (B) to give diaryl
compounds (H). Arylation of compounds (H) yield compounds (1).
##STR00750##
[0512] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 2b, wherein halogen compounds (D)
react with substituted amine compounds (I) to give diaryl compounds
(H). Arylation of compounds (H) yield compounds of Formula (1).
##STR00751##
[0513] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 2c, wherein halogen compounds (B)
react with amine compounds (f'') to give diaryl compounds (h'').
Arylation of compounds (h'') yield compounds (2-C), and subsequent
amination affords compounds of Formula (1).
##STR00752##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted).
[0514] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 2d, wherein halogen compounds (d'')
react with amine compounds (E) to give diaryl compounds (c'').
Arylation of compounds (c'') yield compounds (1-D), and subsequent
amination affords compounds of Formula (1).
##STR00753##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted).
[0515] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 2e, wherein dihalogen compounds (B)
are arylated to give compounds (b''), which react with substituted
amine compounds (F) to yield compounds of Formula (1).
##STR00754##
Arylation, by way of example only, may be accomplished by reaction
of the halogen functionality with an aryl derivatized boronic acid
in the presence of tetrakis(triphenylphosphino) palladium.
[0516] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 2f, wherein compounds (I) are arylated
to give compounds (i''). Compounds (i'') are then reacted with
amine compounds (D) to yield compounds of Formula (1).
##STR00755##
Arylation, by way of example only, may be accomplished by reaction
of the halogen functionality with an aryl derivatized boronic acid
in the presence of tetrakis(triphenylphosphino) palladium.
[0517] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 2g, wherein dihalogen compounds (B)
are arylated giving compounds (b''), which then react with amine
compounds (f'') to give compounds (2-C). Subsequent amination of
compounds (2-C) affords compounds of Formula (1).
##STR00756##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted). Arylation, by way
of example only, may be accomplished by reaction of the halogen
functionality with an aryl derivatized boronic acid in the presence
of tetrakis(triphenylphosphino) palladium. Amination, by way of
example only, may be accomplished by reaction of the halogen
functionality with an appropriate amine.
[0518] Alternatively, compounds of Formula (1) can be synthesized
according to reaction scheme 2h, wherein halogen compounds (I) are
arylated giving compounds (i''), which then react with amine
compounds (d'') to give compounds (2-C). Subsequent amination of
compounds (2-C) affords compounds of Formula (1).
##STR00757##
wherein, Z is CR.sub.1R.sub.1, O, or S, and L is alkylene
(substituted or unsubstituted), alkenylene (substituted or
unsubstituted), heteroalkylene (substituted or unsubstituted), or
heteroalkenylene (substituted or unsubstituted). Arylation, by way
of example only, may be accomplished by reaction of the halogen
functionality with an aryl derivatized boronic acid in the presence
of tetrakis(triphenylphosphino) palladium. Amination, by way of
example only, may be accomplished by reaction of the halogen
functionality with an appropriate amine.
[0519] The synthesis of amine compounds (A), compounds (a''),
compounds (F) and compounds (f'') may be accomplished according to
reaction schemes and methodologies known to one skilled in the art
used to obtain amine containing compounds. By way of example only,
a synthesis of amine compounds (A) is shown in reaction scheme 3a,
wherein formation of para-substituted nitrobenzenes results from
the addition of halogen containing compounds with reactive
nitrobenzenes. Subsequent reduction of such para-substituted
nitrobenzene compounds affords amine compounds (A).
##STR00758##
wherein L is alkylene (substituted or unsubstituted), alkenylene
(substituted or unsubstituted), heteroalkylene (substituted or
unsubstituted), or heteroalkenylene (substituted or unsubstituted).
Reduction, by way of example only, may be accomplished using
hydrogen with palladium on carbon as a catalyst.
[0520] By way of example only, a synthesis of amine compounds (a'')
is shown in reaction scheme 3b, wherein formation of
para-substituted nitrobenzene compounds containing terminal
halogens results from the addition of di-halogen containing
compounds with reactive nitrobenzenes. Subsequent reduction of such
para-substituted nitrobenzene compounds affords compounds
(a'').
##STR00759##
wherein L is alkylene (substituted or unsubstituted), alkenylene
(substituted or unsubstituted), heteroalkylene (substituted or
unsubstituted), or heteroalkenylene (substituted or
unsubstituted).
[0521] By way of example only, a synthesis of amine compounds (A)
is shown in reaction scheme 3c, wherein formation of
para-substituted protected anilines results from the addition of
halogen containing compounds with reactive protected anilines.
Subsequent deprotection of such para-substituted protected anilines
compounds affords amine compounds (A).
##STR00760## [0522] where: Z is O or S; X is halogen; Y is a
tertiary amine; [0523] Prot is any amine protecting group where Q
is Y-L-Z wherein L is alkylene (substituted or unsubstituted),
alkenylene (substituted or unsubstituted), heteroalkylene
(substituted or unsubstituted), or heteroalkenylene (substituted or
unsubstituted).
[0524] By way of example only, a synthesis of amine compounds (F)
is shown in reaction scheme 3d, wherein formation of
para-substituted nitrobenzenes results from the addition of halogen
containing compounds with a reactive nitrobenzene. Reduction of
such para-substituted nitrobenzene compounds affords amine
compounds (A) and subsequent alkylation of the yields substituted
amine compounds (F).
##STR00761##
where: Z is O or S; X is halogen; Y is a tertiary amine [0525]
where Q is Y-L-Z wherein L is alkylene (substituted or
unsubstituted), alkenylene (substituted or unsubstituted),
heteroalkylene (substituted or unsubstituted), or heteroalkenylene
(substituted or unsubstituted).
[0526] By way of example only, a synthesis of amine compounds (f'')
is shown in reaction scheme 3e, wherein formation of
para-substituted nitrobenzenes compounds containing terminal
halogens results from the addition of di-halogen containing
compounds with a reactive nitrobenzene. Reduction of such
para-substituted nitrobenzene compounds affords compounds (a'') and
subsequent alkylation of the yields substituted amine compounds
(f'').
##STR00762##
[0527] where: Z is O or S; X is halogen; Y is a tertiary amine
wherein L is alkylene (substituted or unsubstituted), alkenylene
(substituted or unsubstituted), heteroalkylene (substituted or
unsubstituted), or heteroalkenylene (substituted or
unsubstituted).
[0528] The pyrimidine compounds (B), compounds (E) and compounds
(I) may be synthesized according to reaction schemes and
methodologies known to one skilled in the art, or alternatively
they may be purchased. By way of example only, various pyrimidine
compounds may be obtained using Pinner Pyrimidine Synthesis as
shown in reaction scheme 4a,
##STR00763##
wherein R.sub.1 and R.sub.2 are independently selected from H,
halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and
heteroaryl; R.sub.3 is NH.sub.2, SH, alkyl, or halogen, or the
N--C--N type reagent may be urea. This approach may be used in the
synthesis of amine compounds (E) as shown in reaction scheme 4b
##STR00764##
and the approach may be used to synthesize
2-amino-5-bromopyrimidine as shown in reaction scheme 4c;
##STR00765##
Similarly, amine compounds (I) may be synthesized as shown in
reaction scheme 4d and reaction scheme 4e,
##STR00766##
and to synthesize 2-chloro-5-bromopyrimidine as shown in reaction
scheme 4c;
##STR00767##
Further Forms of Compounds
[0529] For convenience, the form and other characteristics of the
compounds described in this section and other parts herein use a
single formula, such as "Formula (A) or Formula (B)," by way of
example. However, the form and other characteristics of the
compounds described herein apply equally well to all formulas
presented herein that fall within the scope of Formula (A) or
Formula (B). For example, the form and other characteristics of the
compounds described herein can be applied to compounds having the
structure of any of Formula (1) to Formula (54), as well as to all
of the specific compounds that fall within the scope of these
generic formula.
[0530] Compounds of Formula (A) or Formula (B) can be prepared as a
pharmaceutically acceptable salts formed when an acidic proton
present in the parent compound either is replaced by a metal ion,
for example an alkali metal ion, an alkaline earth ion, or an
aluminum ion; or coordinates with an organic base. In addition, the
salt forms of the disclosed compounds can be prepared using salts
of the starting materials or intermediates.
[0531] Compounds of Formula (A) or Formula (B) can be prepared as a
pharmaceutically acceptable acid addition salt (which is a type of
a pharmaceutically acceptable salt) by reacting the free base form
of the compound with a pharmaceutically acceptable inorganic or
organic acid, including, but not limited to, inorganic acids such
as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid metaphosphoric acid, and the like; and organic
acids such as acetic acid, propionic acid, hexanoic acid,
cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic
acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric
acid, Q-toluenesulfonic acid, tartaric acid, trifluoroacetic acid,
citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid,
cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic
acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid,
2-hydroxyethanesulfonic acid, benzenesulfonic acid,
2-naphthalenesulfonic acid,
4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic
acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid),
3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic
acid, lauryl sulfuric acid, gluconic acid, glutamic acid,
hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic
acid.
[0532] Alternatively, compounds of Formula (A) or Formula (B) can
be prepared as a pharmaceutically acceptable base addition salts
(which is a type of a pharmaceutically acceptable salt) by reacting
the free acid form of the compound with a pharmaceutically
acceptable inorganic or organic base, including, but not limited to
organic bases such as ethanolamine, diethanolamine,
triethanolamine, tromethamine, N-methylglucamine, and the like and
inorganic bases such as aluminum hydroxide, calcium hydroxide,
potassium hydroxide, sodium carbonate, sodium hydroxide, and the
like.
[0533] It should be understood that a reference to a
pharmaceutically acceptable salt includes the solvent addition
forms or crystal forms thereof, particularly solvates or
polymorphs. Solvates contain either stoichiometric or
non-stoichiometric amounts of a solvent, and may be formed during
the process of crystallization with pharmaceutically acceptable
solvents such as water, ethanol, and the like. Hydrates are formed
when the solvent is water, or alcoholates are formed when the
solvent is alcohol. Solvates of compounds of Formula (A) or Formula
(B) can be conveniently prepared or formed during the processes
described herein. By way of example only, hydrates of compounds of
Formula (A) or Formula (B) can be conveniently prepared by
recrystallization from an aqueous/organic solvent mixture, using
organic solvents including, but not limited to, dioxane,
tetrahydrofuran or methanol. In addition, the compounds provided
herein can exist in unsolvated as well as solvated forms. In
general, the solvated forms are considered equivalent to the
unsolvated forms for the purposes of the compounds and methods
provided herein.
[0534] Compounds of Formula (A) or Formula (B) include crystalline
forms, also known as polymorphs. Polymorphs include the different
crystal packing arrangements of the same elemental composition of a
compound. Polymorphs usually have different X-ray diffraction
patterns, infrared spectra, melting points, density, hardness,
crystal shape, optical and electrical properties, stability, and
solubility. Various factors such as the recrystallization solvent,
rate of crystallization, and storage temperature may cause a single
crystal form to dominate.
[0535] Compounds of Formula (A) or Formula (B) in unoxidized form
can be prepared from N-oxides of compounds of Formula (A) or
Formula (B) by treating with a reducing agent, such as, but not
limited to, sulfur, sulfur dioxide, triphenyl phosphine, lithium
borohydride, sodium borohydride, phosphorus trichloride,
tribromide, or the like in a suitable inert organic solvent, such
as, but not limited to, acetonitrile, ethanol, aqueous dioxane, or
the like at 0 to 80.degree. C.
[0536] Compounds of Formula (A) or Formula (B) can be prepared as
prodrugs. Prodrugs are generally drug precursors that, following
administration to a subject and subsequent absorption, are
converted to an active, or a more active species via some process,
such as conversion by a metabolic pathway. Some prodrugs have a
chemical group present on the prodrug that renders it less active
and/or confers solubility or some other property to the drug. Once
the chemical group has been cleaved and/or modified from the
prodrug the active drug is generated. Prodrugs are often useful
because, in some situations, they may be easier to administer than
the parent drug. They may, for instance, be bioavailable by oral
administration whereas the parent is not. The prodrug may also have
improved solubility in pharmaceutical compositions over the parent
drug. An example, without limitation, of a prodrug would be a
compound of Formula (A) or Formula (B) which is administered as an
ester (the "prodrug") to facilitate transmittal across a cell
membrane where water solubility is detrimental to mobility but
which then is metabolically hydrolyzed to the carboxylic acid, the
active entity, once inside the cell where water-solubility is
beneficial. A further example of a prodrug might be a short peptide
(polyaminoacid) bonded to an acid group where the peptide is
metabolized to reveal the active moiety.
[0537] Prodrugs may be designed as reversible drug derivatives, for
use as modifiers to enhance drug transport to site-specific
tissues. The design of prodrugs to date has been to increase the
effective water solubility of the therapeutic compound for
targeting to regions where water is the principal solvent. See,
e.g., Fedorak et al., Am. J. Physiol., 269:G210-218 (1995); McLoed
et al., Gastroenterol, 106:405-413 (1994); Hochhaus et al., Biomed.
Chrom., 6:283-286 (1992); J. Larsen and H. Bundgaard, Int. J.
Pharmaceutics, 37, 87 (1987); J. Larsen et al., Int. J.
Pharmaceutics, 47, 103 (1988); Sinkula et al., J. Pharm. Sci.,
64:181-210 (1975); T. Higuchi and V. Stella, Pro-drugs as Novel
Delivery Systems, Vol. 14 of the A.C.S. Symposium Series; and
Edward B. Roche, Bioreversible Carriers in Drug Design, American
Pharmaceutical Association and Pergamon Press, 1987, all
incorporated herein in their entirety.
[0538] Additionally, prodrug derivatives of compounds of Formula
(A) or Formula (B) can be prepared by methods known to those of
ordinary skill in the art (e.g., for further details see Saulnier
et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol: 4,
p. 1985). By way of example only, appropriate prodrugs can be
prepared by reacting a non-derivatized compound of Formula (A) or
Formula (B) with a suitable carbamylating agent, such as, but not
limited to, 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl
carbonate, or the like. Prodrug forms of the herein described
compounds, wherein the prodrug is metabolized in vivo to produce a
derivative as set forth herein are included within the scope of the
claims. Indeed, some of the herein-described compounds may be a
prodrug for another derivative or active compound.
[0539] Sites on the aromatic ring portion of compounds of Formula
(A) or Formula (B) can be susceptible to various metabolic
reactions, therefore incorporation of appropriate substituents on
the aromatic ring structures, such as, by way of example only,
halogens can reduce, minimize or eliminate this metabolic
pathway.
[0540] Compounds of Formula (A) or Formula (B) can be optically
pure enantiomers or a racemic mixture. Compounds of Formula (A) or
Formula (B) can be prepared as their individual stereoisomers by
reacting a racemix mixture of the compound with an optically active
resolving agent to form a pair of diastereoisomeric compounds,
separating the diastereomers and recovering the optically pure
enantiomers.
[0541] The compounds described herein may be labeled isotopically
(e.g. with a radioisotope) or by another other means, including,
but not limited to, the use of chromophores or fluorescent
moieties, bioluminescent labels, or chemiluminescent labels. The
compounds of Formula (A) or Formula (B) may possess one or more
chiral centers and each center may exist in the R or S
configuration. The compounds presented herein include all
diastereomeric, enantiomeric, and epimeric forms as well as the
appropriate mixtures thereof. Compounds of Formula (A) or Formula
(B) can be prepared as their individual stereoisomers by reacting a
racemic mixture of the compound with an optically active resolving
agent to form a pair of diastereoisomeric compounds, separating the
diastereomers and recovering the optically pure enantiomers. While
resolution of enantiomers can be carried out using covalent
diastereomeric derivatives of the compounds described herein,
dissociable complexes are preferred (e.g., crystalline
diastereomeric salts). Diastereomers have distinct physical
properties (e.g., melting points, boiling points, solubilities,
reactivity, etc.) and can be readily separated by taking advantage
of these dissimilarities. The diastereomers can be separated by
chiral chromatography, or preferably, by separation/resolution
techniques based upon differences in solubility. The optically pure
enantiomer is then recovered, along with the resolving agent, by
any practical means that would not result in racemization. A more
detailed description of the techniques applicable to the resolution
of stereoisomers of compounds from their racemic mixture can be
found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers,
Racemates and Resolutions," John Wiley And Sons, Inc., 1981, herein
incorporated by reference in its entirety.
[0542] Additionally, the compounds and methods provided herein may
exist as geometric isomers. The compounds and methods provided
herein include all cis, trans, syn, anti, entgegen (E), and
zusammen (Z) isomers as well as the appropriate mixtures thereof.
In some situations, compounds may exist as tautomers. All tautomers
are included within the formulas described herein are provided by
compounds and methods herein. In additional embodiments of the
compounds and methods provided herein, mixtures of enantiomers
and/or diastereoisomers, resulting from a single preparative step,
combination, or interconversion may also be useful for the
applications described herein.
Pharmaceutical Composition/Formulation/Administration
[0543] For convenience, the form and other characteristics of the
compounds described in this section and other parts herein use a
single formula, such as "Formula (A) or Formula (B)," by way of
example. However, the form and other characteristics of the
compounds described herein apply equally well to all formulas
presented herein that fall within the scope of Formula (A) or
Formula (B). For example, the form and other characteristics of the
compounds described herein can be applied to compounds having the
structure of any of Formula (1) to Formula (54), as well as to all
of the specific compounds that fall within the scope of these
generic formulas.
[0544] A pharmaceutical composition, as used herein, refers to a
mixture of at least one compound of Formula (A) or Formula (B) with
other chemical components, such as carriers, stabilizers, diluents,
dispersing agents, suspending agents, thickening agents, and/or
excipients. The pharmaceutical composition facilitates
administration of the compound to an organism. Pharmaceutical
compositions containing compounds of Formula (A) or Formula (B) can
be administered in therapeutically effective amounts as
pharmaceutical compositions by any conventional form and route
known in the art including, but not limited to: intravenous, oral,
rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal,
vaginal, otic, nasal, and topical administration.
[0545] One may administer the compound in a local rather than
systemic manner, for example, via injection of the compound
directly into an organ, often in a depot or sustained release
formulation. Furthermore, one may administer pharmaceutical
composition containing compounds of Formula (A) or Formula (B) in a
targeted drug delivery system, for example, in a liposome coated
with organ-specific antibody. The liposomes will be targeted to and
taken up selectively by the organ. In addition, the pharmaceutical
composition containing compounds of Formula (A) or Formula (B) may
be provided in the form of a rapid release formulation, in the form
of an extended release formulation, or in the form of an
intermediate release formulation.
[0546] For oral administration, compounds of Formula (A) or Formula
(B) can be formulated readily by combining the active compounds
with pharmaceutically acceptable carriers or excipients well known
in the art. Such carriers enable the compounds described herein to
be formulated as tablets, powders, pills, dragees, capsules,
liquids, gels, syrups, elixirs, slurries, suspensions and the like,
for oral ingestion by a patient to be treated.
[0547] Pharmaceutical preparations for oral use can be obtained by
mixing one or more solid excipient with one or more of the
compounds described herein, optionally grinding the resulting
mixture, and processing the mixture of granules, after adding
suitable auxiliaries, if desired, to obtain tablets or dragee
cores. Suitable excipients are, in particular, fillers such as
sugars, including lactose, sucrose, mannitol, or sorbitol;
cellulose preparations such as: for example, maize starch, wheat
starch, rice starch, potato starch, gelatin, gum tragacanth,
methylcellulose, microcrystalline cellulose,
hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or
others such as: polyvinylpyrrolidone (PVP or povidone) or calcium
phosphate. If desired, disintegrating agents may be added, such as
the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar,
or alginic acid or a salt thereof such as sodium alginate.
[0548] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol
gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0549] Pharmaceutical preparations which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for such administration.
[0550] For buccal or sublingual administration, the compositions
may take the form of tablets, lozenges, or gels formulated in
conventional manner. Parental injections may involve for bolus
injection or continuous infusion. The pharmaceutical composition of
Formula (A) or Formula (B) may be in a form suitable for parenteral
injection as a sterile suspensions, solutions or emulsions in oily
or aqueous vehicles, and may contain formulatory agents such as
suspending, stabilizing and/or dispersing agents. Pharmaceutical
formulations for parenteral administration include aqueous
solutions of the active compounds in water-soluble form.
Additionally, suspensions of the active compounds may be prepared
as appropriate oily injection suspensions. Suitable lipophilic
solvents or vehicles include fatty oils such as sesame oil, or
synthetic fatty acid esters, such as ethyl oleate or triglycerides,
or liposomes. Aqueous injection suspensions may contain substances
which increase the viscosity of the suspension, such as sodium
carboxymethyl cellulose, sorbitol, or dextran. Optionally, the
suspension may also contain suitable stabilizers or agents which
increase the solubility of the compounds to allow for the
preparation of highly concentrated solutions. Alternatively, the
active ingredient may be in powder form for constitution with a
suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0551] The compounds of Formula (A) or Formula (B) can be
administered topically and can be formulated into a variety of
topically administrable compositions, such as solutions,
suspensions, lotions, gels, pastes, medicated sticks, balms, creams
or ointments. Such pharmaceutical compounds can contain
solubilizers, stabilizers, tonicity enhancing agents, buffers and
preservatives.
[0552] Formulations suitable for transdermal administration of
compounds having the structure of Formula (A) or Formula (B) may
employ transdermal delivery devices and transdermal delivery
patches and can be lipophilic emulsions or buffered, aqueous
solutions, dissolved and/or dispersed in a polymer or an adhesive.
Such patches may be constructed for continuous, pulsatile, or on
demand delivery of pharmaceutical agents. Still further,
transdermal delivery of the compounds of Formula (A) or Formula (B)
can be accomplished by means of iontophoretic patches and the like.
Additionally, transdermal patches can provide controlled delivery
of the compounds Formula (A) or Formula (B). The rate of absorption
can be slowed by using rate-controlling membranes or by trapping
the compound within a polymer matrix or gel. Conversely, absorption
enhancers can be used to increase absorption. An absorption
enhancer or carrier can include absorbable pharmaceutically
acceptable solvents to assist passage through the skin. For
example, transdermal devices are in the form of a bandage
comprising a backing member, a reservoir containing the compound
optionally with carriers, optionally a rate controlling barrier to
deliver the compound to the skin of the host at a controlled and
predetermined rate over a prolonged period of time, and means to
secure the device to the skin.
[0553] For administration by inhalation, the compounds of Formula
(A) or Formula (B) may be in a form as an aerosol, a mist or a
powder. Pharmaceutical compositions of Formula (A) or Formula (B)
are conveniently delivered in the form of an aerosol spray
presentation from pressurized packs or a nebuliser, with the use of
a suitable propellant, e.g., dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
or other suitable gas. In the case of a pressurized aerosol the
dosage unit may be determined by providing a valve to deliver a
metered amount. Capsules and cartridges of, such as, by way of
example only, gelatin for use in an inhaler or insufflator may be
formulated containing a powder mix of the compound and a suitable
powder base such as lactose or starch.
[0554] The compounds of Formula (A) or Formula (B) may also be
formulated in rectal compositions such as enemas, rectal gels,
rectal foams, rectal aerosols, suppositories, jelly suppositories,
or retention enemas, containing conventional suppository bases such
as cocoa butter or other glycerides, as well as synthetic polymers
such as polyvinylpyrrolidone, PEG, and the like. In suppository
forms of the compositions, a low-melting wax such as, but not
limited to, a mixture of fatty acid glycerides, optionally in
combination with cocoa butter is first melted.
[0555] In practicing the methods of treatment or use provided
herein, therapeutically effective amounts of compounds of Formula
(A) or Formula (B) provided herein are administered in a
pharmaceutical composition to a mammal having a disease or
condition to be treated. Preferably, the mammal is a human. A
therapeutically effective amount can vary widely depending on the
severity of the disease, the age and relative health of the
subject, the potency of the compound used and other factors. The
compounds can be used singly or in combination with one or more
therapeutic agents as components of mixtures.
[0556] Pharmaceutical compositions may be formulated in
conventional manner using one or more physiologically acceptable
carriers comprising excipients and auxiliaries which facilitate
processing of the active compounds into preparations which can be
used pharmaceutically. Proper formulation is dependent upon the
route of administration chosen. Any of the well-known techniques,
carriers, and excipients may be used as suitable and as understood
in the art. Pharmaceutical compositions comprising a compound of
Formula (A) or Formula (B) may be manufactured in a conventional
manner, such as, by way of example only, by means of conventional
mixing, dissolving, granulating, dragee-making, levigating,
emulsifying, encapsulating, entrapping or compression
processes.
[0557] The pharmaceutical compositions will include at least one
pharmaceutically acceptable carrier, diluent or excipient and a
compound of Formula (A) or Formula (B) described herein as an
active ingredient in free-acid or free-base form, or in a
pharmaceutically acceptable salt form. In addition, the methods and
pharmaceutical compositions described herein include the use of
N-oxides, crystalline forms (also known as polymorphs), as well as
active metabolites of these compounds having the same type of
activity. In some situations, compounds may exist as tautomers. All
tautomers are included within the scope of the compounds presented
herein. Additionally, the compounds described herein can exist in
unsolvated as well as solvated forms with pharmaceutically
acceptable solvents such as water, ethanol, and the like. The
solvated forms of the compounds presented herein are also
considered to be disclosed herein. In addition, the pharmaceutical
compositions may include other medicinal or pharmaceutical agents,
carriers, adjuvants, such as preserving, stabilizing, wetting or
emulsifying agents, solution promoters, salts for regulating the
osmotic pressure, and/or buffers. In addition, the pharmaceutical
compositions can also contain other therapeutically valuable
substances.
[0558] Methods for the preparation of compositions comprising the
compounds described herein include formulating the compounds with
one or more inert, pharmaceutically acceptable excipients or
carriers to form a solid, semi-solid or liquid. Solid compositions
include, but are not limited to, powders, tablets, dispersible
granules, capsules, cachets, and suppositories. Liquid compositions
include solutions in which a compound is dissolved, emulsions
comprising a compound, or a solution containing liposomes,
micelles, or nanoparticles comprising a compound as disclosed
herein. Semi-solid compositions include, but are not limited to,
gels, suspensions and creams. The compositions may be in liquid
solutions or suspensions, solid forms suitable for solution or
suspension in a liquid prior to use, or as emulsions. These
compositions may also contain minor amounts of nontoxic, auxiliary
substances, such as wetting or emulsifying agents, pH buffering
agents, and so forth.
[0559] A summary of pharmaceutical compositions described herein
may be found, for example, in Remington: The Science and Practice
of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company,
1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack
Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L.,
Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y.,
1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems,
Seventh Ed. (Lippincott Williams & Wilkins 1999), herein
incorporated by reference in their entirety.
Methods of Administration and Treatment Methods
[0560] For convenience, the form and other characteristics of the
compounds described in this section and other parts herein use a
single formula, such as "Formula (A) or Formula (B)," by way of
example. However, the form and other characteristics of the
compounds described herein apply equally well to all formulas
presented herein that fall within the scope of Formula (A) or
Formula (B). For example, the form and other characteristics of the
compounds described herein can be applied to compounds having the
structure of any of Formula (1) to Formula (54), as well as to all
of the specific compounds that fall within the scope of these
generic formulas.
[0561] The compounds of Formula (A) or Formula (B) can be used in
the preparation of medicaments for the treatment of diseases or
conditions in which c-kit receptor activity contributes to the
pathology and/or symptomology of the disease. In addition, a method
for treating any of the diseases or conditions described herein in
a subject in need of such treatment, involves administration of
pharmaceutical compositions containing at least one compound of
Formula (A) or Formula (B), or a pharmaceutically acceptable salt,
pharmaceutically acceptable N-oxide, pharmaceutically active
metabolite, pharmaceutically acceptable prodrug, or
pharmaceutically acceptable solvate thereof, in therapeutically
effective amounts to said subject
[0562] The compositions containing the compound(s) described herein
can be administered for prophylactic and/or therapeutic treatments.
In therapeutic applications, the compositions are administered to a
patient already suffering from a disease or condition, in an amount
sufficient to cure or at least partially arrest the symptoms of the
disease or condition. Amounts effective for this use will depend on
the severity and course of the disease or condition, previous
therapy, the patient's health status, weight, and response to the
drugs, and the judgment of the treating physician. It is considered
well within the skill of the art for one to determine such
therapeutically effective amounts by routine experimentation
(including, but not limited to, a dose escalation clinical
trial).
[0563] Compositions containing the compound(s) described herein can
be used to treat a disease-state or condition selected from:
neoplastic diseases, including, but not limited to, mastocytosis,
canine mastocytoma, human gastrointestinal stromal tumor, small
cell lung cancer, non-small cell lung cancer, acute myelocytic
leukemia, acute lymphocytic leukemia, myelodysplastic syndrome,
chronic myelogenous leukemia, colorectal carcinomas, gastric
carcinomas, gastrointestinal stromal tumors, testicular cancers,
glioblastomas, and astrocytomas; allergic diseases, including, but
not limited to, asthma, allergic rhinitis, allergic sinusitis,
anaphylactic syndrome, urticaria, angioedema, atopic dermatitis,
allergic contact dermatitis, erythema nodosum, erythema multiforme,
cutaneous necrotizing venulitis and insect bite skin inflammation
and blood sucking parasitic infestation; inflammatory diseases
including, but not limited to, rheumatoid arthritis,
conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty
arthritis and other arthritic conditions; autoimmune diseases,
including, but not limited to, multiple sclerosis, psoriasis,
intestine inflammatory disease, ulcerative colitis, Crohn's
disease, rheumatoid arthritis and polyarthritis, local and systemic
scleroderma, systemic lupus erythematosus, discoid lupus
erythematosus, cutaneous lupus, dermatomyositis, polymyositis,
Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy,
and proliferative glomerulonephritis; graft-versus-host disease,
including, but not limited to, organ transplantation graft
rejection, such as, but not limited to, kidney transplantation,
pancreas transplantation, liver transplantation, heart
transplantation, lung transplantation, or bone marrow
transplantation; metabolic syndrome, including, but not limited to,
type I diabetes, type II diabetes, or obesity; CNS related
disorders, including, but not limited to, depression, dysthymic
disorder, cyclothymic disorder, bipolar depression, severe or
"melancholic" depression, atypical depression, refractory
depression, seasonal depression, anorexia, bulimia, premenstrual
syndrome and post-menopause syndrome, as mental slowing and loss of
concentration, pessimistic worry, agitation, self-deprecation and
decreased libido, as anxiety disorders including anxiety associated
with hyperventilation and cardiac arrhythmias, phobic disorders,
obsessive-compulsive disorder, posttraumatic stress disorder, acute
stress disorder, and generalized anxiety disorder, as psychiatric
disorders such as panic attacks, including psychosis, delusional
disorders, conversion disorders, phobias, mania, delirium,
dissociative episodes including dissociative amnesia, dissociative
fugue and dissociative suicidal behavior, self-neglect, violent or
aggressive behavior, trauma, borderline personality, and acute
psychosis as schizophrenia including paranoid schizophrenia,
disorganized schizophrenia, catatonic schizophrenia, and
undifferentiated schizophrenia; neurodegenerative disease,
including, but not limited to, Alzheimer's disease, Parkinson's
disease, Huntington's disease, the prion diseases, Motor Neuron
Disease (MND), and Amyotrophic Lateral Sclerosis (ALS); pain,
including, but not limited to, acute pain, postoperative pain,
chronic pain, nociceptive pain, cancer pain, neuropathic pain, and
psychogenic pain syndromes; substance use disorders, including, but
not limited to, drug addiction, drug abuse, drug habituation, drug
dependence, withdrawal syndrome and overdose, prion diseases,
cancers, heart diseases, fibrotic diseases, idiopathic pulmonary
arterial hypertension (IPAH), and primary pulmonary hypertension
(PPH); in a patient in need of such treatment, the method
comprising administering to the patient an effective amount of a
compound described herein, or a tautomer, prodrug, solvate, or salt
thereof.
[0564] In the case wherein the patient's condition does not
improve, upon the doctor's discretion the administration of the
compounds may be administered chronically, that is, for an extended
period of time, including throughout the duration of the patient's
life in order to ameliorate or otherwise control or limit the
symptoms of the patient's disease or condition. In the case wherein
the patient's status does improve, upon the doctor's discretion the
administration of the compounds may be given continuously or
temporarily suspended for a certain length of time (i.e., a "drug
holiday").
[0565] Once improvement of the patient's conditions has occurred, a
maintenance dose is administered if necessary. Subsequently, the
dosage or the frequency of administration, or both, can be reduced,
as a function of the symptoms, to a level at which the improved
disease or condition is retained. Patients can, however, require
intermittent treatment on a long-term basis upon any recurrence of
symptoms.
[0566] In certain instances, it may be appropriate to administer
therapeutically effective amounts of at least one of the compounds
described herein (or a pharmaceutically acceptable salts,
pharmaceutically acceptable N-oxides, pharmaceutically active
metabolites, pharmaceutically acceptable prodrugs, and
pharmaceutically acceptable solvates thereof) in combination with
another therapeutic agent. By way of example only, if one of the
side effects experienced by a patient upon receiving one of the
compounds herein is inflammation, then it may be appropriate to
administer an anti-inflammatory agent in combination with the
initial therapeutic agent. Or, by way of example only, the
therapeutic effectiveness of one of the compounds described herein
may be enhanced by administration of an adjuvant (i.e., by itself
the adjuvant may only have minimal therapeutic benefit, but in
combination with another therapeutic agent, the overall therapeutic
benefit to the patient is enhanced). Or, by way of example only,
the benefit of experienced by a patient may be increased by
administering one of the compounds described herein with another
therapeutic agent (which also includes a therapeutic regimen) that
also has therapeutic benefit. In any case, regardless of the
disease or condition being treated, the overall benefit experienced
by the patient may simply be additive of the two therapeutic agents
or the patient may experience a synergistic benefit. For example,
synergistic effects can occur with compounds of Formula (A) or
Formula (B) and other substances used in the treatment of
neoplastic disease, allergy disease, inflammatory disease,
autoimmume disease, graft-versus-host disease, metabolic syndrome,
CNS related disorders, neurodegenerative disease, pain, substance
abuse disorders, prion diseases, cancers, heart diseases, fibrotic
diseases, idiopathic pulmonary arterial hypertension (IPAH), or
primary pulmonary hypertension (PPH). Examples of such
bronchodilators, including, but not limited to,
.beta..sub.2-agonists, methylxanthines and anticholinergics;
anti-inflammatory agents, including, but not limited to,
corticosteroids and cromolyns, leukotriene antagonists, and IgE
blockers, including but not limited to, omalizumab, also known as
xolair. Where the compounds described herein are administered in
conjunction with other therapies, dosages of the co-administered
compounds will of course vary depending on the type of co-drug
employed, on the specific drug employed, on the disease or
condition being treated and so forth. In addition, when
co-administered with one or more biologically active agents, the
compound provided herein may be administered either simultaneously
with the biologically active agent(s), or sequentially. If
administered sequentially, the attending physician will decide on
the appropriate sequence of administering protein in combination
with the biologically active agent(s).
[0567] In any case, the multiple therapeutic agents (one of which
is one of the compounds described herein) may be administered in
any order or even simultaneously. If simultaneously, the multiple
therapeutic agents may be provided in a single, unified form, or in
multiple forms (by way of example only, either as a single pill or
as two separate pills). One of the therapeutic agents may be given
in multiple doses, or both may be given as multiple doses. If not
simultaneous, the timing between the multiple doses may vary from
more than zero weeks to less than four weeks. In addition, the
combination methods, compositions and formulations are not to be
limited to the use of only two agents; we envision the use of
multiple therapeutic combinations.
[0568] In addition, the compounds of Formula (A) or Formula (B) may
also be used in combination with procedures that may provide
additional or synergistic benefit to the patient. By way of example
only, patients are expected to find therapeutic and/or prophylactic
benefit in the methods described herein, wherein pharmaceutical
composition of Formula (A) or Formula (B) and/or combinations with
other therapeutics are combined with genetic testing to determine
whether that individual is a carrier of a mutant gene that is known
to be correlated with certain diseases or conditions.
[0569] The compounds of Formula (A) or Formula (B) and combination
therapies can be administered before, during or after the
occurrence of a disease or condition, and the timing of
administering the composition containing a compound can vary. Thus,
for example, the compounds can be used as a prophylactic and can be
administered continuously to subjects with a propensity to
conditions or diseases in order to prevent the occurrence of the
disease or condition. The compounds and compositions can be
administered to a subject during or as soon as possible after the
onset of the symptoms. The administration of the compounds can be
initiated within the first 48 hours of the onset of the symptoms,
preferably within the first 48 hours of the onset of the symptoms,
more preferably within the first 6 hours of the onset of the
symptoms, and most preferably within 3 hours of the onset of the
symptoms. The initial administration can be via any route
practical, such as, for example, an intravenous injection, a bolus
injection, infusion over 5 minutes to about 5 hours, a pill, a
capsule, transdermal patch, buccal delivery, and the like, or
combination thereof. A compound is preferably administered as soon
as is practicable after the onset of a disease or condition is
detected or suspected, and for a length of time necessary for the
treatment of the disease, such as, for example, from about 1 month
to about 3 months. The length of treatment can vary for each
subject, and the length can be determined using the known criteria.
For example, the compound or a formulation containing the compound
can be administered for at least 2 weeks, preferably about 1 month
to about 5 years, and more preferably from about 1 month to about 3
years.
[0570] The pharmaceutical composition described herein may be in
unit dosage forms suitable for single administration of precise
dosages. In unit dosage form, the formulation is divided into unit
doses containing appropriate quantities of one or more compound.
The unit dosage may be in the form of a package containing discrete
quantities of the formulation. Non-limiting examples are packaged
tablets or capsules, and powders in vials or ampoules. Aqueous
suspension compositions can be packaged in single-dose
non-reclosable containers. Alternatively, multiple-dose reclosable
containers can be used, in which case it is typical to include a
preservative in the composition. By way of example only,
formulations for parenteral injection may be presented in unit
dosage form, which include, but are not limited to ampoules, or in
multi-dose containers, with an added preservative.
[0571] The daily dosages appropriate for the compounds of Formula
(A) or Formula (B) described herein are from about 0.03 to 2.5
mg/kg per body weight. An indicated daily dosage in the larger
mammal, including, but not limited to, humans, is in the range from
about 0.5 mg to about 100 mg, conveniently administered in divided
doses, including, but not limited to, up to four times a day or in
retard form. Suitable unit dosage forms for oral administration
comprise from about 1 to 50 mg active ingredient. The foregoing
ranges are merely suggestive, as the number of variables in regard
to an individual treatment regime is large, and considerable
excursions from these recommended values are not uncommon. Such
dosages may be altered depending on a number of variables, not
limited to the activity of the compound used, the disease or
condition to be treated, the mode of administration, the
requirements of the individual subject, the severity of the disease
or condition being treated, and the judgment of the
practitioner.
[0572] Toxicity and therapeutic efficacy of such therapeutic
regimens can be determined by standard pharmaceutical procedures in
cell cultures or experimental animals, including, but not limited
to, for determining the LD.sub.50 (the dose lethal to 50% of the
population) and the ED.sub.50 (the dose therapeutically effective
in 50% of the population). The dose ratio between the toxic and
therapeutic effects is the therapeutic index and it can be
expressed as the ratio between LD.sub.50 and ED.sub.50. Compounds
exhibiting high therapeutic indices are preferred. The data
obtained from cell culture assays and animal studies can be used in
formulating a range of dosage for use in human. The dosage of such
compounds lies preferably within a range of circulating
concentrations that include the ED.sub.50 with minimal toxicity.
The dosage may vary within this range depending upon the dosage
form employed and the route of administration utilized.
Kits/Articles of Manufacture
[0573] For use in the therapeutic applications described herein,
kits and articles of manufacture are also described herein. Such
kits can comprise a carrier, package, or container that is
compartmentalized to receive one or more containers such as vials,
tubes, and the like, each of the container(s) comprising one of the
separate elements to be used in a method described herein. Suitable
containers include, for example, bottles, vials, syringes, and test
tubes. The containers can be formed from a variety of materials
such as glass or plastic.
[0574] For example, the container(s) can comprise one or more
compounds described herein, optionally in a composition or in
combination with another agent as disclosed herein. The
container(s) optionally have a sterile access port (for example the
container can be an intravenous solution bag or a vial having a
stopper pierceable by a hypodermic injection needle). Such kits
optionally comprising a compound with an identifying description or
label or instructions relating to its use in the methods described
herein.
[0575] A kit will typically may comprise one or more additional
containers, each with one or more of various materials (such as
reagents, optionally in concentrated form, and/or devices)
desirable from a commercial and user standpoint for use of a
compound described herein. Non-limiting examples of such materials
include, but not limited to, buffers, diluents, filters, needles,
syringes; carrier, package, container, vial and/or tube labels
listing contents and/or instructions for use, and package inserts
with instructions for use. A set of instructions will also
typically be included.
[0576] A label can be on or associated with the container. A label
can be on a container when letters, numbers or other characters
forming the label are attached, molded or etched into the container
itself; a label can be associated with a container when it is
present within a receptacle or carrier that also holds the
container, e.g., as a package insert. A label can be used to
indicate that the contents are to be used for a specific
therapeutic application. The label can also indicate directions for
use of the contents, such as in the methods described herein.
ILLUSTRATIVE EXAMPLES
[0577] The following examples provide illustrative methods for
making and testing the effectiveness and safety of the compounds of
Formula (A) or Formula (B). These examples are provided for
illustrative purposes only and not to limit the scope of the claims
provided herein. All of the methods disclosed and claimed herein
can be made and executed without undue experimentation in light of
the present disclosure. It will be apparent to those of skill in
the art that variations may be applied to the methods and in the
steps or in the sequence of steps of the method described herein
without departing from the concept, spirit and scope of the claims.
All such similar substitutes and modifications apparent to those
skilled in the art are deemed to be within the spirit, scope and
concept of the appended claims.
Example 1
Synthesis of substituted nitro-benzene compounds
Example 1a
Diethyl-[2-(4-nitro-phenoxy)-ethyl]-amine
##STR00768##
[0579] Diethyl-[2-(4-nitro-phenoxy)-ethyl]-amine can be synthesized
by the following procedure. To a solution of 4-nitro-phenol (36.0
mmol) in toluene (40 mL) is added cesium carbonate (53.8 mmol)
followed by (2-chloro-ethyl)-diethyl-amine hydrochloride (28.7
mmol) and the reaction mixture is heated at 100.degree. C. for 2 h.
The reaction mixture is cooled down and the solid is filtered under
vacuum and washed with warm toluene. The filtrate is concentrated
to afford 3.35 g of diethyl-[2-(4-nitro-phenoxy)-ethyl]-amine (39%)
that is used in the next step without further purification.
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.10-8.08 (m, 2H),
6.86-6.84 (m, 2H), 4.05 (t, J=4.0 Hz, 2H), 2.81 (t, J=4.0 Hz), 2.55
(q, J=8.0 Hz, 4H), 0.98 (t, J=8.0 Hz, 6H). MS (m/z) (M+1).sup.+
230.3.
Example 1b
Diethyl-[2-(4-nitro-phenylsulfanyl)-ethyl]-amine
##STR00769##
[0581] Diethyl-[2-(4-nitro-phenylsulfanyl)-ethyl]-amine can be
synthesized by the following procedure. To a solution of
4-nitro-thiophenol (3.6.0 mmol) in toluene (40 mL) is added cesium
carbonate (53.8 mmol) followed by (2-chloro-ethyl)-diethyl-amine
hydrochloride (28.7 mmol). The reaction mixture is heated at
100.degree. C. for 2 h. The reaction mixture is cooled down and the
solid is filtered under vacuum and washed with warm toluene. The
filtrate is concentrated to afford
diethyl-[2-(4-nitro-phenylsulfanyl)-ethyl]-amine that is used in
the next step without further purification. .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 8.23-8.11 (m, 2H), 7.35-7.33 (m, 2H), 3.13 (t,
J=8.0 Hz, 2H), 2.77 (t, J=8.0 Hz, 2H), 2.60 (q, J=8.0 Hz, 4H), 1.05
(t, J=8.0 Hz, 6H). MS (m/z) (M+1).sup.+ 255.2.
Example 1c
1-(2-Chloro-ethoxy)-4-nitro-benzene
##STR00770##
[0583] 1-(2-Chloro-ethoxy)-4-nitro-benzene can be synthesized by
the following procedure. To a solution of 4-nitro-phenol (28.7
mmol) in absolute ethanol (15 mL) is added cesium carbonate (28.7
mmol) followed by 1-bromo-2-chloro-ethane (86.2 mmol). The reaction
mixture is heated at 80.degree. C. for 8 h. The reaction mixture is
cooled down and quenched with water and extracted with EtOAc. The
organic layer is washed with water, brine, dried over
Na.sub.2SO.sub.4, and concentrated to afford an orange residue that
upon trituration with EtOH gives
1-(2-chloro-ethoxy)-4-nitro-benzene (66%). MS (m/z) (M+1).sup.+
202.2.
Example 1d
4-[2-(4-Nitro-phenyl)-ethyl]-morpholine
##STR00771##
[0585] 4-[2-(4-Nitro-phenyl)-ethyl]-morpholine can be synthesized
by the following procedure. A solution of
1-(2-bromo-ethyl)-4-nitro-benzene (8.7 mmol) in anhydrous DMF (15
mL) and morpholine (17.3 mmol) is heated at 80.degree. C. under a
nitrogen atmosphere for 8 h. The reaction mixture is cooled down
and quenched with water and extracted with EtOAc. The organic layer
is washed with water, brine, dried over Na.sub.2SO.sub.4, and
concentrated to afford 4-[2-(4-nitro-phenyl)-ethyl]-morpholine
(93%) as a yellow oil. .sup.1HNMR (400 MHz, CDCl.sub.3) .delta.
8.15-8.13 (m, 2H), 7.38-7.36 (m, 2H), 6.86-6.84 (m, 2H), 3.75 (m,
4H), 2.91 (t, J=8.0 Hz, 2H), 2.65 (t, J=8.0 Hz, 4H), 2.55 (m, 4H).
MS (m/z) (M+1).sup.+ 237.2.
Example 1e
3-Nitrophenyl 4-methylpiperazine-1-carboxylate
##STR00772##
[0587] 3-Nitrophenyl 4-methylpiperazine-1-carboxylate can be
synthesized by the following procedure. A dry flask containing
3-nitro-phenol (28 mmol) and triphosgene (18.7 mmol) in 100 mL
dichloromethane is cooled in an ice-water bath.
Diisopropylethylamine (28 mmol) is slowly added. The reaction is
stirred at rt for 2 h and then refluxed for another 2 h. The
mixture is concentrated to dryness. The residue is dissolved in 100
mL of THF and triethylamine (40 mmol) and N-methylpiperazine (30
mmol) are added. The mixture is stirred overnight and concentrated.
The residue is dissolved in dichloromethane and washed with 10%
NaHCO.sub.3. The organic layer is separated, dried over sodium
sulfate, and concentrated. The crude product is used in the next
step without further purification.
Example 1f
4-Nitrophenyl 4-methylpiperazine-1-carboxylate
##STR00773##
[0589] 4-Nitrophenyl 4-methylpiperazine-1-carboxylate can be
synthesized by the following procedure. A dry flask containing
4-nitro-phenol (28 mmol) and triphosgene (18.7 mmol) in 100 mL
dichloromethane is cooled in an ice-water bath.
Diisopropylethylamine (28 mmol) is slowly added. The reaction is
stirred at rt for 2 h and then refluxed for another 2 h. The
mixture is concentrated to dryness. The residue is dissolved in 100
mL of THF and triethylamine (40 mmol) and N-methylpiperazine (30
mmol) are added. The mixture is stirred overnight and concentrated.
The residue is dissolved in dichloromethane and washed with 10%
NaHCO.sub.3. The organic layer is separated, dried over sodium
sulfate, and concentrated. The crude product is used in the next
step without further purification.
Examples 1g
Diethyl-[2-(3-nitro-phenoxy)-ethyl]-amine
##STR00774##
[0591] Diethyl-[2-(3-nitro-phenoxy)-ethyl]-amine can be synthesize
by the following procedure. To a solution of 3-nitro-phenol (7.2
mmol) in anhydrous EtOH (20 mL), cesium carbonate (10.8 mmol) is
added followed by (2-chloro-ethyl)-diethyl-amine hydrochloride (7.0
mmol) and the reaction mixture is refluxed for 12 h. The reaction
mixture is cooled down and the solid filtered under vacuum and
washed with warm EtOH. The filtrate is concentrated, dissolved in
DCM (50 mL), washed with water, brine, dried over Na.sub.2SO.sub.4,
and concentrated to afford 1.45 g of the title compound (84%) that
is used without further purification. .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 7.82-8.80 (m, 1H), 7.74-7.73 (m, 1H), 7.43-7.38
(m, 1H), 7.23-7.21 (m, 1H), 4.12 (dt, J=8.0 and 4.0 Hz, 2H), 2.91
(dt. J=8.0 and 4.0 Hz, 2H), 2.69-2.63 (m, 4H), 1.11-1.06 (m, 6H).
MS (m/z) (M+1).sup.+ 239.2.
Examples 1h
2-Hydroxy-4-nitro-benzoic acid methyl ester
##STR00775##
[0593] 2-Hydroxy-4-nitro-benzoic acid methyl ester can be
synthesized by the following procedure. To a suspension of
2-hydroxy-4-nitro-benzoic acid (5.4 mmol) in anhydrous ACN (20 mL),
1,8-diazabicyclo[5.4.0]undec-7-ene (5.4 mmol) is added drop wise
followed by methyl iodide (5.4 mmol). The reaction is stirred at rt
for 1 h. The solvent is removed under reduced pressure and the
yellow residue is dissolved in DCM (50 mL) washed with 2N HCl
(2.times.20 mL), 5% Na.sub.2CO.sub.3 (2.times.30 mL), brine, dried
over Na.sub.2SO.sub.4 and concentrated to afford
2-hydroxy-4-nitro-benzoic acid methyl ester as a pale yellow solid
(84%). MS (m/z) (M+1).sup.+ 198.1.
Example 1i
2-(2-Diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-ben-
zoic acid methyl ester
##STR00776##
[0595]
2-(2-Diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylami-
no]-benzoic acid methyl ester can be prepared by the following
procedure. To a solution of 2-hydroxy-4-nitro-benzoic acid methyl
ester (2.5 mmol) in DMF (10 mL), is added cesium carbonate (3.5
mmol) followed by (2-chloro-ethyl)-diethyl-amine hydrochloride (3.5
mmol). The reaction mixture is heated at 80.degree. C. for 8 h.
After this time the reaction is cooled down, diluted with water (50
mL) and extracted with EtOAc (3.times.30 mL). The combined organic
layer is washed with water (2.times.20 mL), brine, dried over
Na.sub.2SO.sub.4 and concentrated to afford
2-(2-diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylam-
ino]-benzoic acid methyl ester (69%) as a yellow oil that is used
without further purification. .sup.1HNMR (400 MHz, DMSO) .delta.
7.48 (d, J=8 Hz, 1H), 6.20-6.19 (m, 1H), 6.14-6.12 (m, 1H), 5.88
(bs, 2H), 3.92 (t, J=8.0 Hz, 2H), 3.64 (s, 3H), 2.77 (t. J=8.0 Hz,
2H), 2.56 (q, J=8.0 Hz, 4H), 10.97 (t, J=8.0 Hz, 6H). MS (m/z)
(M+1).sup.+ 267.2.
Example 1j
3-Nitrophenethyl methanesulfonate
##STR00777##
[0597] 3-Nitrophenethyl methanesulfonate can be synthesized by the
following procedure. To a solution of 2-(3-nitrophenyl)ethanol
(17.9 mmol) and triethylamine (23.3 mmol) in DCM (50 mL), is added
methanesulfonyl chloride (18.8 mmol) in DCM (10 mL) at 0.degree. C.
under a nitrogen atmosphere. After the addition is complete, the
reaction is allowed to warm to rt and it is stirred for another 2
h. The solvent is removed and the residue is dissolved in DCM (100
mL). The organic layer is washed with water, dried over
Na.sub.2SO.sub.4 and concentrated to afford 3-nitrophenethyl
methanesulfonate (98%) that is used without further purification.
MS (m/z) (M+1).sup.+ 246.2.
Example 1k
N,N-Diethyl-2-(3-nitrophenyl)ethanamine
##STR00778##
[0599] N,N-diethyl-2-(3-nitrophenyl)ethanamine can be prepared by
the following procedure. A mixture of diethyl amine (9.0 mmol) and
K.sub.2CO.sub.3 (9.9 mmol) in ACN (50 mL) is refluxed for 1 h under
nitrogen atmosphere. To the above mixture, a solution of
3-nitrophenethyl methanesulfonate (8.2 mmol) in ACN (10 mL) is
added and the mixture is refluxed for 1 h. The solvent is removed
and the residue is dissolved in DCM (100 mL). The organic layer is
washed with water, dried over Na.sub.2SO.sub.4 and concentrated to
afford a residue which is purified by silica gel column
chromatography (EtOAc:hexane=30:70) to afford
N,N-diethyl-2-(3-nitrophenyl)ethanamine (75%). .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 8.04-8.10 (m, 2H), 7.51-7.55 (d, J=7.6 Hz, 1H),
7.43 (t, J=7.8 Hz, 1H), 2.81-2.88 (m, 2H), 2.67-2.74 (m, 2H), 2.59
(q, J=7.2 Hz, 4H), 1.04 (t. J=7.2 Hz, 6H). MS (m/z) (M+1).sup.+
223.2.
Example 1l
3-nitrobenzyl 4-methylpiperazine-1-carboxylate
##STR00779##
[0601] 3-nitrobenzyl 4-methylpiperazine-1-carboxylate can be
synthesized by the following procedure. To a suspension of NaH (60%
weight in mineral oil, 12.0 mmol) in THF (20 mL), is added
(3-nitrophenyl)methanol (8.0 mmol) slowly. The reaction mixture is
stirred at rt for 5 min. A solution of
4-methylpiperazine-1-carbonyl chloride (10.0 mmol) in THF (5 mL) is
added to the above reaction mixture and stirred for 3 h. Upon
reaction completion, H.sub.2O (1 mL) is added to quench the
reaction. The solvent is removed and the residue is dissolved in
EtOAc (100 mL). The organic layer is washed with water, dried over
Na.sub.2SO.sub.4 and concentrated to afford a residue which is
purified by silica gel column chromatography (EtOAc:hexane=30:70)
to afford 3-nitrobenzyl 4-methylpiperazine-1-carboxylate (80%).
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.20 (s, 1H), 8.15 (d,
J=7.8 Hz, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.53 (t, J=7.8 Hz, 1H), 5.20
(s, 2H), 3.50-3.55 (m, 4H), 2.29 (s, 3H). MS (m/z) (M+1).sup.+
280.2.
Example 1m
2-(methoxycarbonyl)-5-nitrophenyl
4-methylpiperazine-1-carboxylate
##STR00780##
[0603] To a dry flask are added 2-hydroxy-4-nitro-benzoic acid
methyl ester (40 mmol) (from Example 1h) and triphosgene (26.6
mmol) and DCM (100 mL). The reaction mixture is cooled to 0.degree.
C. and diisopropylethylamine (40 mmol) is added slowly. After
addition the mixture is warmed to rt. After 1 h at this temperature
it is refluxed for 1 h. The mixture is cooled down and the solvents
are removed. THF (100 mL), Et.sub.3N (80 mmol), and N-methyl
piperazine (80 mmol) are added and the mixture is stirred at rt
overnight. The solvent is removed and the residue dissolved in
EtOAc. Phases are separated upon addition of a 10% solution of
NaHCO.sub.3. The organic phase is washed with brine, dried on
Na.sub.2SO.sub.4 and evaporated. The crude is used in the following
reaction.
Example 1n
2-(2-Diethylamino-ethoxy)-5-nitro-benzoic acid ethyl ester
##STR00781##
[0605] 2-(2-Diethylamino-ethoxy)-5-nitro-benzoic acid ethyl ester
can be synthesized by the following procedure. A solution of methyl
5-nitrosalicylate (7.61 mmol) in anhydrous EtOH (20 mL) is treated
with Cs.sub.2CO.sub.3 (11.4 mmol) and
(2-chloro-ethyl)-diethyl-amine hydrochloride (7.61 mmol). The
reaction mixture is stirred at 80.degree. C. for 4 h, then the
solvent is removed and the thick oil residue is purified by HPLC
(ACN gradient 10-90%) to afford the title compounds (25%).
.sup.1HNMR (400 MHz, DMSO) .delta. 9.58 (b.s. 1H), 8.53-8.54 (m,
1H), 8.50-8.47 (m, 1H), 4.58-4.57 (m, 2H), 4.31 (q, J=8.0 Hz, 2H),
3.61-3.60 (m, 2H), 3.32-3.27 (m, 4H), 1.33 (t, J=8.0 Hz, 3H), 1.24
(t, J=8.0 Hz, 6H); MS (m/z) (M+1).sup.+ 311.1.
Example 2
Synthesis of Substituted Aniline Compounds
Example 2a
4-(2-Diethylamino-ethoxy)-phenylamine
##STR00782##
[0607] 4-(2-Diethylamino-ethoxy)-phenylamine can be synthesized by
the following procedure. To a solution of
diethyl-[2-(4-nitro-phenoxy)-ethyl]-amine (14.0 mmol) (from Example
1a) in MeOH (20 mL), in a Parr pressure bottle, is added Pd (10% on
carbon, 50% wet, 10% weight,). The suspension is shaken at 50 psi
of H2 for 2 h. The reaction mixture is filtered through celite. The
solvent is removed and the residue is dissolved in MeOH (20 mL) and
treated with HCl (1 eq of a 4N solution in dioxane) to afford the
4-(2-diethylamino-ethoxy)-phenylamine as hydrochloride salt (99%).
.sup.1HNMR (400 MHz, DMSO) .delta. 6.98-6.91 (m, 4H), 4.30 (t,
J=4.0 Hz, 2H), 3.47 (t, J=4.0 Hz), 3.20 (m, 4H), 1.24 (t, J=8.0 Hz,
6H). MS (m/z) (M+1).sup.+ 209.3.
Example 2b
4-(2-Diethylamino-ethylsulfanyl)-phenylamine
##STR00783##
[0609] 4-(2-Diethylamino-ethylsulfanyl)-phenylamine can be
synthesized by the following procedure. A suspension of
diethyl-[2-(4-nitro-phenylsulfanyl)-ethyl]-amine (3.9 mmol) (from
Example 1b) and SnCl.sub.2 2H.sub.2O (15.7 mmol) in absolute
ethanol (30 mL) is heated at 70.degree. C. for 2 h. The solvent is
removed under vacuum and the residue is dissolved in 5% NaOH and
extracted with EtOAc (3.times.50 mL). The organic layer is washed
with 5% NaOH (1.times.50 mL), water (1.times.50 mL), brine, dried
over Na.sub.2SO.sub.4 and concentrated to afford
4-(2-diethylamino-ethylsulfanyl)-phenylamine (91%). .sup.1HNMR (400
MHz, CDCl.sub.3) .delta. 8.23-8.11 (m, 2H), 7.35-7.33 (m, 2H), 3.13
(t, J=8.0 Hz, 2H), 2.77 (t, J=8.0 Hz, 2H), 2.60 (q, J=8.0 Hz, 4H),
1.05 (t, J=8.0 Hz, 6H). MS (m/z) (M+1).sup.+ 255.2.
Example 2c
4-(2-Chloro-ethoxy)-phenylamine
##STR00784##
[0611] 4-(2-Chloro-ethoxy)-phenylamine can be synthesized by the
following procedure. A suspension of
1-(2-chloro-ethoxy)-4-nitro-benzene (1.5 mmol) (from Example 1c)
and SnCl.sub.2.2H.sub.2O (5.9 mmol) in absolute ethanol (120 mL) is
heated at 70.degree. C. for 2 h. The solvent is removed under
vacuum and the residue is dissolved in 5% NaOH and extracted with
EtOAc (3.times.50 mL). The organic layer is washed with 5% NaOH
(1.times.50 mL), water (1.times.50 mL), brine, and dried over
Na.sub.2SO.sub.4 and reduced to dryness. The dark crude residue is
purified by silica chromatography using a mixture of
DCM:MeOH:NH.sub.4OH=9:1:0.1 to isolate
4-(2-chloro-ethoxy)-phenylamine (90%) which is converted in the
hydrochloride salt by treatment with HCl (1 eq of a 4N solution in
dioxane). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.35-7.33 (m,
2H), 7.16-7.05 (m, 2H), 4.38 (m, 2H), 3.87 (m, 2H). MS (m/z)
(M+1).sup.+ 173.1.
Example 2d
4-(2-Morpholin-4-yl-ethyl)-phenylamine
##STR00785##
[0613] 4-(2-Morpholin-4-yl-ethyl)-phenylamine can be synthesized by
the following procedure. To a solution of
4-[2-(4-nitro-phenyl)-ethyl]-morpholine (14.0 mmol) (from Example
1d) in MeOH (20 mL), in a Parr pressure bottle, is added Pd (10% on
carbon, 50% wet, 10% weight). The reaction mixture is shaken at 50
psi of H.sub.2 for 2 h. The reaction mixture is filtered through
celite. The solvent is removed to afford
4-(2-morpholin-4-yl-ethyl)-phenylamine. MS (m/z) (M+1).sup.+
207.2.
Example 2e
3-Aminophenyl 4-methylpiperazine-1-carboxylate
##STR00786##
[0615] 3-Aminophenyl 4-methylpiperazine-1-carboxylate can be
synthesized with the following procedure. The crude 3-nitrophenyl
4-methylpiperazine-1-carboxylate (28 mmol) (from Example 1e) is
dissolved in MeOH (100 mL) and added Pd (5% on carbon, 50% wet, 10%
weight). The flask is charged with a hydrogen balloon and stirred
overnight. The mixture is filtered through celite. The filtrate is
concentrated and further purified by silica gel column
chromatography (DCM:MeOH=30:70) to afford 3-aminophenyl
4-methylpiperazine-1-carboxylate (81%). .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 7.11 (m, 1H), 6.52-6.47 (m, 2H), 6.44 (s, 1H),
3.71 (br, 4H), 3.63 (br, 2H), 2.52 (br, 4H), 2.38 (s, 3H). MS (m/z)
(M+1).sup.+ 236.1.
Example 2f
4-aminophenyl 4-methylpiperazine-1-carboxylate
##STR00787##
[0617] 4-Aminophenyl 4-methylpiperazine-1-carboxylate can be
synthesized with the following procedure. The crude 4-nitrophenyl
4-methylpiperazine-1-carboxylate (28 mmol) (from Example 1f) is
dissolved in MeOH (100 mL) followed by addition of Pd (5% on
carbon, 50% wet, 10% weight) The flask is charged with a hydrogen
balloon for overnight stirring. The mixture is filtered through
celite. The filtrate is concentrated and purified by silica gel
column chromatography (DCM:MeOH=30:70) to afford the
4-methyl-piperazine-1-carboxylic acid 4-amino-phenyl ester (80%).
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 6.88 (d, J=7.8 Hz, 2H),
6.55 (d, J=7.8 Hz, 2H), 3.73 (br, 2H), 3.63 (br, 4H), 2.53 (br,
4H), 2.40 (s, 3H). MS (m/z) (M+1).sup.+ 236.1.
Example 2g
3-(2-Diethylamino-ethoxy)-phenylamine
##STR00788##
[0619] 3-(2-Diethylamino-ethoxy)-phenylamine can be prepared by the
following procedure. To a solution of
diethyl-[2-(3-nitro-phenoxy)-ethyl]-amine (2.72 mmol) (from Example
1g) in EtOH (20 mL) is added SnCl.sub.2.2H.sub.2O (10.9 mmol). The
suspension is refluxed for 2 h. After this time the solvent is
removed under reduced pressure. The residue is dissolved in 5% NaOH
(50 mL) and extracted with EtOAc (3.times.50 mL). The organic layer
is washed once with 5% NaOH (20 mL), brine, dried over
Na.sub.2SO.sub.4 and concentrated to afford the aniline as a brown
oil (80%). MS (m/z) (M+1).sup.+ 209.1.
Example 2h
4-Amino-2-(2-diethylamino-ethoxy)-benzoic acid methyl ester
##STR00789##
[0621] 3-(2-Diethylamino-ethoxy)-phenyl-amine can be prepared by
the following procedure. In a Parr pressure bottle, a solution of
diethyl-[2-(3-nitro-phenoxy)-ethyl]-amine (2.72 mmol) (from Example
1i) in MeOH (10 mL) is added Pd (5% on carbon, 50% wet, 10%
weight). The suspension is shaken at 40 psi of H2 for 2 h. The
reaction is filtered through celite. The solvent is removed under
reduced pressure to afford the title compound in quantitative
yield. MS (m/z) (M+1).sup.+ 267.1.
Example 2i
3-(2-(diethylamino)ethyl)benzenamine
##STR00790##
[0623] 3-(2-(Diethylamino)ethyl)benzenamine can be synthesized by
the following procedure. To a solution of
N,N-diethyl-2-(3-nitrophenyl)ethanamine (12.2 mmol) (from Example
1k) in MeOH (40 mL) is added Pd (5% on carbon, 50% wet, 10%
weight). The suspension is stirred under a balloon of H.sub.2 for 2
h. The reaction is filtered through celite. The solvent is removed
under reduced pressure to afford the title compound in quantitative
yield. .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 7.04-7.09 (m, 1H),
6.58-6.61 (m, 1H), 6.50-6.54 (m, 2H), 3.62 (br, 2H), 2.65-2.70 (m,
4H), 2.61 (q, J=7.2 Hz, 4H), 1.07 (t. J=7.2 Hz, 6H). MS (m/z)
(M+1).sup.+ 192.2.
Example 2j
3-aminobenzyl 4-methylpiperazine-1-carboxylate
##STR00791##
[0625] 3-Aminobenzyl 4-methylpiperazine-1-carboxylate can be
prepared by the following procedure. A suspension of 3-nitrobenzyl
4-methylpiperazine-1-carboxylate (1.5 mmol) (from Example 1l) and
SnCl.sub.2.2H.sub.2O (5.9 mmol) in absolute ethanol (120 mL) is
heated at 80.degree. C. for 2 h. The solvent is removed under
vacuum and the residue is dissolved in 5% NaOH and extracted with
EtOAc (3.times.50 mL). The organic layer is washed with 5% NaOH
(1.times.50 mL), water (1.times.50 mL), brine, and dried over
Na.sub.2SO.sub.4. The dark crude residue is purified by silica
chromatography (DCM:MeOH=70:30) to afford 3-aminobenzyl
4-methylpiperazine-1-carboxylate (90%). .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 7.13 (t, J=7.7 Hz, 1H), 6.71-6.75 (m, 1H),
6.66-6.68 (m, 1H), 6.61-6.65 (m, 1H), 5.03 (s, 2H), 3.70 (br, 2H),
3.52 (t, J=5.0 Hz, 4H), 2.32-2.44 (m, 4H), 2.30 (s, 3H). MS (m/z)
(M+1).sup.+ 250.2.
Example 2l
2-(Methoxycarbonyl)-5-aminophenyl
4-methylpiperazine-1-carboxylate
##STR00792##
[0627] 2-(Methoxycarbonyl)-5-aminophenyl
4-methylpiperazine-1-carboxylate can be prepared by the following
procedure. The crude 2-(methoxycarbonyl)-5-nitrophenyl
4-methylpiperazine-1-carboxylate (30 mmol) (From Example 1m) is
dissolved in MeOH (100 mL) followed by addition of Pd (5% on
carbon, 50% wet, 10% weight). The flask is charged with a hydrogen
balloon for overnight stirring. The mixture is filtered over
celite. The filtrate is concentrated and further purified by silica
gel column chromatography (DCM:MeOH=30:70) to afford
2-(methoxycarbonyl)-5-aminophenyl
4-methylpiperazine-1-carboxylate.
Example 2m
5-Amino-2-(2-diethylamino-ethoxy)-benzoic acid ethyl ester
##STR00793##
[0629] 5-Amino-2-(2-diethylamino-ethoxy)-benzoic acid ethyl ester
can be synthesized by the following procedure. To
2-(2-Diethylamino-ethoxy)-5-nitro-benzoic acid ethyl ester (1.6
mmol) (from Example 1n) in MeOH (12 mL) in a Parr pressure bottle
is added Pd (5% on carbon, 50% wet, 10% weight). The suspension is
shaken at 40 psi of H.sub.2 for 2 h. The reaction is filtered
through celite. The solvent is removed under reduced pressure to
afford the title compound in quantitative yield. MS (m/z)
(M+1).sup.+ 281.1.
Example 2n
6-Amino-3H-benzooxazol-2-one
##STR00794##
[0631] 6-Amino-3H-benzooxazol-2-one can be synthesized by the
following procedure. A solution of 6-nitro-3H-benzooxazol-2-one
(7.22 mmol) in a 1:3 mixture EtOH:MeOH (24 mL) is treated with Pd
(5% on carbon, 50% wet, 10% weight). The flask is charged with a
hydrogen balloon and stirred overnight. The mixture is filtered
over celite and the filtrate is concentrated to afford the
6-amino-benzoxazole-2-one as light brown powder (95%). .sup.1HNMR
(400 MHz, DMSO-d.sub.6) .delta. 11.06 (b.s., 1H), 6.74 (d, J=8.2
Hz, 1H), 6.49 (d, J=2.0 Hz, 1H), 6.35 (dd, J=2.1 and 8.3 Hz, 1H),
4.96 (s, 2H). MS (m/z) (M+1).sup.+ 151.1.
Example 3
Synthesis of 5-bromo-2-aminopyrimidine compounds
Example 3a
(5-Bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl-amine
##STR00795##
[0633]
(5-Bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl-amine
can be synthesized by the following procedure. A dry flask charged
with 4-(2-diethylamino-ethoxy)-phenylamine (6.1 mmol) (from Example
2a), p-TSA (6.1 mmol), 2-chloro-5-bromo-pyrimidine (6.1 mmol) in
NMP (5 mL) is heated in a microwave oven at 210.degree. C. for 15
min. The reaction mixture is diluted with water and extracted with
EtOAc (5.times.70 mL). The organic layer is washed with water,
brine, dried over Na.sub.2SO.sub.4, and concentrated. Purification
by silica chromatography (DCM:MeOH NH.sub.4OH=95:5:0.1) affords
5-bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl-amine
(50%). .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.37 (s, 2H),
7.43-7.40 (m, 2H), 7.02 (s, 1H), 6.91-6.89 (m, 2H), 4.06 (t, J=4.0
Hz, 2H), 2.90 (t, J=4.0 Hz, 2H), 2.67 (q, J=8.0 Hz, 4H), 1.09 (t,
J=8.0 Hz, 6H). MS (m/z) (M+1).sup.+ 366.1.
Example 3b
(5-Bromo-pyridin-2-yl)-[4-(2-diethylamino-ethylsulfanyl)-phenyl]-amine
##STR00796##
[0635]
(5-Bromo-pyridin-2-yl)-[4-(2-diethylamino-ethylsulfanyl)-phenyl]-am-
ine can be synthesized by the following procedure. A dry flask
charged with 4-(2-diethylamino-ethylsulfanyl)-phenylamine (6.1
mmol) (from Example 2b), p-TSA (6.1 mmol),
2-chloro-5-bromo-pyrimidine (6.1 mmol) in NMP (5 mL) is heated in a
microwave oven at 210.degree. C. for 15 min. The reaction mixture
is diluted with water and extracted with EtOAc (5.times.70 mL). The
organic layer is washed with water, brine, dried over
Na.sub.2SO.sub.4, and concentrated. Purification by silica
chromatography (DCM:MeOH:NH.sub.4OH=95:5:0.1) affords
(5-bromo-pyridin-2-yl)-[4-(2-diethylamino-ethylsulfanyl)-phenyl]-amine.
MS (m/z) (M+1).sup.+ 282.1.
Example 3c
5-Bromo-pyrimidin-2-yl)-[4-(2-chloro-ethoxy)-phenyl-amine
##STR00797##
[0637] 5-Bromo-pyrimidin-2-yl)-[4-(2-chloro-ethoxy)-phenyl-amine
can be synthesized by the following procedure. A dry flask charged
with 4-(2-chloro-ethoxy)-phenylamine (6.7 mmol) (from Example 2c),
p-TSA (6.7 mmol), 2-chloro-5-bromo-pyrimidine (6.7 mmol), and NMP
(5 mL) is heated in a microwave oven at 210.degree. C. for 15 min.
The reaction mixture is diluted with water and extracted with EtOAc
(5.times.70 mL). The organic layer is washed with water, brine,
dried over Na.sub.2SO.sub.4, and concentrated. Purification by
automated silica chromatography using a mixture of EtOAc:Hexane
affords 5-bromo-pyrimidin-2-yl)-[4-(2-chloro-ethoxy)-phenyl-amine
(33%). .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.35 (s, 2H),
7.39-7.33 (m, 2H), 7.19 (s, 1H), 6.86 (m, 2H), 4.15 (t, J=6.0 Hz,
2H), 3.74 (t, J=6.0 Hz, 2H). MS (m/z) (M+1).sup.+ 329.1.
Example 3d
(5-Bromo-pyrimidin-2-yl)-[-(2-morpholin-4-yl-ethyl)-phenyl]-amine
##STR00798##
[0639]
(5-Bromo-pyrimidin-2-yl)-[-(2-morpholin-4-yl-ethyl)-phenyl]-amine
can be synthesized by the following procedure. A dry flask charged
with 4-(2-morpholin-4-yl-ethyl)-phenylamine (6.1 mmol) (from
Example 2d), p-TSA (6.1 mmol), 2-chloro-5-bromo-pyrimidine (6.1
mmol) in NMP (5 mL) is heated in a microwave oven at 210.degree. C.
for 15 min. The reaction mixture is diluted with water and
extracted with EtOAc (5.times.70 mL). The organic layer is washed
with water, brine, dried over Na.sub.2SO.sub.4, and concentrated.
Purification by silica chromatography
(DCM:MeOH:NH.sub.4OH=95:5:0.1) affords
(5-bromo-pyrimidin-2-yl)-[-(2-morpholin-4-yl-ethyl)-phenyl]-amine
(50%). .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 9.75 (S, 1H),
8.58 (s, 2H), 7.60 (d, J=8.4 Hz, 2H), 7.16 (d, J=8.4 Hz, 2H), 3.59
(t, J=4.4 Hz, 4H), 2.69 (t, J=8.0 Hz, 2H), 2.49 (t, J=8.0 Hz, 2H),
2.34 (m, 4H). MS (m/z) (M+1).sup.+ 363.1.
Example 3e
(5-Bromo-pyrimidin-2-yl)-[3-(2-diethylamino-ethoxy)-phenyl]-amine
##STR00799##
[0641]
(5-Bromo-pyrimidin-2-yl)-[3-(2-diethylamino-ethoxy)-phenyl]-amine
can be synthesized by the following procedure. A 25 ml flask is
charged with 3-(2-diethylamino-ethoxy)-phenyl]-amine (1.7 mmol),
2-chloro-5-bromo-pyrimidine (1.7 mmol), p-TSA (1.7 mmol) and NMP (2
mL). The flask is evacuated and irradiated in a microwave oven at
210.degree. C. for 15 min. The reaction mixture is diluted with
water and extracted with a EtOAc:THF 4:1 solution (5.times.50 mL).
The organic layer is washed with brine, dried over
Na.sub.2SO.sub.4, and concentrated. Purification by HPLC (ACN
gradient 10-90%) affords the title compounds (63%). MS (m/z)
(M+1).sup.+ 366.1.
Example 3f
4-(5-Bromo-pyrimidin-2-ylamino)-benzoic acid methyl ester
##STR00800##
[0643] 4-(5-Bromo-pyrimidin-2-ylamino)-benzoic acid methyl ester
can be synthesized by the following procedure. A 25 ml flask is
charged with p-amino methyl benzoate (3.3 mmol)
2-chloro-5-bromo-pyrimidine (3.3 mmol), p-TSA (1.5 mmol) and NMP (2
mL). The flask is evacuated and irradiated in a microwave oven at
210.degree. C. for 15 min. The reaction mixture is diluted with
water and extracted with EtOAc (5.times.50 mL). The organic layer
is washed with brine, dried over Na.sub.2SO.sub.4, and
concentrated. Purification by HPLC (ACN gradient 10-90%) affords
the title compounds (30%). .sup.1HNMR (400 MHz, DMSO-d.sub.6)
.delta. 10.34 (s, 1H), 8.70 (s, 2H), 7.92-7.86 (m, 4H), 3.82 (s,
3H). MS (m/z) (M+1).sup.+ 308.1.
Example 3g
5-(5-Bromo-pyrimidin-2-ylamino)-2-methoxy-phenol
##STR00801##
[0645] 5-(5-Bromo-pyrimidin-2-ylamino)-2-methoxy-phenol can be
synthesized by the following procedure. A 25 ml flask is charged
with 5-amino-2-methoxy-phenol (3.5 mmol)
2-chloro-5-bromo-pyrimidine (3.5 mmol), p-TSA (1 mmol) and NMP (2
mL). The flask is evacuated and irradiated in a microwave oven at
210.degree. C. for 15 min. The reaction mixture is diluted with
water and extracted with DCM (5.times.50 mL). The organic layer is
washed with brine, dried over Na.sub.2SO.sub.4, and concentrated.
Purification by HPLC (ACN gradient 10-90%) affords the title
compounds (25%). .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 9.56
(s, 1H), 8.51 (s, 2H), 7.18 (d, J, 4 Hz, 1H), 7.02 (dd, J=8.0 and
4.0 Hz, 1H), 6.83 (d, J=8.0 Hz, 1H), 3.72 (s, 3H), 3.17 (s, 1H). MS
(m/z) (M+1).sup.+ 297.1.
Example 3h
[4-(5-Bromo-pyrimidin-2-ylamino)-phenyl]-methanol
##STR00802##
[0647] [4-(5-Bromo-pyrimidin-2-ylamino)-phenyl]-methanol can be
synthesized by the following procedure. To a solution of
4-aminobenzyl alcohol (8.12 mmol) and 5-bromo-2-chloro-pyrimidine
(9.74 mmol) in 2-propanol (20 mL) is added sodium iodide (8.12
mmol) and diisopropylethylamine (16.2 mmol). The reaction mixture
is heated in the microwave oven at 200.degree. C. for 15 min.
Purification by silica chromatography using hexane:EtOAc=7:3
affords [4-(5-bromo-pyrimidin-2-ylamino)-phenyl]-methanol (44%).
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.36 (s, 2H), 7.49 (d,
J=8.8 Hz, 2H), 7.28 (d, J=8.4 Hz, 2H) 7.07 (bs, 1H), 4.60 (s, 2H).
MS (m/z) (M+1).sup.+ 280.3.
Example 3i
4-Methyl-piperazine-1-carboxylic acid
4-(5-bromo-pyrimidin-2-ylamino)-phenyl ester
##STR00803##
[0649] 4-Methyl-piperazine-1-carboxylic acid
4-(5-bromo-pyrimidin-2-ylamino)-phenyl ester can be synthesized by
the following procedure. To a solution of
4-methyl-piperazine-1-carboxylic acid 4-amino-phenyl ester-(1.06
mmol) (from Example 2f) in NMP (2 mL) are added
5-bromo-2-chloro-pyrimidine (1.06 mmol) and pTSA (1.06 mmol). The
flask is evacuated twice and heated in a microwave oven at
210.degree. C. for 10 min. The reaction mix is diluted with water
and extracted with DCM. The organic layer is washed with water,
brine, dried over Na.sub.2SO.sub.4 and concentrated. The crude
mixture is purified by HPLC (ACN gradient 10-90) to afford
4-methyl-piperazine-1-carboxylic acid
4-(5-bromo-pyrimidin-2-ylamino)-phenyl ester (25%). MS (m/z)
(M+1).sup.+ 393.25.
Example 3l
2-(4-(5-Bromopyrimidin-2-ylamino)phenyl)ethanol
##STR00804##
[0651] 2-(4-(5-Bromopyrimidin-2-ylamino)phenyl)ethanol can be
synthesized by the following procedure. A mixture of
2-(4-aminophenyl)ethanol (0.72 mol), 2-chloro-5-bromo-pyrimidine
(0.72 mol), NaI (0.72 mol), and diisopropylethylamine (1.45 mol) in
n-butanol (400 mL) is heated at reflux overnight. The reaction is
cooled to rt and the mixture is diluted with water. The light
yellow solid that precipitates is filtered to give
2-(4-(5-bromopyrimidin-2-ylamino)phenyl)ethanol (57%). .sup.1HNMR
(300 MHz, DMSO-d.sub.6) .delta. 9.722 (s, 1H), 8.52 (s, 2H), 7.55
(m, 2H), 7.09 (d, 2H), 4.64 (m, 1H), 3.52 (m, 2H), 2.65 (m,
2H).
Example 4
Synthesis of 5-substituted-2-chloropyrimidine compounds
Example 4a
4-(2-Chloropyrimidin-5-yl)benzaldehyde
##STR00805##
[0653] 4-(2-Chloropyrimidin-5-yl)benzaldehyde can be synthesized by
the following procedure. To a solution of 2-chloro-5-bromo
pyrimidine (2.58 mmol) in DMF (2 mL) are added 4-formyl boronic
acid (2.84 mmol), K.sub.2CO.sub.3 (5.96 mmol of a 5M aq solution)
and Pd(PPh.sub.3).sub.4 (0.129 mmol). The reaction is evacuated
twice and heated at 120.degree. C. for 5 min. The reaction mixture
is diluted with a sat. aq NH.sub.4Cl and extracted with DCM
(3.times.50 mL). The organic layer is washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated. Purification by silica
chromatography using hexane:EtOAc=8:2 affords
4-(2-chloropyrimidin-5-yl)benzaldehyde (53%).
Example 4b
Tert-butyl 2-(4-(2-chloropyrimidin-5-yl)benzylamino)acetate
##STR00806##
[0655] Tert-butyl 2-(4-(2-chloropyrimidin-5-yl)benzylamino)acetate
can be synthesized by the following procedure. To a solution of
4-(2-chloropyrimidin-5-yl)benzaldehyde (1.37 mmol) (from Example
4a), phenylglycine tert-butylester (1.37 mmol) and
diisopropylethylamine (1.64 mmol) in DCM (20 mL) is added
MgSO.sub.4 and the mixture is stirred overnight. MgSO.sub.4 is
filtered and the filtrate is diluted with a sat. aq NH.sub.4Cl and
extracted with DCM (3.times.50 mL). The organic layer is washed
with brine, dried over Na.sub.2SO.sub.4 and concentrated.
Purification by silica chromatography using a hexane EtOAc=8:2
affords tert-butyl 2-(4-(2-chloropyrimidin-5-yl)benzylamino)acetate
(33%).
Example 4c
2-Chloro-5-(4-methoxy-phenyl)-pyrimidine
##STR00807##
[0657] 2-Chloro-5-(4-methoxy-phenyl)-pyrimidine can be synthesized
by the following procedure. To a solution of 2-chloro-5-bromo
pyrimidine (7.7 mmol) in DMF (1.5 mL), 4-methoxy boronic acid (8.9
mmol), K.sub.2CO.sub.3 (16.2 mmol of a 5M aq solution) and
Pd(PPh.sub.3).sub.4 (0.38 mmol) are added. The reaction is
evacuated twice and heated at 120.degree. C. for 5 min. After this
time the reaction mixture is diluted with a sat. aq NH.sub.4Cl and
extracted with DCM (3.times.50 mL). The organic layer is washed
with brine, dried over Na.sub.2SO.sub.4 and concentrated.
Purification by silica chromatography using a hexane:EtOAc=8:2
affords 2-chloro-5-(4-methoxy-phenyl)-pyrimidine (59%). .sup.1HNMR
(400 MHz, CDCl.sub.3) .delta. 8.79 (s, 2H), 7.50 (d, J=8.0 Hz, 2H),
7.05 (d, J=8.0 Hz, 2H), 3.87 (s, 3H). MS (m/z) (M+1).sup.+
221.1.
Example 4d
4-(2-Chloro-pyrimidin-5-yl)-benzoic acid
##STR00808##
[0659] 4-(2-Chloro-pyrimidin-5-yl)-benzoic acid can be synthesized
by the following procedure. To a solution of 2-chloro-5-bromo
pyrimidine (9.9 mmol) in DMF (10 mL) are added benzoic
acid-4-boronic acid (10.9 mmol), K.sub.2CO.sub.3 (20.8 mmol of a 5M
aq solution) and Pd(PPh.sub.3).sub.4 (0.49 mmol). The reaction is
evacuated twice and heated at 80.degree. C. for 2 h. Addition with
water promotes the separation of the desired compound. The solid is
washed with water and dried under vacuum to afford
4-(2-chloro-pyrimidin-5-yl)-benzoic acid (51%). MS (m/z)
(M+1).sup.+ 235.1.
Example 5
Synthesis of 5-substituted-2-aminopyrimidine compounds
Example 5a
[4-(2-Diethylamino-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-a-
mine
##STR00809##
[0661]
[4-(2-diethylamino-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin--
2-yl]-amine can be synthesized by the following procedure. To a
solution of
(5-bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl-amine
(0.32 mmol) (from Example 3a) in glyme (1 mL) is added
4-methoxyphenylboronic acid (0.33 mmol), aqueous potassium
carbonate (0.57 mmol), and Pd(PPh.sub.3).sub.4 (0.027 mmol). The
reaction is heated at reflux for 15 min and the solvent is removed.
The residue is dissolved in DCM, washed with sat. aq NH.sub.4Cl
(2.times.20 mL), dried over Na.sub.2SO.sub.4, and concentrated.
Purification by HPLC (ACN gradient 10-90%) affords the title
compound (47%). The product is dissolved in MeOH and treated with
MeSO.sub.3H (1 eq) to afford
[4-(2-diethylamino-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]--
amine as its mesylate salt (quantitative). .sup.1HNMR (400 MHz,
MeOD) .delta. 8.64 (s, 2H), 7.50-7.47 (m, 4H), 7.02-6.96 (m, 4H),
4.29 (t, J=4.8 Hz, 2H), 3.75 (s, 3H), 3.54 (t, J=4.8 Hz, 2H),
3.33-3.24 (m, 4H), 2.61 (s, 3H), 1.30 (t, J=7.2 Hz, 6H). MS (m/z)
(M+1).sup.+ 393.3.
Example 5b
[4-(2-Diethylamino-ethylsulfanyl)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin--
2-yl]-amine
##STR00810##
[0663]
[4-(2-Diethylamino-ethylsulfanyl)-phenyl]-[5-(4-methoxy-phenyl)-pyr-
imidin-2-yl]-amine can be synthesized by the following procedure.
To a solution of
(5-bromo-pyridin-2-yl)-[4-(2-diethylamino-ethylsulfanyl)-phenyl]-amine
(0.32 mmol) (from Example 3b) in glyme (1 mL) is added
4-methoxyphenylboronic acid (0.33 mmol), aqueous potassium
carbonate (0.57 mmol), and Pd(PPh.sub.3).sub.4 (0.027 mmol). The
reaction is heated at reflux for 15 min and the solvent is removed.
The residue is dissolved in DCM, washed with sat aq NH.sub.4Cl.
(2.times.20 mL), dried over Na.sub.2SO.sub.4, and concentrated.
Purification by HPLC (ACN gradient 10-90%) affords the title
compound. The product is dissolved in MeOH and treated with
MeSO.sub.3H (1 eq) to afford
[4-(2-diethylamino-ethylsulfanyl)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-
-2-yl]-amine as its mesylate salt (quantitative). .sup.1HNMR (400
MHz, CD.sub.3OD) .delta. 8.69 (s, 2H) 7.82-7.80 (m, 2H), 7.55-7.48
(m, 4H), 7.05-7.03 (m, 2H), 3.84 (s, 3H), 3.24-3.18 (m, 8H), 2.70
(s, 3H), 1.25 (t, J=8.0 Hz, 6H). MS (m/z) (M+1).sup.+ 409.2.
Example 5c
[5-(4-Methoxy-phenyl)-pyrimidin-2-yl]-[4-(2-morpholin-4-yl-ethyl)-phenyl]--
amine
##STR00811##
[0665]
[5-(4-Methoxy-phenyl)-pyrimidin-2-yl]-[4-(2-morpholin-4-yl-ethyl)-p-
henyl]-amine can be synthesized by the following procedure. To a
solution of
(5-bromo-pyrimidin-2-yl)-[-(2-morpholin-4-yl-ethyl)-phenyl]-amine
(0.32 mmol) (from Example 3d) in glyme (1 mL) is added
4-methoxyphenylboronic acid (0.33 mmol), aqueous potassium
carbonate (0.57 mmol), and Pd(PPh.sub.3).sub.4 (0.027 mmol). The
reaction is heated at reflux for 15 min and the solvent is then
removed. The residue is dissolved in DCM, washed with sat. aq
NH.sub.4Cl (2.times.20 mL), dried over Na.sub.2SO.sub.4, and
concentrated. Purification by HPLC (ACN gradient 10-90%) affords
[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-[4-(2-morpholin-4-yl-ethyl)-phenyl]-
-amine which is converted to the corresponding hydrochloride salt
by treatment with 4N HCl. .sup.1HNMR (400 MHz, CD.sub.3OD) .delta.
8.65 (s, 2H), 7.56-754 (m, 2H), 7.49-7.46 (m, 2H), 7.27-7.25 (m,
2H), 6.97-6.95 (m, 2H), 4.02 (t, J=4.3 Hz, 2H), 3.74 (s, 3H), 3.72
(t, J=4.3 Hz, 2H), 3.48 (d, J=4.3 Hz, 2H), 3.34-3.30 (m, 2H),
3.16-3.10 (m, 2H), 3.03-2.99 (m, 2H). MS (m/z) (M+1).sup.+
391.2.
Example 5d
[4-(2-Chloro-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-amine
##STR00812##
[0667]
[4-(2-Chloro-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]--
amine can be synthesized by the following procedure. To a solution
of 5-bromo-pyrimidin-2-yl)-[4-(2-chloro-ethoxy)-phenyl-amine (0.32
mmol) (from Example 3c) in glyme (1 mL) is added
4-methoxyphenylboronic acid (0.33 mmol), aqueous potassium
carbonate (0.57 mmol), and Pd(PPh.sub.3).sub.4 (0.027 mmol). The
reaction is heated at reflux for 15 min and the solvent is removed.
The residue is dissolved in DCM, washed with sat. aq NH.sub.4Cl
(2.times.20 mL), dried over Na.sub.2SO.sub.4, and concentrated.
Purification by HPLC (ACN gradient 10-90%) gives the
[4-(2-chloro-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-amine.
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.53 (s, 2H), 7.50 (d,
J=8.8 Hz, 2H), 7.43 (d, J=8.8 Hz, 2H), 6.95 (d, J=8.8 Hz, 2H), 6.86
(d, J=8.8 Hz, 2H), 4.17 (t, J=5.2 Hz, 2H), 3.79-3.77 (m, 5H). MS
(m/z) (M+1).sup.+ 356.2.
Example 5e
(5-(4-Methoxy-phenyl)-pyrimidin-2-yl]-[4-(2-morpholin-4-yl-ethoxy-phenyl]--
amine
##STR00813##
[0669]
(5-(4-Methoxy-phenyl)-pyrimidin-2-yl]-[4-(2-morpholin-4-yl-ethoxy-p-
henyl]-amine can be synthesized by the following procedure. A dry
flask charged with
[4-(2-chloro-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-amine
(0.14 mmol) (from Example 5d), NaI (0.14 mmol), morpholine (0.14
mmol), diisopropylethylamine (0.14 mmol) and DMF (0.5 mL) is heated
in the microwave oven at 200.degree. C. for 8 min. The reaction is
diluted with water and extracted with EtOAc (5.times.20 mL). The
organic layer is washed with water, brine, dried over
Na.sub.2SO.sub.4, and concentrated. Purification by HPLC (ACN
gradient 10-90%) affords
(5-(4-methoxy-phenyl)-pyrimidin-2-yl]-[4-(2-morpholin-4-yl-ethoxy-phenyl]-
-amine (36%) as a triflate salt. .sup.1HNMR (400 MHz, CDCl.sub.3)
.delta. 10.04 (s, 1H), 9.58 (s, 2H), 7.73-7.69 (m, 2H), 7.69-7.60
(m, 2H), 7.05-6.96 (m, 4H), 4.62-3.98 (brm 4H), 3.79 (s, 3H),
3.75-3.72 (brm, 2H), 3.61-3.50 (brm, 4H), 3.21 (brm, 2H). MS (m/z)
(M+1).sup.+ 407.1.
Example 5f
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}benzaldehyde
##STR00814##
[0671]
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzal-
dehyde can be synthesized by the following procedure. To a solution
of
(5-bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl]-amine
(2 g, 5.48 mmol) (from Example 3a) in THF:water (30 mL:15 mL) is
added 4-formyl-phenylboronic acid (6 mmol), K.sub.2CO.sub.3 (12
mmol) and Pd(PPh.sub.3).sub.2Cl.sub.2 (0.25 mmol). The reaction
mixture is heated at 65.degree. C. for 2 h. After removal of the
THF, the residue is diluted with dichloromethane and water. Then
the organic layer is separated, dried over sodium sulfate, and
concentrated. Further purification by silica chromatography
(DCM:MeOH=20:80) affords the
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzaldehyde
(80%). MS (m/z) (M+1).sup.+ 391.2.
Example 5g
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-benz-
aldehyde
##STR00815##
[0673]
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluo-
ro-benzaldehyde can be synthesized by the following procedure. To a
solution of
(5-bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl]-amine
(5.48 mmol) (from Example 3a) in THF:water (30 mL: 15 mL) is added
3-fluoro-4-formyl-phenyl-boronic acid (6 mmol), K.sub.2CO.sub.3 (12
mmol) and Pd(PPh.sub.3).sub.2Cl.sub.2 (0.25 mmol). The reaction
mixture is heated at 65.degree. C. for 2 h. After removal of the
THF, the residue is diluted with dichloromethane and water. Then
the organic layer is separated, dried over sodium sulfate, and
concentrated. Further purification by silica chromatography
(DCM:MeOH=20:80) affords the
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-ben-
zaldehyde (75%). MS (m/z) (M+1).sup.+ 409.2.
Example 5h
(5-{4-[(2-Tert-Butoxy-ethylamino)-methyl]-phenyl}-pyrimidin-2-yl)-[4-(2-di-
ethylamino-ethoxy)-phenyl]-amine
##STR00816##
[0675]
(5-{4-[(2-Tert-butoxy-ethylamino)-methyl]-phenyl}-pyrimidin-2-yl)-[-
4-(2-diethylamino-ethoxy)-phenyl]-amine can be synthesized by the
following procedure. A solution of
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzaldehyde
(0.05 mmol) (from Example 5f) and 2-tert-butoxy-ethylamine (0.1
mmol) in 1 mL dichloromethane is stirred at rt for 1 h. Then
NaB(OAc).sub.3H (0.15 mmol) is added and the reaction is stirred
for 5 h. Purification by preparative LCMS affords
(5-{4-[(2-tert-butoxy-ethylamino)-methyl]-phenyl}-pyrimidin-2-yl)-[4-(2-d-
iethylamino-ethoxy)-phenyl]-amine as a TFA salt. MS (m/z)
(M+1).sup.+ 492.2.
Example 5i
(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-ben-
zylamino)-acetic acid tert-butyl ester
##STR00817##
[0677]
(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-flu-
oro-benzylamino)-acetic acid tert-butyl ester can be synthesized by
the following procedure. A solution of
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-ben-
zaldehyde (0.05 mmol) (from Example 5g) and amino-acetic acid
tert-butyl ester (0.1 mmol) in 1 mL dichloromethane is stirred at
rt for 1 h. Then NaB(OAc).sub.3H (0.15 mmol) is added and the
reaction is stirred for 5 h. Purification by preparative LCMS
affords
(4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-be-
nzylamino)-acetic acid tert-butyl ester as a TFA salt. MS (m/z)
(M+1).sup.+ 524.2.
Example 5j
4-Methyl-piperazine-1-carboxylic acid
3-(5-{4-[(tert-butoxycarbonylmethyl-amino)-methyl]-phenyl}-pyrimidin-2-yl-
amino)-phenyl ester
##STR00818##
[0679] 4-Methyl-piperazine-1-carboxylic acid
3-(5-{4-[(tert-butoxycarbonylmethyl-amino)-methyl]-phenyl}-pyrimidin-2-yl-
amino)-phenyl ester can be synthesized with the following
procedure.
[0680] A mixture of palladium acetate (0.01 mmol), Xantphos (0.012
mmol), potassium tert-butoxide (0.2 mmol),
[4-(2-chloro-pyrimidin-5-yl)-benzylamino]-acetic acid tert-butyl
ester (0.1 mmol) (from Example 4b) and 3-aminophenyl
4-methylpiperazine-1-carboxylate (from Example 2e) (0.3 mmol) in
dioxane (1 mL) is heated at 90.degree. C. for 1 h. Purification is
done using preparative LCMS to afford
4-methyl-piperazine-1-carboxylic acid
3-(5-{4-[(tert-butoxycarbonylmethyl-amino)-methyl]-phenyl}-pyrimidin-2-yl-
amino)-phenyl ester as a TFA salt. MS (m/z) (M+1).sup.+ 533.0.
Example 5k
4-Methyl-piperazine-1-carboxylic acid
4-(5-{4-[(tert-butoxycarbonylmethyl-amino)-methyl]-phenyl}-pyrimidin-2-yl-
amino)-phenyl ester
##STR00819##
[0682] 4-Methyl-piperazine-1-carboxylic acid
4-(5-{4-[(tert-butoxycarbonylmethyl-amino)-methyl]-phenyl}-pyrimidin-2-yl-
amino)-phenyl ester can be synthesized by the following procedure.
A mixture of Palladium acetate (0.01 mmol), Xantphos (0.012 mmol),
potassium tert-butoxide (0.2 mmol),
[4-(2-chloro-pyrimidin-5-yl)-benzylamino]-acetic acid tertbutyl
ester (0.1 mmol) (from Example 4b) and 4-aminophenyl
4-methylpiperazine-1-carboxylate (from Example 2f) (0.3 mmol) in
dioxane (1 mL) is heated at 90.degree. C. for 1 h. Purification by
preparative LCMS to affords 4-methyl-piperazine-1-carboxylic acid
4-(5-{4-[(tertbutoxycarbonylmethyl-amino)-methyl]-phenyl}-pyrimidin-2-yla-
mino)-phenyl ester as a TFA salt. MS (m/z) (M+1).sup.+ 532.4.
Example 5l
4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzoic acid
##STR00820##
[0684] 4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzoic acid
can be prepared by the following procedure. To a solution of
4-(5-bromo-pyrimidin-2-ylamino)-benzoic acid methyl ester (0.3
mmol) (from Example 3f) in DMF (1.5 mL) are added 4-methoxy boronic
acid (0.3 mmol), aq K.sub.2CO.sub.3 (0.68 mmol) and
Pd(PPh.sub.3).sub.4 (0.16 mmol). The reaction mixture is evacuated
twice and heated at 80.degree. C. for 30 min. After this time the
reaction mixture is diluted with a sat. aq NH.sub.4Cl and extracted
with DCM (3.times.30 mL). The organic layer is washed with brine,
dried over Na.sub.2SO.sub.4 and concentrated to afford
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzoic acid methyl
ester that upon trituration with MeOH gives an orange solid (95%).
MS (m/z) (M+1).sup.+ 336.1. This solid is suspended in a
3:2:1=THF:MeOH:H.sub.2O solution (3 mL) and 6N LiOH (0.15 mL) added
and stirred at rt for 12 h. At this point the solvent is removed
and the residue is dissolved in water and extracted with DCM
(3.times.30 mL). The mixture is adjusted to pH.about.2 and
extracted with a 3:1=DCM:IPA mixture (5.times.30 mL). The organic
layer is washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated to afford
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzoic acid as an
orange powder (100%) which is used without further purification.
.sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 10.18 (s, 1H), 8.87 (s,
2H), 7.95-7.87 (m, 4H), 7.71 (d, J=8.0 Hz, 2H), 7.06 (d, J=8.0 Hz,
2H), 3.81 (s, 3H). MS (m/z) (M+1).sup.+ 322.1.
Example 5m
1-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzoyl}-piperidine-4-carb-
oxylic acid amide
##STR00821##
[0686]
1-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzoyl}-piperidine-
-4-carboxylic acid amide can be synthesized by the following
procedure. To a solution of
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzoic acid (from
Example 5l) (0.05 mmol) in anhydrous DMF (1 mL) is added HATU (0.06
mmol), diisopropylethylethylamine (0.12 mmol) and
piperidine-4-carboxylic acid amide (0.08 mmol). The reaction
mixture is stirred at rt for 8 h. The reaction mixture is purified
by HPLC (ACN gradient 10-80%) to afford
1-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzoyl}-piperidine-4-car-
boxylic acid amide (30%) as a fluffy off white solid. MS (m/z)
(M+1).sup.+ 432.2.
Example 5n
(3-Hydroxy-pyrrolidin-1-yl)-{-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-
-phenyl}-methanone
##STR00822##
[0688]
(3-Hydroxy-pyrrolidin-1-yl)-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-yl-
amino]-phenyl}-methanone can be synthesized by the following
procedure. To a solution of
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzoic acid (from
Example 5l) (0.05 mmol) in anhydrous DMF (1 mL), HATU (0.06 mmol),
diisopropylethylethylamine (0.12 mmol) and pyrrolidin-3-ol (0.08
mmol). The reaction mixture is stirred at rt for 8 h. The reaction
mixture is purified by HPLC (ACN gradient 10-80%) to afford the
title compound. .sup.1HNMR (400MHz, DMSO) .delta. 10.00 (s, 1H),
8.85 (s, 2H), 7.88-7.85 (m, 2H), 7.69-7.66 (m, 2H), 7.52-7.49 (m,
2H), 7.07-7.05 (m, 2H), 5.01-4.92 (m, 1H), 4.33-4.23 (m, 1H), 3.81
9s, 3H), 3.67-3.45 9m, 4H), 1.94-1.80 (m, 2H). MS (m/z) (M+1).sup.+
391.2.
Example 5o
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoic
acid
##STR00823##
[0690]
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoi-
c acid can be synthesized by the following procedure. To a solution
of
4-(5-bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl]-amine
(1.1 mmol) (from Example 3a) in DME (2 mL) are added
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.3
mmol), K.sub.2CO.sub.3 aq. (2.3 mmol) and Pd(PPh.sub.3).sub.4 (0.11
mmol). The reaction is evacuated and heated at 80.degree. C. for 1
h. The reaction mixture is diluted with a sat. aq NH.sub.4Cl and
extracted with DCM (3.times.30 mL). The organic layer is washed
with brine, dried over Na.sub.2SO.sub.4 and concentrated to afford
a dark residue that upon trituration with MeOH gives a gray solid
(25%) that is used without further purification. MS (m/z)
(M+1).sup.+ 407.3.
Example 5p
(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoylamino-
)-acetic acid tert-butyl ester
##STR00824##
[0692]
(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzo-
ylamino)-acetic acid tert-butyl ester can be synthesized by the
following procedure. To a solution of
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoic
acid (from Example 5o) (0.195 mmol) in anhydrous DMF (1.5 mL) is
added HATU (0.273 mmol), diisopropylethylethylamine (0.273 mmol)
and glycine tert-butyl ester (0.2 mmol). The mixture is stirred at
rt for 8 h. The reaction mixture is quenched with a 10% aq
K.sub.2CO.sub.3 and extracted with DCM. Purification by HPLC (ACN
gradient 10-90%) affords
(4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoylamin-
o)-acetic acid tert-butyl ester as triflate salt (32%). .sup.1HNMR
(400 MHz, DMSO-d.sub.6) .delta. 9.78 (s, 1H), 9.40 (bs, 1H), 8.91
(t, J=4 Hz, 1H), 8.89 (s, 2H), 7.97 (d, J, 8 Hz, 2H), 7.85 (d,
J=8.0 2H), 7.73 (d, J=8.0 Hz, 2H), 6.99 (d, J=8.0 Hz, 2H), 4.29 (t,
J=4.0 Hz, 2H), 3.92 (d, J=4 Hz, 2H), 3.55-3.51 (m, 2H), 3.27-3.22
(m, 4H), 1.25 (t, J=4.0 Hz, 6H). MS (m/z) (M+1).sup.+ 520.2.
Example 5q
[3-(2-Diethylamino-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-a-
mine
##STR00825##
[0694]
[3-(2-Diethylamino-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin--
2-yl]-amine can be synthesized by the following procedure. To a
solution of
(5-bromo-pyrimidin-2-yl)-[3-(2-diethylamino-ethoxy)-phenyl]-amine
(0.29 mmol) (from Example 3e) in DME (2 mL) are added 4-methoxy
boronic acid (0.35 mmol), aq K.sub.2CO.sub.3 (0.66 mmol) and
Pd(PPh.sub.3).sub.4 (0.029 mmol). The reaction mixture is refluxed
for 30 min. After removal of DME, the residue is dissolved in DCM
and washed with a sat. aq NH.sub.4Cl. The organic layer is dried
over Na.sub.2SO.sub.4 and concentrated under reduced pressure.
Purification of the crude by HPLC (ACN gradient 10-90%) affords
[3-(2-diethylamino-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]--
amine (70%). .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 9.76 (s,
1H), 9.65 (bs 1H), 8.79 (s, 2H), 7.66 (d, J=8.0 Hz, 2H), 7.61 (m,
1H), 7.42 (d, J=8.0 Hz, 1H), 7.24 (t, J=8.0 Hz, 1H), 7.04 (d, J=8.0
HZ, 2H), 6.62 (d, J=8.0 HZ, 1H), 4.34-4.32 (m, 2H), 3.80 (s, 3H),
3.57-3.55 (m, 2H), 3.28-3.23 (m, 4H), 1.26 (t, j=8.0 HZ, 3H). MS
(m/z) (M+1).sup.+ 393.2.
Example 5r
3-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenol
##STR00826##
[0696] 3-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenol can be
prepared by the following procedure. A dry flask charged with
3-amino-phenol (0.18 mmol),
2-chloro-5-(4-methoxy-phenyl)-pyrimidine (0.18 mmol) (from Example
4c), diisopropylethylethylamine (0.09 mmol) in NMP is heated in a
microwave oven at 210.degree. C. for 10 min. The reaction mixture
is diluted with water and extracted with DCM (3.times.20 mL),
washed with brine, dried over Na.sub.2SO.sub.4 and concentrated.
Purification by preparative LCMS (ACN gradient 10-70%) affords
3-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenol (22%).
.sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 8.81 (s, 1H), 8.76 (s,
2H), 7.66-7.63 (m, 2H), 7.36 (t, J=4.0 Hz, 1H), 7.19-7.17 (m, 1H),
7.07-7.03 (M, 3H), 6.38-6.35 (M, 1H), 3.80 (s, 3H). MS (m/z)
(M+1).sup.+ 294.1.
Example 5s
4-Methyl-piperazine-1-carboxylic acid 3 ester
##STR00827##
[0698] 4-Methyl-piperazine-1-carboxylic acid
3-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl ester can be
synthesized by the following procedure. To a solution of
3-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenol (from Example
5r) (0.04 mmol) in DMF is added Cs.sub.2CO.sub.3 (0.09 mmol)
followed by 4-methyl-piperazine-1-carbonyl chloride (0.9 mmol). The
reaction is stirred at rt for 12 h. The reaction mixture is
directly purified by preparative LCMS (ACN gradient 10-70%) to
afford 4-methyl-piperazine-1-carboxylic acid
3-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl ester as TFA
salt (30%). .sup.1HNMR (400 MHz, CD.sub.3OD) .delta. 8.67 (s, 2H),
7.82 (t, J=4.0 Hz, 1H), 7.54-7.52 (m, 2H), 7.47-7.46 (m, 1H), 7.30
(T, J=8.0 Hz, 1H), 7.05-7.02 (m, 2H), 6.78-6.75 (m, 1H), 3.84 (s,
3H), 2.98 (s, 3H). MS (m/z) (M+1).sup.+ 420.2.
Example 5t
2-(2-Diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-ben-
zoic acid methyl ester
##STR00828##
[0700]
2-(2-Diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylami-
no]-benzoic acid methyl ester can be synthesized by the following
procedure. To a solution of 3-(2-diethylamino-ethoxy)-phenylamine
(0.2 mmol) (from Example 2h) in anhydrous dioxane (1.5 mL) is added
Pd(OAc).sub.2 (0.03 mmol), xantphos (0.03 mmol), potassium
tert-butoxide (0.4 mmol) and 2-Cl-5(4-methoxyphenyl)pyrimidine (0.2
mmol) (from Example 4c). The reaction mixture is evacuated twice
and heated at 130.degree. C. for 45 min. The reaction mixture is
filtered and the filtrate concentrated. Purification by preparative
LCMS (ACN gradient 10-40%) and subsequent preparative TLC
(DCM:ACN:MeOH:NH.sub.4OH=8:1:1:0.1) affords
2-(2-diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-be-
nzoic acid methyl ester (20%). MS (m/z) (M+1).sup.+ 451.3.
Example 5u
2-(2-Diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-ben-
zoic acid
##STR00829##
[0702]
2-(2-Diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylami-
no]-benzoic acid can be synthesized by the following procedure. To
a suspension of
2-(2-diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-be-
nzoic acid methyl ester (0.022 mmol) (from example 5t) in a
3:2:1=THF:MeOH:H.sub.2O solution (1 mL) is added 3N LiOH (22 .mu.L)
and the mixture is stirred at rt for 12 h then solvent is removed.
Purification of the crude by preparative LCMS (ACN gradient 10-50%)
affords
2-(2-diethylamino-ethoxy)-4-[5-(4-methoxy-phenyl)-pyrimidin-2-yla-
mino]-benzoic acid. .sup.1HNMR (400 MHz, CD.sub.3OD) .delta. 18.76
(s, 2H), 7.99 (bs, 1H), 7.89 (d, J=8.0 Hz, 2H), 7.57 (d, J=8.0 Hz,
2H), 7.36 (d, J=8.0 Hz, 1H), 7.05 (d, J=8.0 Hz, 2H), 4.53-4.53 (m,
2H), 3.84 (s, 3H), 3.66-3.63 (m, 2H), 3.40-3.37 (m, 4H), 1.38 (t,
J=8.0 Hz, 6H). MS (m/z) (M+1).sup.+ 437.1.
Example 5v
2-Methoxy-5-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenol
##STR00830##
[0704]
2-Methoxy-5-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenol can
be synthesized by the following procedure. To a solution of
5-(5-bromo-pyrimidin-2-ylamino)-2-methoxy-phenol (0.34 mmol) (form
Example 3g) in DMF (1.5 mL) is added 4-methoxy boronic acid (0.41
mmol), K.sub.2CO.sub.3 aq. (0.71 mmol) and Pd(PPh.sub.3).sub.4
(0.17 mmol). The reaction is evacuated twice and heated at
85.degree. C. for 30 min. After this time the reaction mixture is
diluted with a sat. aq NH.sub.4Cl and extracted with DCM
(3.times.30 mL). The organic layer is washed with brine, dried over
Na.sub.2SO.sub.4, concentrated and the crude is purified by HPLC
(ACN gradient 20-70%) (67%). MS (m/z) (M+1).sup.+ 324.1.
Example 5w
N-(3-(2-(diethylamino)ethoxy)-4-methoxyphenyl)-5-(4-methoxyphenyl)pyrimidi-
n-2-amine
##STR00831##
[0706]
[3-(2-Diethylamino-ethoxy)-4-methoxy-phenyl]-[5-(4-methoxy-phenyl)--
pyrimidin-2-yl]-amine can be synthesized by the following
procedure. To a solution of
2-methoxy-5-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenol (0.2
mmol) (from Example 5v) in anhydrous DMF (2 mL) is added
Cs.sub.2CO.sub.3 (0.28 mmol) and (2-chloro-ethyl)-diethyl-amine
(0.2 mmol). The reaction mixture stirred at 80.degree. C. for 8 h
and quenched with water followed by extraction with DCM (3.times.30
mL). The organic layer is washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated. Preparative LCMS purification
affords the title compound (78%). MS (m/z) (M+1).sup.+ 423.1.
Example 5x
1-(2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenoxy}-ethyl)-piperid-
ine-4-carboxylic acid
##STR00832##
[0708]
1-(2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenoxy}-ethyl)--
piperidine-4-carboxylic acid can be synthesized by the following
procedure. To a solution of
[4-(2-chloro-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-amine
(0.042 mmol) (from Example 5d) in DMF (1 ml) is added sodium iodide
(0.050 mmol) and ethyl isonipecotate (0.084 mmol). The reaction is
heated at 120.degree. C. for 12 h. Purification by HPLC (ACN
gradient 10-90%) affords
1-(2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenoxy}-ethyl-
)-piperidine-4-carboxylic acid ethyl ester (50%). MS (m/z)
(M+1).sup.+ 477.0. This solid is suspended in a
3:2:1=THF:MeOH:H.sub.2O solution (0.5 mL) and 6N LiOH (0.126 mmol)
and stirred at rt for 12 h. The reaction mixture is diluted with
DMF and purified by HPLC (ACN gradient 10-90%) to afford
1-(2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenoxy}-ethyl)-
-piperidine-4-carboxylic acid. MS (m/z) (M+1).sup.+ 449.2.
Example 5y
(4-{2-[4-(2-Chloro-ethoxy)-benzyl]-pyrimidin-5-yl}-benzylamino)-acetic
acid tert-butyl ester
##STR00833##
[0710]
(4-{2-[4-(2-Chloro-ethoxy)-benzyl]-pyrimidin-5-yl}-benzylamino)-ace-
tic acid tert-butyl ester can be synthesized by the following
procedure. A mixture of palladium acetate (0.015 mmol), Xantphos
(0.018 mmol), potassium tert-butoxide (0.3 mmol), tert-butyl
2-(4-(2-chloropyrimidin-5-yl)benzylamino)acetate (0.15 mmol) (from
Example 4b) and 4-(2-chloro-ethoxy)-phenylamine (from Example 2c)
(0.45 mmol) in dioxane (2 mL) is heated in the microwave oven at
150.degree. C. for 15 min. Purification by preparative LCMS to
afford
(4-{2-[4-(2-chloro-ethoxy)-benzyl]-pyrimidin-5-yl}-benzylamino)-acetic
acid t-butyl ester as a TFA salt. MS (m/z) (M+1).sup.+ 469.2.
Example 5z
{4-[2-(4-{{2-[4-(Tetrahydro-furan-2-carbonyl)-piperazin-1-yl]-ethoxy}-benz-
yl)-pyrimidin-5-yl]-benzylamino]-acetic acid tert-butyl ester
##STR00834##
[0712]
{4-[2-(4-{{2-[4-(Tetrahydro-furan-2-carbonyl)-piperazin-1-yl]-ethox-
y}-benzyl)-pyrimidin-5-yl]-benzylamino]-acetic acid tert-butyl
ester can be synthesized by the following procedure. To a solution
of
(4-{2-[4-(2-chloro-ethoxy)-benzyl]-pyrimidin-5-yl}-benzylamino)-acetic
acid tert-butyl ester (0.032 mmol) (from Example 5y) in anhydrous
DMF is added sodium iodide (0.0384 mmol) and
1-(tetrahydro-2-furoyl)-piperazine (0.16 mmol). The reaction
mixture is heated at 90.degree. C. for 8 h. Purification by
preparative LCMS (ACN gradient 10-90%) affords
{4-[2-(4-{2-[4-(tetrahydro-furan-2-carbonyl)-piperazin-1-yl]-ethoxy}-benz-
yl)-pyrimidin-5-yl]-benzylamino}-acetic acid tert-butyl ester
(51%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.66 (d, J=8.0 Hz,
2H), 7.62 (d, J=8.8 Hz, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.51 (d, J=8.0
Hz, 2H), 7.46 (d, J=7.2 Hz, 1H), 6.85 (d, J=9.2 Hz, 2H), 4.3 (m,
4H), 3.85 (m, 4H), 3.76 (m, 3H), 3.52 (m, 4H), 2.35 (m, 4H), 2.0
(m, 4H), 1.48 (s, 9H). MS (m/z) (M+1).sup.+ 617.2.
Example 6
Example 6a
{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-methanol
##STR00835##
[0714]
{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-methanol can
be synthesized by the following procedure. To a solution of
[4-(5-bromo-pyrimidin-2-ylamino)-phenyl]-methanol (7.14 mmol) (from
Example 3h) in DMF (56 mL) is added 4-methoxy boronic acid (8.57
mmol), K.sub.2CO.sub.3 aq (21.4 mmol) and Pd(PPh.sub.3).sub.4
(0.714 mmol). The reaction is evacuated twice and heated at
90.degree. C. for 1 h. After this time the reaction mixture is
diluted with a sat. aq NH.sub.4Cl and extracted with ethyl acetate
(3.times.50 mL). The organic layer is washed with brine, dried over
MgSO.sub.4 and concentrated. Purification by silica chromatography
using a hexane:EtOAc=8:2 affords
{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-methanol
(80%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.57 (s, 2H), 7.57
(d, J=8 Hz, 2H), 7.45 (bs, 1H), 7.37 (d, J=8.4 Hz, 2H), 7.30 (d,
J=8.0 Hz, 2H), 6.94 (d, J=8.4 Hz, 2H), 4.61 (s, 2H), 3.79 (s, 3H).
MS (m/z) (M+1) 308.3.
Example 6b
4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzaldehyde
##STR00836##
[0716] 4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzaldehyde
can be synthesized by the following procedure. To a mixture of
{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-methanol
(5.73 mmol) (from Example 5aa) in dioxane is added manganese (IV)
oxide (17.2 mmol) and TBAI (0.014 mmol). The reaction mixture is
heated in the microwave oven at 130.degree. C. for 30 min.
Purification by silica chromatography using hexane:EtOAc=1:1
affords 4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzaldehyde
(52%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.91 (s, 1H), 8.69
(s, 2H), 7.88 (s, 4H), 7.46 (d, J=8.8 Hz, 2H), 7.02 (d, J=8.4 Hz,
2H), 3.87 (s, 3H). MS (m/z) (M+1).sup.+ 306.2.
Example 6c
1-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzyl}-piperidine-4-carbo-
xylic acid amide
##STR00837##
[0718]
1-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzyl}-piperidine--
4-carboxylic acid amide can be synthesized by the following
procedure. To a solution of
4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzaldehyde (0.0328
mmol) (from Example 5ab) in dichloromethane (1 mL) is added
isonipecotamide (0.0768 mmol) and sodium sulfate. The reaction
mixture is stirred at rt for 1 h. Then NaB(OAc).sub.3H (0.0984
mmol) is added and the reaction is stirred for 8 h. Purification by
preparative LCMS affords
1-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzyl}-piperidine-4-carb-
oxylic acid amide (55%) as a TFA salt. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.72 (s, 2H), 7.91 (d, J=8.4 Hz, 2H), 7.56 (d,
J=8.8 Hz, 2H), 7.44 (d, J=8.8 Hz, 2H), 7.05 (d, J=8.8 Hz, 2H), 4.28
(s, 2H), 3.86 (s, 3H), 3.58 (m, 2H), 3.03 (m, 2H), 2.55 (m, 1H),
2.10 (m, 2H), 1.93 (m, 2H). MS (m/z) (M+1).sup.+ 418.2.
Example 6d
(1-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzyl}-piperidin-4-yl)-a-
cetic acid
##STR00838##
[0720]
(1-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-benzyl}-piperidin--
4-yl)-acetic acid can be synthesized by the following procedure. A
mixture of
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzaldehyde (0.0656
mmol) (from Example 5ab), 2-(piperidin-4-yl)acetic acid ethyl ester
(0.197 mmol) and sodium sulfate in dichloromethane (1 ml) is
stirred at rt for 1 h. Then NaB(OAc).sub.3H (0.197 mmol) is added
and the reaction is stirred for 8 h. Purification by preparative
LCMS affords
(1-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzyl}-piperidin-4-yl)--
acetic acid ethyl ester as a TFA salt (46%). MS (m/z) (M+1).sup.+
461.3. This solid is suspended in a 3:2:1=THF:MeOH:H.sub.2O
solution (0.6 mL) and 6N LiOH is added (0.09 mmol). The mixture is
stirred at rt for 12 h. The reaction mixture is diluted in DMF and
purified by HPLC (ACN gradient 10-90%) to afford
(1-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-benzyl}-piperidin-4-yl)--
acetic acid (54%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.70
(s, 2H), 7.88 (d, J=8.0 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 7.42 (d,
J=8.4 Hz, 2H), 7.03 (d, J=8.4 Hz, 2H), 4.25 (s, 2H), 3.84 (s, 3H),
3.5 (m, 2H), 3.3 (m, 2H), 2.3 (m, 2H), 2.04 (m, 3H), 1.49 (m, 2H).
MS (m/z) (M+1).sup.+ 433.2.
Example 6e
2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethanol
##STR00839##
[0722]
2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethanol can
be synthesized by the following procedure. To a solution of
2-(4-(5-bromopyrimidin-2-ylamino)phenyl)ethanol (0.204 mol) (from
Example 3l) in DME (200 mL) is added 4-methoxyphenylboronic acid
(0.214 mol), aq K.sub.2CO.sub.3 (0.408 mol) and Pd(PPh.sub.3).sub.4
(172 mmol). The reaction is heated at reflux for 1 h, cooled to rt
and the solvent evaporated. The residue is dissolved in
dichloromethane, washed with sat. aq NH.sub.4Cl (2.times.200 mL),
dried over Na.sub.2SO.sub.4, and concentrated. Purification by
silica chromatography (petroleum ether:EtOAc=1:1) affords
2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethanol
(46%). .sup.1HNMR (300 MHz, DMSO-d.sub.6) .delta. 8.59 (s, 2H),
7.57 (d, J=8.4 Hz, 2H), 7.43 (d, J=9.0 Hz, 2H), 7.23 (d, J=8.4 Hz,
2H), 6.99 (d, J=9 Hz, 2H), 3.85 (m, 5H), 2.86 (m, 2H).
Example 6f
Methanesulfonic acid
2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl
ester
##STR00840##
[0724] Methanesulfonic acid
2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl ester
can be synthesized by the following procedure. To a solution of
2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethanol
(6.22 mmol) in dichloromethane (30 mL) is added triethylamine (9.33
mmol) and methanesulfonyl chloride (7.47 mmol). The reaction
mixture is stirred at rt for 1.5 h. The reaction is diluted with
H.sub.2O (10 mL) and washed with Na.sub.2CO.sub.3 solution
(3.times.10 mL). The organic layer is washed with brine, dried over
MgSO.sub.4 and concentrated to afford methanesulfonic acid
2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-3-phenyl}-ethyl
ester (99%). .sup.1H NMR (400 MHz, CD.sub.2Cl.sub.2) .delta. 8.54
(s, 2H), 7.56 (d, J=8.8 Hz, 2H), 7.39 (d, J=8.8 Hz, 2H), 7.29 (bs,
1H), 7.14 (d, J=8.4 Hz, 2H), 6.92 (d, J=8.8 Hz, 2H), 4.31 (t, J=6.8
Hz, 2H), 3.76 (s, 3H), 2.95 (t, J=6.8 Hz, 2H), 2.79 (s, 3H). MS
(m/z) (M+1).sup.+ 400.4.
Example 6g
1-(2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl)-piperidi-
ne-3-carboxylic acid amide
##STR00841##
[0726]
1-(2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl)-p-
iperidine-3-carboxylic acid amide can be synthesized according to
the following procedure. To a solution of methanesulfonic acid
2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl ester
(0.050 mmol) in anhydrous DMF is added nipecotamide (0.25 mmol) and
heated at 100.degree. C. for 8 h. Purification by preparative LCMS
affords
1-(2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl)-
-piperidine-3-carboxylic acid amide (80%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.71 (s, 1H), 8.76 (s, 2H), 7.75 (d, J=8.4
Hz, 2H), 7.64 (d, J=8.8 Hz, 2H), 7.20 (d, J=9.2 Hz, 2H), 7.04 (d,
J=8.8 Hz, 2H), 3.80 (s, 3H) 3.55 (m, 2H), 3.3 (m, 2H), 2.95 (m,
4H), 2.6 (m, 1H), 1.95 (m, 2H), 1.70 (m, 2H). MS (m/z) (M+1).sup.+
432.3.
Example 6h
4-[2-(3-Hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoic acid
##STR00842##
[0728] 4-[2-(3-Hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoic
acid can be synthesized according to the following procedure. To a
solution of 3-amino benzyl alcohol (8.1 mmol) in NMP (8 mL), in a
microwave vial, is added 4-(2-chloro-pyrimidin-5-yl)-benzoic acid
(8.1 mmol) (from Example 4d) and p-TSA (5.2 mmol). The vial is
evacuated twice and then heated in a microwave oven at 210.degree.
C. for 15 min. The reaction mixture is quenched with water, the
precipitated solid is filtered, washed with additional water, then
EtOAc and dried under vacuum to afford
4-[2-(3-hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoic acid
(68%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.89 (s, 1H),
8.92 (s, 2H), 8.03-8.01 (m, 2H), 7.88-7.86 (m, 2H), 7.76 (b.s, 1H),
7.70-68 (m, 1H), 7.26-7.24 (m, 1H) 6.94-6.92 (m, 1H), 4.49 (m, 2H).
MS (m/z) (M+1).sup.+ 322.2.
Example 6i
{4-[2-(3-Hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-acetic
acid tert-butyl ester
##STR00843##
[0730]
{4-[2-(3-Hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-a-
cetic acid tert-butyl ester can be synthesized according to the
following procedure. A solution of
4-[2-(3-hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoic (from
Example 5ah) (1.7 mmol), HATU (2.39 mmol), diisopropylethylamine
(2.5 mmol), and glycine t-butyl ester in anhydrous DMF, is stirred
at rt for 8 h. After this time the reaction mixture is purified by
HPLC (ACN gradient 10-90) to afford
4-[2-(3-hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoylamino-
}-acetic acid tert-butyl ester (39%). MS (m/z) (M+1).sup.+
435.1.
Example 6j
{4-[2-(3-Formyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-acetic
acid tert-butyl ester
##STR00844##
[0732]
{4-[2-(3-Formyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-acetic
acid tert-butyl ester can be synthesized by the following
procedure. To a mixture of
{4-[2-(3-hydroxymethyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-acetic
acid tert-butyl ester (0.39 mmol) (from example 5ai) in dioxane is
added manganese (IV) oxide (1.95 mmol) and TBAI (0.014 mmol). The
reaction mixture is heated in the microwave oven at 150.degree. C.
for 30 min. The reaction mixture is filtered and the filtrated is
concentrated under reduced pressure to afford
{4-[2-(3-formyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-acetic
acid tert-butyl ester (71%). MS (m/z) (M+1).sup.+ 433.2.
Example 6k
{4-[2-(3-Pyrrolidin-1-ylmethyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}--
acetic acid tert-butyl ester
##STR00845##
[0734]
{4-[2-(3-Pyrrolidin-1-ylmethyl-phenylamino)-pyrimidin-5-yl]-benzoyl-
amino}-acetic acid tert-butyl ester can be synthesized by the
following procedure. To a solution
{4-[2-(3-formyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-acetic
acid tert-butyl ester (0.046 mmol) (from Example 5aj) in
dichloromethane (1 mL) is added pyrrolidine (0.138 mmol) and sodium
sulfate. The reaction mixture is stirred at rt for 1 h. Then
NaB(OAc).sub.3H (0.138 mmol) is added and the reaction is stirred
for 8 h. After this time the reaction mixture is purified by
preparative LCMS to afford
{4-[2-(3-pyrrolidin-1-ylmethyl-phenylamino)-pyrimidin-5-yl]-benzoylamino}-
-acetic acid tert-butyl ester (55%) as a TFA salt. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 10.05 (s, 1H), 8.94-8.92 (m, 3H),
7.99-7.85 (m, 6H), 7.41 (m, 1H), 7.14-7.12 (m, 1H), 4.35 (d, J=4.0
Hz, 2H), 3.93 (d, J=4.0 Hz, 2H), 3.41-3.40 (m, 2H), 3.15-3.10 (m,
2H), 2.15-2.10 (m, 2H), 1.90-1.89 (m, 2H), 1.43 (s, 9H). MS (m/z)
(M+1).sup.+ 488.3.
Example 6l
4-Methyl-piperazine-1-carboxylic acid
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl ester
##STR00846##
[0736] 4-Methyl-piperazine-1-carboxylic acid
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl ester can be
synthesized by the following procedure. A suspension of
4-methyl-piperazine-1-carboxylic acid 4-amino-phenyl ester (0.166
mmol) (from example 3i), 4-methoxy phenyl boronic acid (0.199
mmol), K.sub.2CO.sub.3 (0.36 mmol) and Pd(PPh.sub.3).sub.4 (0.0166
mmol) in a 5:1 mixture of DME:H.sub.2O (1.5 mL) is heated at
80.degree. C. for 10 min. The reaction mixture is cooled to rt,
diluted with dichloromethane, washed with NH.sub.4Cl, and dried
under reduced pressure. The crude is purified by a short silica
column using a mixture 9.5:0.5:0.1=DCM:MeOH:NH.sub.4OH to afford
4-methyl-piperazine-1-carboxylic acid
4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl ester as white
powder (86%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.53 (s,
2H), 7.57 (d, J=8.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 2H), 7.12 (b.s,
1H), 7.0.2 (m, 2H), 6.95 (m, 2H), 3.79 (s, 3H), 3.71-3.69 (m, 4H),
2.51-2.50 (m, 4H). MS (m/z) (M+1).sup.+ 420.2.
[0737] A methanolic solution of this solid is treated with 1
equivalent of MeSO.sub.3H and lyophilized to afford the
correspondent mesylate salt as yellow solid in quantitative yield.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.48 (s, 2H), 7.55-7.52
(m, 2H), 7.35-7.33 (m, 2H), 6.93-6.90 (m, 2H), 6.85-6.83 (m, 2H),
4.30-4.28 (m, 2H), 3.64 (s, 3H), 3.41-3.40 (m, 2H), 2.94-2.91 (m,
4H), 2.79 (s, 3H). MS (m/z) (M+1).sup.+ 420.2.
Example 6m
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine
##STR00847##
[0739]
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2--
amine can be prepared by the following procedure. To a mixture of
2-chloro-5-(4-methoxy-phenyl)-pyrimidine (0.40 mmol) (from Example
4c) and 3-(2-(diethylamino)ethyl)benzenamine (0.40 mmol) (from
example 2i) in 0.5 mL of 1,4-dioxane is added p-TSA monohydrate
(1.2 mmol). The reaction mixture is heated at 90.degree. C.
overnight. The crude mixture is purified by preparative LCMS to
afford
N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine
as a TFA salt. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 12.24 (s,
1H), 10.95 (s, 1H), 8.67 (s, 2H), 7.50-7.60 (m, 2H), 7.26-7.44 (m,
3H), 7.04-7.12 (m, 1H), 6.96-7.02 (m, 2H), 3.81 (s, 3H), 3.42 (m,
2H), 3.04-3.26 (m, 6H), 1.39 (m, 6H). MS (m/z) (M+1).sup.+
377.2.
Example 6n
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate
##STR00848##
[0741] 3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate can be prepared by the following
procedure. To a mixture of 2-chloro-5-(4-methoxy-phenyl)-pyrimidine
(0.40 mmol) (from Example 4c) and 3-aminobenzyl
4-methylpiperazine-1-carboxylate (0.40 mmol) (from Example 2j) in
1,4-dioxane (0.5 mL) is added p-TSA monohydrate (1.2 mmol). The
reaction mixture is heated at 90.degree. C. overnight. The crude
mixture is purified by preparative LCMS to afford
3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl
4-methylpiperazine-1-carboxylate as a TFA salt. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 11.15 (s, 1H), 8.61 (s, 2H), 7.72-7.77 (m,
1H), 7.30-7.38 (m, 3H), 7.04-7.07 (m, 1H), 6.95-7.00 (m, 2H), 4.20
(s, 2H), 3.70-4.10 (m, 4H), 3.80 (s, 3H), 3.30-3.52 (m, 4H), 2.75
(s, 3H). MS (m/z) (M+1).sup.+ 434.2.
Example 6o
(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzylamino--
6)-acetic acid tert-butyl ester
##STR00849##
[0743]
(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzy-
lamino)-acetic acid tert-butyl ester can be prepared by the
following procedure. A mixture of
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzaldehyde
(from Example 5f) (0.02 mol), triethylamine (0.06 mmol) and
tert-butyl glycine ester (0.04 mmol) in THF (0.1 mL) is stirred at
ambient temperature for 0.5 h in the presence of excess anhydrous
Na.sub.2SO.sub.4. NaBH(OAc).sub.3 (0.1 mmol) is added and the
mixture is further stirred for 1 h. MeOH is added and the resultant
crude mixture is purified by preparative LCMS to yield the title
compound. .sup.1H NMR (400 MHz, D.sub.2O) .delta. 8.68 (s, 2H),
7.71 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.3 Hz, 2H), 7.42 (d, J=9 Hz,
2H), 7.07 (d, J=9.1 Hz, 2H), 4.4 (d, J=5.1 Hz, 2H), 4.34 (s, 2H),
3.91 (s, 2H), 3.62 (t, J=4.8 Hz, 2H), 3.34 (m, 4H), 1.46 (s, 9H),
1.34 (t, J=7.3, Hz, 6H). MS (m/z) (M+1).sup.+ 506.3.
Example 6p
[4-(2-Dimethylamino-ethyl)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-a-
mine
##STR00850##
[0745]
[4-(2-Dimethylamino-ethyl)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin--
2-yl]-amine can be prepared by the following procedure. A mixture
of 4-(2-dimethylamino-ethyl)-phenylamine (0.1 mmol), p-TSA (0.05
mmol) and 2-chloro-5-(4-methoxy-phenyl)-pyrimidine (from Example
4c) (0.1 mmol) in NMP (0.2 mL) is heated by microwave at
215.degree. C. for 15 min to afford the crude mixture which is
purified by preparative LCMS to yield the title compound. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 12.1 (s, 1H), 11.5 (s, 1H), 8.67
(s, 2H), 7.63 (d, J=8.3 Hz, 1H), 7.41 (d, J=8.6 Hz, 2H), 7.19 (d,
J=8.3 Hz, 2H), 7.04 (d, J=8.7 Hz, 2H), 3.87 (s, 3H), 3.01 (m, 2H),
2.82 (s, 6H), 2.09 (m, 2H). MS (m/z) (M+1).sup.+ 349.2.
Example 6q
3-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-propionic
acid
##STR00851##
[0747]
3-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-propionic
acid can be prepared by the following procedure.
3-(4-Amino-phenyl)-propionic acid (1.0 mmol), p-TSA (0.25 mmol) and
2-chloro-5-(4-methoxy-phenyl)-pyrimidine (from Example 4c) (1.0
mmol) are dissolved in NMP (2 mL) and heated by microwave at
215.degree. C. for 15 min to afford the crude
3-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-propionic
acid. MS (m/z) (M+1).sup.+ 350.2.
Example 6r
[4-(3-Diethylamino-propyl)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-a-
mine
##STR00852##
[0749]
4-(3-Diethylamino-propyl)-phenyl]-[5-(4-methoxy-phenyl)-pyrimidin-2-
-yl]-amine can be prepared by the following procedure. Diethylamine
(10 mmol), EDC (25 mmol) and DMAP (0.1 mmol) are dissolved in
dichloromethane (3 mL) and added to the crude
3-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-propionic
acid dissolved in NMP (from example 5ao) at rt. After 3 h, sat. aq
NH.sub.4Cl is added and the mixture is extracted with EtOAc. The
combined extracts are dryed over anhydrous Na.sub.2SO.sub.4 and
solvent is removed. Purification by preparative HPLC yields
N,N-diethyl-3-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-propi-
onamide.
[0750]
N,N-Diethyl-3-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-
-propionamide (0.1 mmol) is heated at reflux with lithium aluminum
hydride in THF (1.0 M, 1.0 mmol) for 4 h. MeOH is added at rt to
quench the reaction. Purification by preparative LCMS affords the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.4 (s,
1H), 8.62 (s, 2H), 8.59 (s, 1H), 7.61 (d, J=8.3 Hz, 2H), 7.43 (d,
J=8.6 Hz, 2H), 7.17 (d, J=8.2 Hz, 2H), 7.02 (d, J=8.6 Hz, 2H), 3.86
(s, 3H), 3.1 (m, 4H), 3.96 (s, 1H), 3.0 (m, 2H), 2.71 (t, J=7.2,
2H), 2.06 (m, 2H), 1.27 (t, J=7.3 Hz, 6H). MS (m/z) (M+1).sup.+
391.2.
Example 6s
Synthesis of
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-ben-
zoic acid
##STR00853##
[0752]
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluo-
ro-benzoic acid can be prepared by the following procedure.
(5-Bromo-pyrimidin-2-yl)-[4-(2-diethylamino-ethoxy)-phenyl-amine
(from Example 3a) (1 mmol), Pd(PPh.sub.3).sub.4 (0.1 mmol),
3-fluoro-4-methoxycarbonyl-benzeneboronic acid (1.5 mmol) are
dissolved in 2 mL of DMF. After purging with nitrogen,
Na.sub.2CO.sub.3 (0.4 mL of a 5M aq solution) is added and the
mixture is heated in the microwave at 120.degree. C. for 20 min.
The resultant mixture is diluted with EtOAc and water. After
extraction with EtOAc and drying with anhydrous Na.sub.2SO.sub.4,
the solvent is removed to afford the crude mixture which is
purified by preparative HPLC to yield
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-ben-
zoic acid. MS (m/z) (M+1).sup.+ 425.2.
Example 6t
Synthesis of tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzamido)acetate
##STR00854##
[0754] Tert-butyl
2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobe-
nzamido)-acetate can be prepared by the following procedure.
4-{2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-2-fluoro-ben-
zoic acid (from Example 5) (0.05 mmol), HATU (0.075 mmol),
amino-acetic acid tert-butyl ester (0.05 mmol) and
diisopropylethylamine (0.1 mmol) in DMF (0.1 mL) are stirred at rt
for 2 h. Purification by preparative LCMS affords the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 11.8 (s, 1H),
10.6 (s, 1H), 8.72 (s, 2H), 8.25 (t, J=8.1 Hz, 1H), 7.6 (d, J=4.1
Hz, 2H), 7.41 (t, J=8.1 Hz, 1H), 7.28 (m, 1H), 6.95 (d, J=8.7 Hz,
2H), 4.52 (s, 2H), 4.2 (d, J=4.6 Hz, 2H), 3.5 (s, 2H), 3.3 (m, 4H),
2.73 (m, 2H), 1.52 (s, 9H), 1.46 (t, J=7.1 Hz, 6H). MS (m/z)
(M+1).sup.+ 538.3.
Example 6u
N'-(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoyl)--
hydrazinecarboxylic acid tert-butyl ester
##STR00855##
[0756]
N'-(4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-be-
nzoyl)-hydrazinecarboxylic acid tert-butyl ester can be prepared by
the following procedure.
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoic
acid (from Example 5o) (0.3 mmol), hydrazinecarboxylic acid
tert-butyl ester (0.36 mmol), EDC (0.42 mmol) and DMAP (0.03 mmol)
in DMF:THF (0.5:0.5 mL) are stirred at rt for 1 h. The resultant
mixture is diluted with EtOAc and water. After further extraction
with EtOAc and drying of the combined organic phases with anhydrous
Na.sub.2SO.sub.4, the solvent is removed to afford the crude
mixture which is purified by silica chromatography (10% MeOH in
DCM) to yield the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.6 (s, 2H), 7.89 (d, J=8.3 Hz, 1H), 7.56 (d, J=8.3 Hz,
2H), 7.51 (d, J=9 Hz, 2H), 7.22 (s, 1H), 6.92 (d, J=9 Hz, 2H), 4.1
(t, J=6.2 Hz, 2H), 3.02 (s, 1H), 2.91 (t, J=6.2 Hz, 2H), 2.68 (dd,
J=14.3, 7.1 Hz, 4H), 1.51 (s, 9H), 1.1 (t, J=7.1 Hz, 6H). MS (m/z)
(M+1).sup.+ 521.2.
Example 6v
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-N-phenoxy-ben-
zamide
##STR00856##
[0758]
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-N-phen-
oxy-benzamide can be prepared by the following procedure.
4-{2-[4-(2-Diethylamino-ethoxy)-phenylamino]-pyrimidin-5-yl}-benzoic
acid from (Example 5o) (0.03 mmol), o-phenyl-hydroxylamine (0.04
mmol), HATU (0.04 mmol) and diisopropylethylamine (0.1 mmol) in DMF
(0.1 mL) are stirred at rt for 1 h. The resultant mixture is
purified by preparative LCMS to yield title compound. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 9.28 (s, 1H), 8.68 (d, J=7.2 Hz, 2H),
8.15 (d, J=8.3 Hz, 1H), 8.01 (d, J=8.3 Hz, 1H), 7.57-7.6 (m, 5H),
7.35 (dd, J=8.6, 7.5 Hz, 1H), 7.2 (d, J=7.8 Hz, 1H), 7.08 (t, J=7.3
Hz, 1H), 6.91 (dd, J=8.9, 5.3 Hz, 2H), 4.39 (dd, J=9.1, 4.6 Hz,
2H), 3.96 (s, 1H), 3.52 (dd, J=8.7, 3.7 Hz, 2H), 3.3 (m, 4H), 1.39
(dt, J=7.3, 1.3 Hz, 6H). MS (m/z) (M+1).sup.+ 498.2.
Example 6w
5-(4-methoxyphenyl)-N-(3-nitrophenyl)pyrimidin-2-amine
##STR00857##
[0760] 5-(4-methoxyphenyl)-N-(3-nitrophenyl)pyrimidin-2-amine can
be prepared by the following procedure.
2-Chloro-5-(4-methoxy-phenyl)-pyrimidine (3.0 mmol) (from Example
4c), 3-nitroaniline (3.0 mmol) and p-TSA (0.9 mmol) are dissolved
in NMP (3 mL) and heated at 215.degree. C. for 15 min by microwave.
The reaction mixture is partitioned with NaHCO.sub.3/EtOAc. The
organic layer is washed with brine, dried over magnesium sulfate,
filtered and the solvent is removed. The crude product is purified
by silica chromatography with hexanes:EtOAc (2:1) as the eluant
(31%). MS (m/z) (M+1).sup.+ 323.2.
Example 6x
N1-(5-(4-methoxyphenyl)pyrimidin-2-yl)benzene-1,3-diamine
##STR00858##
[0762] N1-(5-(4-methoxyphenyl)pyrimidin-2-yl)benzene-1,3-diamine
can be prepared by the following procedure. To a solution
5-(4-methoxyphenyl)-N-(3-nitrophenyl)pyrimidin-2-amine (0.9 mmol)
(from Example 5au) in EtOH (50 mL) is added Pd (10% on carbon, 50%
wet, 10% weight). The reaction vessel is evacuated and backfilled
with hydrogen. The contents are stirred under a hydrogen atmosphere
for 8 h, filtered through celite and reduced to dryness (70%). MS
(m/z) (M+1).sup.+ 293.2.
Example 6y
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1--
carboxamide
##STR00859##
[0764]
N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpipera-
zine-1-carboxamide can be prepared by the following procedure. To a
solution of
N1-(5-(4-methoxyphenyl)pyrimidin-2-yl)benzene-1,3-diamine (0.34
mmol) (From Example 5av) in THF (7 mL) are added
diisopropylethylamine (0.75 mmol) and triphosgene (0.10 mmol).
After stirring for 30 min at rt, 1-methylpiperazine (1.02 mmol) is
added and stirring is continued for 1 h. The reaction is
partitioned between dichloromethane and water. The organic layer is
washed with brine, dried over magnesium sulfate, filtered and the
solvent is removed. The crude product is crystallized from
dichloromethane to afford the desired product as a white
crystalline solid (50%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.63 (s, 1H), 8.76 (s, 2H), 8.49 (s, 1H), 7.83 (t, J=2.0
Hz, 1H), 7.64 (d, J=8.4 Hz, 2H), 7.37 (d, J=7.0 Hz, 1H), 7.13 (t,
J=8.0 Hz, 1H), 7.05 (d, J=7.0 Hz, 1H), 7.04 (d, J=8.0 Hz, 2H), 3.80
(s, 3H), 3.44 (bs, 4H), 2.33 (bs, 4H), 2.22 (s, 3H). MS (m/z)
(M+1).sup.+ 419.2.
Example 6z-1
Methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-
-carboxylate
##STR00860##
[0766] Methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate can be prepared by the following procedure. A solution of
methanesulfonic acid
2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl ester
(10.0 mmol) (from Example 5af) and methyl piperidine-4-carboxylate
(50.0 mmol) in DMF (60 mL) is heated at 100.degree. C. for 8 h. The
reaction is cooled to rt and poured into water (600 mL). The white
precipitate is filtered, washed with water and air dried. The crude
precipitate is purified by silica chromatography with
dichloromethane methanol (3%) as eluant (77%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.63 (s, 1H), 8.76 (s, 2H), 7.67 (d,
J=8.4 Hz, 2H), 7.64 (d, J=8.4 Hz, 2H), 7.13 (d, J=8.2 Hz, 2H), 7.04
(d, J=8.2 Hz, 2H), 3.80 (s, 3H), 3.60 (s, 3H), 2.86 (bd, J=10.0 Hz,
2H), 2.67 (bt, J=8.4, 2H), 2.41 (dt, J=8.4 Hz, 1H), 2.31 (m, 1H),
2.01 (bt, J=10.0 Hz, 2H), 1.81 (bd, J=10.0 Hz, 2H), 1.57 (m, 2H).
MS (m/z) (M+1).sup.+ 447.4.
Example 6z-2
1-(4-(5-(4-methoxyphenyl
pyrimidin-2-ylamino)phenethyl)piperidine-4-carboxylic acid
hydrochloride
##STR00861##
[0768]
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-
-carboxylic acid hydrochloride can be prepared by the following
procedure. To a solution of methyl
1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carbo-
xylate (3.9 mmol) (from Example 5ay) in methanol:THF:water=3:2:1
(38 mL total) is added LiOH (2.0 mL of a 6N solution) and the
mixture is stirred at rt for 12 h. The reaction is reduced to 50%
of its volume, water (100 mL) is added and the contents are
neutralized with 3M HCl. The resulting white precipitate is
filtered, triturated repeatedly with acetonitrile, and dried under
vacuum (96%). The white precipitate is suspended in acetonitrile
(30 mL) and treated with HCl (3.7 mL of a 4M solution in dioxane).
After stirring for 1 h the reaction is reduced to dryness and dried
under vacuum to yield a bright yellow precipitate (99%). .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.71 (bs, 1H), 9.76 (s, 1H),
8.78 (s, 2H), 7.75 (d, J=8.4 Hz, 2H), 7.65 (d, J=8.4 Hz, 2H), 7.20
(d, J=8.2 Hz, 2H), 7.04 (d, J=8.2 Hz, 2H), 3.80 (2, 3H), 3.57 (m,
2H), 3.21 (m, 2H), 3.01 (m, 4H), 2.06 (m, 2H), 1.92 (m, 2H). MS
(m/z) (M+1).sup.+ 469.1.
Example 7
Example 7a
2-(methoxycarbonyl)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate
##STR00862##
[0770]
2-(methoxycarbonyl)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)pheny-
l 4-methylpiperazine-1-carboxylate can be prepared by the following
procedure. To a flask under nitrogen atmosphere containing dry
dioxane (8 mL) are added Pd(OAc).sub.2 (0.1 mmol), Xantphos (0.12
mmol) followed by 2-(methoxycarbonyl)-5-aminophenyl
4-methylpiperazine-1-carboxylate (1 mmol) (from Example 2l),
2-chloro-5-(4-methoxy-phenyl)-pyrimidine (1.5 mmol) (from Example
4c) and KOtBu (1.5 mol). The reaction mixture is heated at
90.degree. C. for 2 h and the crude is purified by preparative LCMS
to yield
2-(methoxycarbonyl)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl
4-methylpiperazine-1-carboxylate (76%). MS (m/z) (M+1).sup.+
478.2.
Example 7b
2-(2-Diethylamino-ethoxy)-5-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-ben-
zoic acid ethyl ester
##STR00863##
[0772]
2-(2-Diethylamino-ethoxy)-5-[5-(4-methoxy-phenyl)-pyrimidin-2-ylami-
no]-benzoic acid ethyl ester synthesized by the following
procedure. A 15 ml flask is charged with
5-amino-2-(2-diethylamino-ethoxy)-benzoic acid ethyl ester (0.19
mmol), 2-chloro-5-(4-methoxy-phenyl)-pyrimidine (0.19 mmol), p-TSA
(0.22 mmol) and NMP (2 mL). The flask is evacuated and irradiated
in a microwave oven at 210.degree. C. for 15 min. The reaction
mixture is diluted with water and extracted with DCM (5.times.50
mL). The organic layer is washed with brine, dried over
Na.sub.2SO.sub.4, and concentrated. Purification by preparative
LCMS (ACN gradient 10-70%) affords the title compounds (20%) as TFA
salt. .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 9.77 (s, 1H), 9.29
(b.s 1H), 8.78 (s, 2H), 8.14-8.15 (m, 1H), 7.98-7.95 (m, 1H),
7.66-7.64 (m, 2H), 7.21-7.18 (m, 1H), 7.05-7.03 (m, 2H), 4.37-4.35
(m, 2H), 4.28- (q, J=8.0 Hz, 2H), 3.80 (s, 3H), 3.55-3.54 (m, 2H),
3.32-3.27 (m, 4H), 1.32 (t, J=8.0 Hz, 3H), 1.24 (t, J=8.0 Hz, 6H).
MS (m/z) (M+1).sup.+ 465.2.
Example 7c
2-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)acetic acid
##STR00864##
[0774] 2-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)acetic
acid can be prepared by the following procedure. To a mixture of
2-chloro-5-(4-methoxy-phenyl)-pyrimidine (1.0 mmol) (from Example
4c) and 2-(3-aminophenyl)acetic acid (1.0 mmol) in 1,4-dioxane (2
mL) is added p-TSA monohydrate (1.0 mmol). The reaction mixture is
heated at 90.degree. C. for 5 h. After the reaction is complete,
the solvent is removed. The residue is dissolved in EtOAc and
washed with water, dried over MgSO.sub.4 and concentrated to afford
a pale yellow solid which is used in the next step without
purification. MS (m/z) (M+1).sup.+ 336.1.
Example 7d
2-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin--
1-yl)ethanone
##STR00865##
[0776]
2-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpip-
erazin-1-yl)ethanone can be prepared by the following procedure. A
mixture of
2-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)acetic acid
(from Example 5bc) (0.05 mmol), HATU (0.075 mmol),
1-methylpiperazine (0.05 mmol) and diisopropylethylamine (0.1 mmol)
in DMF (0.5 mL) is stirred at rt for 2 h. Purification with
preparative LCMS affords the title compound. MS (m/z) (M+1).sup.+
418.2.
Example 7e
6-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-3H-benzooxazol-2-one
##STR00866##
[0778]
6-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-3H-benzooxazol-2-one
can be synthesized by the following procedure. A dry flask charged
with 6-amino-3H-benzooxazol 2-one (2.03 mmol) (from Example 2n),
p-TSA (0.61 mmol), 2 5-(4-methoxy-phenyl)-pyrimidin-2-ylamine (2.03
mmol), and NMP (5 mL) is heated by microwave at 210.degree. C. for
15 min. The reaction mixture is diluted with water and extracted
with EtOAc (3.times.20 mL). The organic layer is washed with water,
brine, dried over Na.sub.2SO.sub.4, and concentrated. The crude oil
is titrated with hexane to afford the title compound as an off
white solid (40%). .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 11.47
(s, 1H), 9.79 (s, 1H), 8.78 (s, 2H), 7.94 (b.s. 1H), 7.65 (d, J=2.0
Hz, 2H), 7.44-7.41 (m, 3H), 7.05-7.01 (m, 3H), 3.89 (s, 3H). MS
(m/z) (M+1).sup.+ 335.2.
Example 7f
6-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-3H-benzooxazole-2-thione
##STR00867##
[0780]
6-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-3H-benzooxazole-2-thio-
ne can be prepared by the following procedure. A dry flask charged
with
6-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-3H-benzooxazol-2-one
(0.45 mmol) (from Example 5be), Lawesson's reagent (1.8 mmol), and
a 5:1 mixture of THF:toluene (6 ml) is heated by microwave at
160.degree. C. for 45 min. The reaction mixture is diluted with
water and extracted with EtOAc (3.times.20 mL). The organic layer
is washed with water, brine, dried over Na.sub.2SO.sub.4, and
concentrated. The crude mixture is purified by silica
chromatography using a 9:1 mixture DCM:MeOH as eluent to afford
6-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-3H-benzooxazole-2--
thione as a yellow solid (48% based on recovered starting
material). .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 10.0 (s, 1H),
8.82 (s, 2H), 8.19 (b.s. 1H), 7.68-7.66 (m, 2H), 7.57 (dd, J=2.0
and 8.0 Hz, 1H), 7.19 (d, J=8.0 Hz, 1H), 7.05 (d, J=8.0 Hz, 2H),
3.89 (s, 3H). MS (m/z) (M+1).sup.+ 351.2.
Example 7g
[2-(4-Isopropyl-piperazin-1-yl)-benzooxazol-6-yl]-[5-(4-methoxy-phenyl)-py-
rimidin-2-yl]-amine
##STR00868##
[0782]
[2-(4-Isopropyl-piperazin-1-yl)-benzooxazol-6-yl]-[5-(4-methoxy-phe-
nyl)-pyrimidin-2-yl]-amine can be synthesized by the following
procedure. A dry flask charged with
6-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-3H-benzooxazole-2-thione
(0.034 mmol) (from example 5bf), N-isopropyl piperazine (1 mL), and
THF (0.5 mL) is heated by microwave at 150.degree. C. for 10 min.
Purification by preparative LCMS affords the title compound as TFA
salt. .sup.1HNMR (400 MHz, CD.sub.3OD) .delta. 8.65 (s, 2H), 8.12
(bs, 1H), 7.55 (d, J=8.0 Hz, 2H), 7.3-7.30 (m, 2H), 7.05-7.03 (m,
2H), 5.46 (b.m 2H), 3.84 (s, 3H), 3.67-3.32 (m, 5H), 1.43 (d, J=8.0
Hz, 6H). MS (m/z) (M+1).sup.+ 445.8.
Example 7h
{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-acetaldehyde
##STR00869##
[0784]
{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-acetaldehyde
can be synthesized by the following procedure. Dess-Martin reagent
(4.35 mmol) is suspended in anhydrous THF (20 mL) and NaHCO.sub.3
(10 mmol) is added. The suspension is stirred at rt for 15 min then
a solution of
2-{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethanol
(from Example 5ae) (3.11 mmol) in THF (10 mL) is added. The
stirring is continued for 15 min, after that the reaction mixture
is diluted with EtOAc and washed with a 5% NaHCO.sub.3 solution
(1.times.50 mL), brine (1.times.50 mL), dried over
Na.sub.2SO.sub.4, and concentrated to afford a light brown solid.
The crude is purified by HPLC (ACN 30-90% gradient) to afford
{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-acetaldeh-
yde as off white solid (70%). .sup.1HNMR (400 MHz, DMSO-d.sub.6)
.delta. 9.75 (s, 1H), 9.67 (s, 1H), 8.78 (s, 2H), 7.77 (d, J=8.0
Hz, 2H), 7.65 (d, J=8.0 Hz, 2H), 7.15 (d, J=8.0 Hz, 2H), 7.04 (d,
J=8.0 Hz, 2H), 3.80 (s, 3H), 3.69 (s, 2H). MS (m/z) (M+1).sup.+
320.2.
Example 7i
(R)-1-(2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethyl)-pipe-
ridine-3-carboxylic acid
##STR00870##
[0786]
(R)-1-(2-{4-[5-(4-Methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-ethy-
l)-piperidine-3-carboxylic acid can be synthesized by the following
procedure. To a solution of
{4-[5-(4-methoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-acetaldehyde
(0.31 mmol) in DCM (10 mL) (R)-nipecotic acid (0.44 mmol) is added.
The solution is stirred at rt for 1 h then NaB(OAc).sub.3H is added
at once and the stirring is continued for an additional hour. The
solvent is removed under reduced pressure and the residue is
purified by HPLC (ACN gradient 10-90%) to afford the title
compound. .sup.1HNMR (600 MHz, DMSO-d.sub.6) .delta. 10.43 (b.s,
1H), 9.71 (s, 1H), 8.78 (s, 2H), 7.74 (d, J=8.3 Hz, 1H), 7.63 (d,
J=8.0 Hz, 2H), 7.19 (d, J=8.7 Hz, 2H), 7.03 (d, J=8.0 Hz, 2H), 3.79
(s, 3H), 3.69-3.67 (m, 2H), 3.56-3.53 (m, 2H), 3.29-3.25 (m, 2H),
3.02-2.95 (m, 2H), 2.91-2.86 (m, 2H), 2.07-20.4 (m, 1H), 1.91-1.83
(m, 2H). MS (m/z) (M+1).sup.+ 433.1.
[0787] The exemplary compounds given in Table 1 can be synthesized
according to the conditions described in examples 1-7.
Example 8
Pharmaceutical Compositions
Example 8a
Parenteral Composition
[0788] To prepare a parenteral pharmaceutical composition suitable
for administration by injection, 100 mg of a water-soluble salt of
a compound of Formula (A) or Formula (B) is dissolved in DMSO and
then mixed with 10 mL of 0.9% sterile saline. The mixture is
incorporated into a dosage unit form suitable for administration by
injection.
Example 8b
Oral Composition
[0789] To prepare a pharmaceutical composition for oral delivery,
100 mg of a compound of Formula (A) or Formula (B) is mixed with
750 mg of lactose. The mixture is incorporated into an oral dosage
unit, such as a hard gelatin capsule, which is suitable for oral
administration.
Example 8c
Inhalation Composition
[0790] To prepare a pharmaceutical composition for inhalation
delivery, 25 mg of a compound of Formula (A) or Formula (B) is
mixed with 2 mL of 95% ethanol and 100 mL of 0.9% sodium chloride
solution. The mixture is incorporated into an inhalation delivery
unit, such as a nebulizer, which is suitable for inhalation
administration.
Example 8d
Suppository Composition
[0791] To prepare a pharmaceutical composition for rectal delivery
[such as twelve 1.8 g. cocao butter base, medicated suppositories
containing 300 mg of a compound of Formula (A) or Formula (B)], 3.6
g. of a compound of Formula (A) or Formula (B) is mixed with 18 g.
of cocoa butter. The mixture is gently fused and the resulting melt
is poured into molds to form suppositories suitable for rectal
administration.
Example 9
Functional Assay of c-Kit Inhibition
[0792] The compounds described herein are tested for inhibition of
SCF dependent proliferation using Mo7e cells which endogenously
express c-kit in a 96 well format. Briefly, two-fold serially
diluted test compounds (Cmax=10 .mu.M) are evaluated for their
antiproliferative activity on Mo7e cells stimulated with human
recombinant SCF. After 48 hour incubation at 37.degree. C., cell
viability is measured by using a MTT calorimetric assay from
Promega.
[0793] Exemplary test compounds are evaluated using the functional
assay described above for inhibition of the c-kit receptor. The
ability of compounds of Formula (A) or Formula (B) to antagonize
50% of the specified c-kit receptor yields IC.sub.50 values for the
compounds tested. In certain embodiments compounds of Formula (A)
or Formula (B) have IC.sub.50 values greater than about 10 .mu.M,
while in other embodiments compounds of Formula (A) or Formula (B)
have IC.sub.50 values between about 1 .mu.M and about 10 .mu.M. In
still other embodiments, compounds of Formula (A) or Formula (B)
have IC.sub.50 values between about 0.1 .mu.M and about 1 .mu.M.
While in even further embodiments, compounds of Formula (A) or
Formula (B) have IC.sub.50 values less than about 0.1 .mu.M.
[0794] It is understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to be included within the spirit
and purview of this application and scope of the appended claims.
All publications, patents, and patent applications cited herein are
hereby incorporated by reference for all purposes.
* * * * *